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ABSTRACT
Molecular Mechanisms of G Protein - Receptor Coupling
Janna Eugenievna Slessareva
A big diversity in heterotrimeric G proteins and their cognate receptors raises many
questions about the mechanisms that regulate the specificity of signaling along G proteinmediated pathways. The major goal of this project was to understand how the selectivity of G
protein-receptor coupling is achieved at the level of the G protein-receptor interface. Additional
goals of this project were to assess the generality of molecular mechanisms controlling G
protein-receptor coupling selectivity and to investigate how agonist may regulate G proteinreceptor interactions. Molecular determinants of G protein-receptor coupling were studied by
reconstitution of exogenously supplied, purified G protein heterotrimers with receptors of
interest expressed in Sf9 cell membranes. The receptor coupling activity of native G proteins was
compared with that of chimeric G proteins, containing chimeric Gα subunits composed from
different regions of Gi1α, Gqα and Gtα. We found a prominent role for the N- and C- terminus
and α4 helix-α4/β6 loop domain of Gα for receptor coupling and speculate that the N- and Ctermini cooperate to couple receptors. Data demonstrate that multiple and distinct determinants
of selectivity exist for individual receptor families and suggest that receptors recognize specific
patterns formed by the amino acids of Gα on the receptor recognition surface. We also show that
individual receptors distinguish themselves by the EC50 with which they interact with Gi1,
indicating that G protein concentration may regulate G protein-receptor coupling. We obtained
evidence that agonist concentration can regulate the selectivity of G protein-receptor coupling by
demonstrating that chimeric G proteins unable to couple receptors at agonist concentrations used
for native G proteins, were able to form the ternary complex at higher agonist concentration and,
with some exceptions, exchange guanine nucleotides. Additionally, results suggest that G
proteins play a more active role in receptor coupling than previously thought. Furthermore,
results supporting the existence of multiple active receptor states indicate that the two-state
receptor activation model needs to be changed. This project presents interesting findings
regarding the molecular mechanisms that regulate G protein-receptor coupling and contributes to
better understanding of GPCRs function.
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CHAPTER I. INTRODUCTION
1. INTRODUCTION AND SIGNIFICANCE
G protein coupled receptors (GPCRs) can be activated by a variety of extracellular
signals including hormones, photons and odorants. G proteins, in turn, couple GPCRs to
different intracellular effectors such as enzymes and ion channels (Gilman, 1987). G proteins are
heterotrimers composed of α, β and γ subunits. There are 20 α subunits, 6 β subunits and 12 γ
subunits which can produce many different combinations. G proteins are classified by the nature
of their α subunits. They are divided into 4 different families based on their amino acid sequence
homology, which include Gs, Gi/o, Gq/11 and G12/13. G proteins are active in their GTP bound
form and inactive in GDP bound form. Ligand activated receptors promote GDP/GTP exchange
on G protein α subunits, thereby activating the G protein and dissociating α and βγ subunits.
Then α and βγ subunits modulate their effectors. Activation is terminated by the intrinsic
GTPase activity of α subunits (Neer, 1995; Gilman, 1987). GPCRs are grouped into four classes
based on the amino acid sequence similarity. These include Class I. Rhodopsin-type receptors,
Class II. Secretin/glucagon receptors, Class III. Metabotropic glutamate/calcium sensor receptor
and Class IV. “Gi-vomeronasal” pheromone receptors (Wess, 1998). The total number of human
GPCRs is close to 750 (Vassilatis et al., 2003). Given such a big number of GPCRs and G
proteins, it is important to know how the selectivity of G protein-receptor coupling is achieved
(Wess, 1998). As it will be described later, there are different mechanisms in living cells that
regulate G protein-receptor coupling. At the molecular level the selectivity of G protein-receptor
coupling is determined by the amino acid sequences of both receptors and G proteins. However,
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the individual amino acids of G proteins and receptors controlling G protein-receptor coupling
selectivity remain to be defined.
G proteins and GPCRs are involved in numerous cell signaling pathways (Gudermann et
al., 2000; Offermanns, 2001). Dysfunctions of G proteins and receptors are implicated in a
growing number of diseases (Iiri et al., 1998; Farfel et al., 1999; Levine, 1999; Spiegel, 1999).
Therefore, studying the mechanisms of G protein-receptor interactions may suggest new
approaches in treating disease states and may help to develop new drugs that act at the G proteinreceptor interface. One strategy involves blocking multiple receptors coupled to the same G
protein without the use of multiple antagonists. For example, enhanced Gq signaling over time
produces cardiac hypertrophy and apoptotic heart failure (Zolk et al., 2000). Interestingly,
Akhter et al. demonstrated that it is possible to inhibit myocardial hypertrophy in vivo by
blocking the response from heart Gq coupled receptors using a peptide corresponding to the C
terminus of Gqα (Akhter et al., 1998). Using Gq/11 knock-out mice Wettschureck et al.
demonstrated recently that Gq/11-mediated pathways are essential for cardiac hypertrophy
induced by pressure overload, making it an attractive drug therapy target (Wettschureck et al.,
2001). There is also the possibility of developing a strategy to specifically block G protein
coupling with a receptor of interest. In addition, chimeric Gα subunits may serve as a tool for
novel drug discovery (Milligan and Rees, 1999). Overall, this project will contribute to our
understanding of the mechanisms underlying selectivity in G protein-receptor interactions.

2. MUSCARINIC RECEPTORS
Muscarinic receptor subtypes. Molecular cloning has identified five molecularly distinct
members of the human muscarinic receptor family that are designated M1-M5 (Bonner et al.,
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1987; Hulme et al., 1990). Muscarinic receptor subtypes share high sequence homology,
especially in the transmembrane domains, where there is about 90% sequence conservation
(Bonner, 1989). M1, M3 and M5 receptors preferentially couple to G proteins from the Gq/11
class which leads to activation of phospholipase Cβ (PLCβ) and, in turn, to breakdown of
membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5triphosphate (IP3) and diacylglycerol (DAG). M2 and M4 receptors preferentially couple to G
proteins from the Gi/o class, which leads to inhibition of adenylyl cyclase and to activation of K+
channels, which is a βγ-mediated response (Wess, 1996). Besides these well characterized
responses muscarinic receptors regulate other signaling processes, including regulation of
additional ion channels ( Hulme et al., 1990; Hosey et al., 1999) and stimulation of MAP kinase
pathways (Gutkind, 1998).
Tissue distribution and functional role. Techniques ranging from subtype-selective
antagonist binding, northern blot analysis, in situ hybridization and subtype-specific antibodies
have demonstrated that muscarinic receptors are present in many peripheral tissues including
heart, smooth muscle and exocrine glands and also in many regions of the CNS (Hulme et al.,
1990; Wess, 1996). Peripheral muscarinic receptors mediate the action of acetylcholine on
parasympathetically innervated tissues while central muscarinic receptors are involved in
regulation of higher cognitive functions and extrapyramidal motor function (Wess, 1996).
Although many tissues express several different muscarinic receptors, some of the muscarinic
responses are thought to be mediated by a particular receptor subtype. For example, the M2
receptor is the predominant form of muscarinic receptors in the heart where it mediates negative
chronotropic and ionotropic effects. M3 receptors mediate smooth muscle contraction and
glandular secretion (Caulfield, 1993). M1 receptors in the cerebral cortex and hippocampus are
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thought to be involved in memory and learning. M4 receptors in striatum play a role in
regulation of motor function (Levey et al., 1991). The function of M5 receptor, which is
expressed at low levels in CNS and in some peripheral tissues, is not clear yet. However, a recent
study suggests that M5 receptors play a role in facilitating dopamine release in striatum and in
the dilation of cerebral blood vessels (Yamada et al., 2001).
Structure of the GPCRs. Muscarinic receptors belong to the rhodopsin-like family of the
GPCR superfamily and share a common overall structure, consisting of 7 transmembrane helices
connected by the extracellular (o2-o4) and intracellular (i1-i3) loops. The N terminus of the
receptor (o1) is located at the extracellular surface while the C terminus is located at the
intracellular surface (Wess, 1998). The fourth intracellular loop (i4) is formed when the
palmitoylated C terminus attaches to membrane. Ligands bind to receptors from different classes
in different modes depending on their nature. For example, biogenic amines and nucleotides bind
to the receptor core within the plane of the bilayer, small peptides (≤ 40 amino acids) bind to
both the core and extracellular loops, polypeptides (≤ 90 amino acids) bind to the extracellular
loops and the N terminus and glycoproteins (≥ 30 kD) bind to the N terminus (Ji et al., 1998).
Muscarinic receptor ligands bind to transmembrane helixes in the receptor core (Wess, 1996).
The intracellular receptor surface is involved in G protein coupling. The seven transmembrane
helices are arranged in a helical bundle. Before the crystal structure of the first GPCR became
available, a model of arrangement of transmembrane helices had been proposed by Baldwin
(Baldwin, 1993; Baldwin, 1994; Unger et al., 1997). This “Baldwin model” predicts an
anticlockwise connectivity of transmembrane helices as viewed from the extracellular side.
Recently a crystal structure of rhodopsin, a prototypical GPCR, has been determined at 2.8 Å
resolution (Palczewski et al., 2000) supporting the anticlockwise connectivity of transmembrane
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helices as predicted by the “Baldwin model”. This first detailed model of a GPCR allowed us to
view receptor mutagenesis data in the context of the three-dimensional structure and provided
structural information for the modeling of the G protein–receptor interactions.
Muscarinic receptors have several potential N-glycosylation sites (Asn-X-Ser/Thr) at the
N terminus. However mutational studies indicate that glycosylation is not required for ligand
binding or G protein coupling (Ohara et al., 1990; van Koppen and Nathanson, 1990). Two
conserved cysteine residues in o1 and o2 loops of muscarinic receptors form a disulfide bond,
which is important for receptor folding but not required for ligand binding (Hulme et al., 1990).
Acetylcholine binds to the receptor in a cleft between transmembrane helices about 10-15 Å from
membrane surface. A conserved Asp residue in TM III is thought to be important for interactions
with the positively charged ammonium/amino head of muscarinic receptor ligands. Other amino
acids shown to be important for ligand binding include Tyr in TM VII, Thr in TM IV and Thr in
TM V (Wess, 1996).
Muscarinic receptor agonists. An extensive review of muscarinic receptor agonists can
be found in Goodman and Gilman’s “The Pharmacological Basis of the Therepeutics” (Goodman
& Gilman's, 2001) Briefly, muscarinic receptor agonists are divided into naturally occurring
alkaloids (pilocarpine, muscarine, arecoline) and choline esters (acetylcholine, methacholine,
carbachol, bethanechol). Muscarinic agonists are used in ophthalmology (pilocarpine for
glaucoma), for treatment of gastrointestinal and urinary bladder disorders (bethanechol) and for
treatment of xerostomia (pilocarpine). Methacholine is useful for diagnosis of bronchial
hyperreactivity and asthmatic conditions. There are also other synthetic muscarinic receptor
agonists available. Oxotremorine is the pharmacologically active metabolite of the synthetic
agent tremorine. Oxotremorine is a selective muscarinic receptor agonist equipotent to
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acetylcholine. Because of the high amino acid sequence homology between muscarinic receptor
subtypes and especially because the amino acids that are thought to be involved in agonist
binding are identical, selective muscarinic agonists are not available at present. McN-A-343 was
proposed to be a selective M1 agonist, however this selectivity appeared to be functional as
opposed to subtype-selective.
Muscarinic receptor antagonists. An extensive review of muscarinic receptor
antagonists can be found in Goodman and Gilman’s “The Pharmacological Basis of the
Therepeutics” (Goodman & Gilman's, 2001). Briefly, muscarinic receptor antagonists are
divided into naturally occurring alkaloids (atropine, scopolamine), semisynthetic derivatives of
these alkaloids (homatropine, tropicamide, ipratropium) and synthetic agents (pirenzepine,
tolterodine). Several antagonists have been developed that show some degree of subtype
selectivity, however no agent is completely selective. For example, pirenzepine is selective for
M1 receptors in comparison to M2 and M3 receptors but has comparable affinity for M4
receptor. Telenzepine is a higher potency analog of pirenzepine. AF-DX116 and tripitamine are
selective for M2 receptors. Hexahydro-sila-difenidol and darifenacin are selective for M3
receptors. Also mamba toxins have shown selectivity for M1 and M4 receptor subtypes
(Caulfield and Birdsall, 1998). Muscarinic receptor antagonists are used to treat gastrointestinal
tract disorders (pirenzepine, belladonna alkaloids), chronic obstructive pulmonary disease
(ipratropium), motion sickness (scopolamine), anticholinesterase and mushroom poisoning
(atropine). They are also useful in ophthalmology (atropine, cyclopentolate).
Muscarinic receptor domains involved in G protein coupling. Receptor domains
involved in G protein coupling have been extensively investigated using mutagenesis (loss of
function and gain of function approaches) and were found to be located at the intracellular side
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of the receptor. Using hybrid M1/M2 receptors Kubo et al first demonstrated that the i3 loop
plays an important role in G protein coupling (Kubo et al., 1988). Later it was demonstrated that
only 8-15 N and C terminal amino acids of i3 (Ni3 and Ci3) are critical for G protein coupling
(Wess, 1998; Strader et al., 1994). Mutagenesis studies by different investigators precisely
identified amino acids in both Ni3 and Ci3 regions involved in G protein coupling and
demonstrated that Ni3 residues involved in coupling selectivity are primarily hydrophobic or
uncharged and lie on the hydrophobic side of an amphiphilic α helix (Wess, 1998). Detailed
analysis of Ni3 identified Tyr254 of M3 receptor as residue important for Gq coupling (Bluml et
al., 1994a; Bluml et al., 1994b). Gain of function studies with M2 and M3 receptors identified 4
conserved amino acids in Ci3 important for M1, M2 and M5 receptor coupling as Ala488,
Ala489, Leu492 and Ser493 (residue numbers as in M3 sequence), which are known as “AALS
motif” (Blin et al., 1995). Corresponding amino acids in M2 and M4 receptors have been
identified as Val385, Thr386, Ile389 and Leu390 (residue numbers as in M2 sequence) and
known as “VTIL motif” ( Liu et al., 1995; Kostenis et al., 1997a). These amino acids are located
in a helically arranged i3/TM VI junction and together with amino acids from Ni3 define
hydrophobic surfaces important for G protein coupling. However because Ni3 and Ci3 are
thought to be spatially close they may form one G protein recognition surface (Wess, 1998).
Burstein et al similarly identified amino acids of M5 receptor in Ni3 and Ci3 regions and
proposed that these residues form a G protein binding pocket with a hydrophobic core and
positively charged lip (Burstein et al., 1998). Although the i3 loop is important for G protein
coupling, it is not the only determinant of coupling selectivity. Blin et al demonstrated that the i2
loop of M3 receptor is also important for proper Gq recognition (Blin et al., 1995). Residues
within i2 that have been shown to be important for G protein coupling include the “DRY” motif,
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which is conserved among most GPCRs (Fraser et al., 1989; Zhu et al., 1994; Jones et al., 1995)
and a Pro-Leu motif (Moro et al., 1993). Gain of function studies by Blin et al (Blin et al., 1995)
identified amino acids of M3 receptor in the i2 loop important for Gq coupling selectivity as
Ser168, Arg171, Arg176 and Arg183. The C terminus of muscarinic receptor does not play an
important role in G protein coupling selectivity, although 8-16 amino acids of i4 proximal to the
membrane may play a role in G protein coupling. The i1 loop also does not contribute
significantly to G protein coupling selectivity (Wess, 1998). Because the length and amino acid
sequence of the i1 loop are conserved in the muscarinic receptor family, the i1 loop mostly plays
a role in receptor structural integrity (Moro et al., 1994). In summary, receptor regions important
for G protein coupling selectivity are i2, Ni3 and Ci3. Studies by different groups suggest that
these regions cooperate to achieve efficient G protein coupling and activation (Wess, 1998).

3. HETEROTRIMERIC G PROTEINS
Gα subunits. More than 20 different Gα subunits encoded by 17 distinct genes have been
identified. On the basis of their amino acid sequence homology Gα subunits are divided into four
families: Gs, which includes several splice variants of Gsα and Golfα, Gi/o, which includes
Gi1α, Gi2α, Gi3α and splice variants; Go1α, Go2α; Gt1α, Gt2α; Ggustα; Gzα, Gq/11, which
includes Gqα, G11α, G14α, G15α, G16α and G12/13, which includes G12α and G13α (Neer,
1995; Hamm, 1998). Among the well characterized activities of Gα subunits are activation of
adenylyl cyclase by Gsα, inhibition of adenylyl cyclase by Giα, activation of cGMP
phosphodiesterase by Gtα and activation of phospholipase C by Gqα. In addition, Gqα can
directly stimulate the activity of Bruton’s tyrosine kinase in vitro and in vivo (Bence et al.,
1997). G12α and G13α can couple to thrombin, thromboxane and angiotensin receptors (Barr et
8

al., 1997) and have been shown to regulate Na+/H+ exchange (Voyno-Yasenetskaya et al., 1994).
G13α has also been shown to activate radixin (Vaiskunaite et al., 2000).
Several crystal structures of Gα subunits in both active and inactive conformations and as
complexes with Gβγ subunits have been solved. These include Gtα·GTPγS·Mg2+ (Noel et al.,
1993), Gtα·GDP·Mg2+ (Lambright et al., 1994), Gi1α·GTPγS·Mg2+ (Coleman et al., 1994),
Gi1α·GDP (Mixon et al., 1995), Gi1α·GDPGβ1γ2 (Wall et al., 1995) and Gtα/Giα1·GDPGtβγ
(Lambright et al., 1996). Gα subunits contain two domains: the ras-like GTPase domain, which
is involved in the guanine nucleotide binding and GTP hydrolysis; and the helical domain with
yet unclear function. The α helical domain is inserted into the GTPase domain. The domains are
connected by two flexible linkers. The GTPase domain consists of a six-stranded β-sheet (β1-β6)
surrounded by six helices (α1-α5 and αG). The helical domain consists of a central helix (αA)
surrounded by five shorter helices (αB-αF). The guanine nucleotide binds in the cleft between
the GTPase and the helical domains. In the GTPase domain the guanine nucleotide-binding site
is formed by five polypeptide loops (G-1 through G-5), which are highly conserved and define
the G protein superfamily, which include heterotrimeric G proteins, Ras and its homologs, and
elongation factors Tu and G.
Most Gα subunits (except Gtα) are S-palmitoylated at a cysteine (or cysteines) at the Nterminus and others (Goα, Giα, Gzα, Gtα) are also N-myristoylated at Gly-2. These lipid
modifications help target Gα subunits to the plasma membrane to which they are loosely
attached. In addition, palmitoylation is a dynamic process which may be involved in the
trafficking of Gα between membrane and cytosol (Milligan et al., 1995; Wedegaertner et al.,
1995). The Gi1α family members (except Gzα) can be ADP-ribosylated by pertussis toxin at a
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cysteine residue, four amino acids from the C terminus, thus inhibiting receptor coupling
(Gilman, 1987). Gsα can be ADP-ribosylated at Arg-201 by cholera toxin, which allows GTP
binding but inhibits GTPase activity of Gsα (Gilman, 1987) resulting in constitutively active
Gsα.
The Gi1α is a 40.3 kD protein, which is widely expressed in different tissues (Jones and
Reed, 1987). Gi1α is both myristoylated (at glycine through an amide linkage) and palmitoylated
(at cysteine through thioester linkage) at the N terminus and attached to the membrane surface.
Dissociation of GDP from Gi1α is slow (0.03 min-1) (Linder et al., 1990) and is almost
undetectable in the heterotrimer.
There are two isoforms of Gtα (transducin) – one present in the rod outer segments
(Gt1α) and the other present in cones (Gt2α). Both of them activate cGMP phosphodiesterase by
coupling to the light activated rhodopsin (Gt1α) or cone-opsins (Gt2α) (Gilman, 1987; Chabre
and Deterre, 1989). Gtα has a very low basal rate of GDP/GTP exchange which is required for
the low noise signaling in the visual system. Gtα is activated by rhodopsin very rapidly and one
molecule of activated rhodopsin may activate several hundred Gtα subunits, resulting in a
dramatic signal amplification (Chabre and Deterre, 1989).
The Gqα is a 43 kD protein which stimulates phospholipase Cβ (Smrcka et al., 1991;
Taylor et al., 1991; Hepler et al., 1993). It is expressed in many tissues, with tissues of particular
interest being the heart, as Gqα can be a novel target for heart failure (Wettschureck et al., 2001)
and platelets, because a defect in platelet activation is seen in Gqα null mice (Shenker et al.,
1991; Offermanns, 2001). The GDP dissociation rate from Gqα is unusually slow. In addition,
Gqα does not readily bind GTPγS so that concentrations of GTPγS as high as 30 µM are required
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for half-maximal activity (Hepler et al., 1993). These properties delayed identification and
purification of Gqα in a functionally active state and pose difficulty for reconstitution
experiments.
The conformational changes that occur in Gα when it goes from the GTP bound form to
the GDP bound form are mostly localized to so-called switch regions. Switch I corresponds to
the linker 2 (αF-β2 loop), switch II is the β3/α2 loop and α2 helix in the GTPase domain, switch
III is a β4/α3 turn in the GTPase domain and switch IV is αB/αC loop in the helical domain
(Mixon et al., 1995).
In the Gi1α·GTPγS·Mg2+ conformation, switches II and III are ordered but 32 N terminal
and 10 C terminal residues are disordered (Coleman et al., 1994). In the Gi1α·GDP·Mg2+
conformation switches II and III are disordered but N terminal (amino acids 8-32 in the
structure) and C terminal (amino acids 344-354) residues fold into a compact microdomain
(Mixon et al., 1995). In the heterotrimer, N terminal residues (N terminus and αN helix) of Gi1α
unfold to interact with Gβ. Thus the N terminus is stabilized by contacts with Gβ. In contrast, the
C terminus is disordered in the heterotrimer as a result of the loss of interactions with the N
terminus (Wall et al., 1995). The C terminus, which is a major Gα receptor interaction domain,
is stabilized upon receptor interaction (Kisselev et al., 1998). In the heterotrimer, Gα makes two
contact surfaces with Gβ. The first contact surface is in β2, β3, α2 region, including switch II.
The second contact surface is the interface between N terminus of Gα and the side of the β
propeller of Gβ (Wall et al., 1995).
Gβγ subunits. Six different β and twelve different γ subunits have been described
(Clapham and Neer, 1997). The β and γ subunits bind very tightly and can only be separated by
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denaturation. Thus the Gβγ dimer can be viewed as a functional monomer. In theory, 72 different
βγ combinations can be formed, however there is evidence suggesting that not all combinations
are possible (Clapham and Neer, 1997). The functional importance of such diversity is not clear
because most of the βγ complexes have similar functional properties. The β subunits share a high
sequence homology while the γ subunits are more diverse.
The Gβ is composed of two types of structural regions: N terminal amphipathic α helix
followed by the 7-membered β-propeller structure (Wall et al., 1995; Lambright et al., 1996;
Sondek et al., 1996). Each of the 7 β-sheets contains 4 antiparallel strands which radiate from a
central core. Amino acid sequence of Gβ contains 7 WD repeats. The WD motif is about 40
amino acids long, contains conserved amino acids, and is frequently terminated by a Trp-Asp
dipeptide (WD). The WD repeat in βγ begins at the turn between the 3rd and 4th strands of a βsheet and ends at the same position in the next β-sheet (Sondek et al., 1996). Thus a WD repeat
does not correspond to a defined folded domain. WD repeats are not unique to Gβ subunits and
occur in about 40 other proteins with diverse functions (Neer et al., 1994).
Gγ is mostly helical. The N terminus of Gγ forms a coiled-coil with the N terminal helix
of Gβ. The rest of Gγ extends across Gβ contacting propeller blades 5, 6 and 7. Thus Gγ forms
extensive interactions with Gβ, binding to Gβ in the extended conformation and making no
contacts with itself (Sondek et al., 1996). The C terminus of Gγ contains the CAAX motif. This
motif directs the Gγ prenylation – either farnesylation or gerenylgeranylation (Casey, 1994).
Lipid modifications are attached to the cysteine via a thioester bond and serve for membrane
attachment of Gβγ (Simonds et al., 1991).
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Gβγ greatly enhances Gα binding to the receptor (Heithier et al., 1992; Phillips and
Cerione, 1992) . Although Gα is the main determinant of receptor coupling, both Gβ and Gγ
subunits have been shown to interact directly with the receptor (Phillips and Cerione, 1992;
Heithier et al., 1992; Kisselev et al., 1994; Taylor et al., 1996; Azpiazu et al., 1999; Ernst et al.,
2000). Gα prevents Gβγ from interaction with effectors. Upon dissociation from Gα, Gβγ can
interact with a great number of downstream targets (Clapham and Neer, 1997). Gβγ has been
shown to interact with phospholipases β2 and β3 (Morris and Scarlata, 1997; Rhee and Bae,
1997), adenylyl cyclases AC II, AC IV, AC VII (activation) and AC I (inhibition) (Sunahara et
al., 1996), K+ and Ca2+ ion channels (Logothetis et al., 1987; Schneider et al., 1997), G proteincoupled receptor kinases (Pitcher et al., 1992; Pitcher et al., 1998) and phosphoinositide 3kinases (p110γ) (Tang and Downes, 1997; Vanhaesebroeck et al., 1997). Other potential Gβγ
effectors include Raf1 protein kinase (Pumiglia et al., 1995) and Btk and Tsk nonreceptor
tyrosine kinases (Langhans-Rajasekaran et al., 1995).
The G protein cycle. G proteins cycle between GDP-bound inactive conformation and
GTP-bound active conformation. The details of this cycle have been described in several review
papers (Gilman, 1987; Neer, 1995; Hamm, 1998). When GDP is bound to an α subunit, it
associates with a βγ subunit to form a heterotrimer which can interact with receptors. Agonist
binding to receptor causes conformational changes in the receptor structure which allows it to
interact with G protein heterotrimer. Activated receptor then promotes release of GDP from Gα.
This leads to the formation of the ternary complex of the agonist, receptor and G protein in the
guanine-nucleotide free state. This so-called “empty pocket” conformation of Gα has high
affinity for activated receptor and it is able to stabilize the high affinity state of the receptor for
agonist. Affinity shift assay (described below) is able to detect the formation of the ternary
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complex as an enhanced level of agonist binding. Because the concentration of GTP in cells is
much higher than the concentration of GDP, GTP binds to Gα, which leads to dissociation of Gα
from Gβγ and from receptor. Then both Gα and Gβγ are free to interact with their target
effectors. Gα has an intrinsic GTPase activity so it hydrolyzes GTP to GDP and inorganic
phosphate which leads to the dissociation of Gα from the effector. The GDP-bound Gα has a
high affinity for Gβγ so it associates with Gβγ thus terminating Gβγ activity. The GDP-bound G
protein heterotrimer is then able to enter a new activation cycle.

4. G PROTEIN-RECEPTOR INTERACTIONS
Affinity Shift Assay. Receptors can exist in at least two affinity states for agonist – a low
affinity state, which represents uncoupled receptors and a high affinity state, which represents
receptors coupled to an appropriate G protein, or receptors in the active conformation
(spontaneous isomerisation). As described above, the ternary complex of agonist, receptor and
guanine nucleotide-free G protein represents the high affinity receptor state. The ability of a
specific G protein to interact with a receptor of interest and stabilize the high affinity state of the
receptor can be studied in the affinity shift activity assay. This assay is based on early work with
native receptors (Asano et al., 1985; Pobiner et al., 1991) and has been completely described for
several recombinant receptors (Figler et al., 1996; Clawges et al., 1997; Cabrera-Vera et al.,
2002). In the affinity shift assay, partially purified membranes, containing the expressed
receptor, are reconstituted with saturating amounts of purified, exogenous, G proteins. A
radioligand binding assay with a low concentration of agonist (near the KD for the high affinity
state) is used to determine the fold- enhancement (affinity shift) in agonist binding by
reconstitution with G protein. Affinity shift assay allows us to measure the G protein-receptor
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interaction directly and eliminates interference from other proteins which may modulate the
activity of downstream effectors. In addition, this reconstitution approach allows control of the
stoichiometry of receptors and G proteins, which is hard to achieve in transfection experiments.
GPCR models. There are several receptor models that describe ligand-receptor
interactions (Kenakin, 1996). The extended ternary complex model (Figure A) remains the most
widely accepted model of GPCR activation (Samama et al., 1993). According to this model,
receptors exist in equilibrium between inactive R and active R* conformations. The R*
conformation is stabilized by guanine-nucleotide free G protein heterotrimers and binds agonists
with the highest affinity. Thus agonists shift the equilibrium toward the accumulation of R*.
However, receptors are able to undergo spontaneous isomerisation from the R to R* in the
absence of agonists. This is described as a constitutive receptor activity. Constitutive receptor
activity leads to agonist-independent activation of G proteins and downstream signaling
cascades. Inverse agonists are able to destabilize active receptor complexes and prevent agonistindependent signaling.
To characterize the effects of ligands in more detail the cubic ternary complex model,
which takes into consideration all the previous models, has been described (Kenakin, 1996;
Weiss et al., 1996). The first face of the cube represents the effect of ligand on receptor
activation. The second face describes the interactions between receptors and G proteins. The
third face describes the effect of ligand on G protein-receptor interactions. The cube is completed
by microreversibility with the appropriate constants. Despite the fact that this model has too
many constants and is not very useful for the modeling of data, it is complete and useful in
describing and predicting receptor behavior.
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Interestingly, new experimental data suggest that the two-state receptor activation model
(R↔R*) cannot be applied in all cases (Chidiac, 1998) and that the conformation of the HR*G
complex may depend on the identity of the agonist (Krumins and Barber, 1997). In addition, the
possible existence of receptor-specific multiple G protein conformation states (Wenzel-Seifert
and Seifert, 2000) may further complicate the model. It is also important to note that kinetic
considerations are not included in these models. Shea et al. recently proposed the cubic ternary
complex activation model which modifies the cubic ternary model by including G protein
activation and deactivation steps (Shea et al., 2000).
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α = [HR*G][R*]/[HR*][R*G]
β = [HR*][R]/[HR][R*]

FIGURE A. The extended ternary complex model
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Structural considerations. In recent years several G protein-receptor interaction models
have been proposed (Lichtarge et al., 1996; Oliveira et al., 1999; Grishina and Berlot, 2000).
When the high resolution structure of rhodopsin in the ground state became available
(Palczewski et al., 2000), modeling of the G protein-receptor complex was raised to a new level
(Hamm, 2001). However, because the structure was solved for the inactive state of rhodopsin,
many questions remain unanswered. The guanine nucleotide is buried in the cleft between
GTPase and α helical domains of Gα, and thought to be approximately 30 Å away from the
membrane surface. Because the intracellular receptor loops are not long enough to directly
contact the GDP in this cleft, the receptor must act at a distance to promote nucleotide release.
The most widely accepted view is that receptor interaction with the C terminus (and probably
amino acids in the α5 helix and α4/β6 loop) of Gα leads to the conformational changes that are
propagated to the β6/α5 loop. The β6/α5 loop (TCAT motif) is known to contact the guanine
nucleotide directly. Thus the receptor can promote GDP release by weakening the binding
interactions (Wess, 1998). Recently Kisselev et al. proposed a two-site sequential fit model for
the signal transfer from the activated receptor to the G protein (Kisselev et al., 1999). According
to this model, sites with distinct conformations on R* can be specifically recognized by the C
terminus of Gα and the farnesylated C terminus of Gγ. Upon binding of the first matching pair of
domains, conformational changes in the R* and/or G protein occur that lead to the subsequent
binding of the second matching pair of domains.

5. SELECTIVITY OF G PROTEIN-RECEPTOR COUPLING
The question of selectivity. Many different heterotrimers can be produced from the 20 α
subunits, 6 β subunits and 12 γ subunits. Many GPCRs are known to date and most of them
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include multiple subtypes. Therefore, the question of selectivity in G protein-receptor coupling
arises (Gudermann et al., 1996; Wess, 1998). There are examples of both promiscuous and
highly selective interactions between receptors and G proteins. For example, the thyrotropinreleasing hormone receptor has been shown to couple with G proteins from all 4 classes
(Laugwitz et al., 1996). In contrast, gonadotropin-releasing hormone receptor has been shown to
mediate multiple signaling pathways by coupling only to Gq/11 proteins (Gudermann et al.,
2000). An even higher degree of selectivity has been seen in studies utilizing antisense
nucleotides in vivo. One example demonstrates that the G13 heterotrimer composed of α13β1γ3
subunits couples angiotensin AT1A receptor to increase intracellular Ca2+ in rat portal vein
myocytes (Macrez-Lepretre et al., 1997). However, this level of specificity is usually not seen in
vitro.
Most GPCRs couple only with a distinct subset of G proteins expressed in the cell and
therefore are described as Gs, Gi/o or Gq coupled receptors. Interestingly, G protein coupling
preferences of individual GPCRs is often relative rather than absolute because the receptor can
couple with other G proteins but with reduced efficiency. In general, functionally important
amino acids are very conserved. However, if they mutate, they often do so in groups to maintain
a common function. Correlated mutational behavior is described as a tendency of sequence
patterns to remain conserved or to mutate pair-wise. Using such correlated mutation analysis,
which is a sequence-only based technique, Horn et al. have come to the conclusion that such low
efficiency coupling is a result of a recent divergent evolutionary process (Horn et al., 2000).
Because the molecular mechanism of G protein-receptor coupling is not completely understood,
at present it is impossible to predict the G protein coupling preferences of a newly cloned GPCR
based only on its sequence.
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Mechanisms controlling selectivity of coupling. There are many mechanisms that
control the G protein-receptor coupling. Cells can regulate the selectivity of G protein-receptor
coupling by localizing certain components of the signal transduction pathway into microdomains
so that there is no mixing of components between different compartments (Neubig, 1994; Albert
and Robillard, 2002). There are also examples of polarized cells that distribute receptors and G
proteins asymmetrically (von Zastrow et al., 1993; Keefer et al., 1994). The expression level of
specific G proteins or receptors in the cell can also dictate the selectivity of coupling
(Gudermann et al., 1996). Accessory proteins have also been shown to regulate G proteinreceptor coupling. For example, Natochin et al. had demonstrated that AGS3 (Activator of G
protein Signaling 3) inhibits GDP dissociation from Gi1α (Natochin et al., 2000a). In addition,
once a G protein is activated, the selectivity of downstream pathway activation can be regulated
by the intrinsic rate of GTP hydrolysis of the specific Gα (Neer, 1995) which in turn can be
regulated by RGS (Regulators of G protein Signaling) proteins (Hepler, 1999), which act as
GTPase-activating proteins for Gα (Hepler, 1999; Wieland and Chen, 1999).
It is often the case that receptors, which mediate functionally related responses, couple to
the same G protein. For example, pancreatic acinar cells respond to acetylcholine, bombesin and
cholecystokinin by activating phospholipase C through Gq (Xu et al., 1998; Xu et al., 1999).
Activation of PLC results in mobilization of Ca2+ from intracellular stores, which ultimately
leads to exocytotic release of digestive enzymes from pancreatic acini. Interestingly, Xu et al.
demonstrated that each agonist produced different pattern of Ca2+ wave propagation, which was
shown to be modulated by RGS proteins (Xu et al., 1999). The factors that influence G proteinreceptor coupling selectivity in vitro include receptor density, G protein and agonist
concentrations (Wess, 1998).
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Gα domains involved in receptor coupling selectivity. Gα is thought to be the major
receptor contact subunit in the G protein heterotrimer. Several Gα domains have been implicated
in receptor coupling selectivity. Although the distinction has to be made between the
Gα domains required for general G protein coupling and the Gα domains involved in the
regulation of coupling selectivity, these receptor interaction domains often overlap.
The C terminus of Gα has been shown to interact with receptors using different
experimental approaches (West, Jr. et al., 1985; Hamm et al., 1988; Conklin et al., 1993;
Natochin et al., 2000b). With respect to selectivity, it has been demonstrated that substitution of
the last five C terminal residues of Gqα with corresponding sequences of Giα, Goα or Gzα
allowed PLCβ stimulation by receptors normally coupled to Gi/o such as A1 adenosine, D2
dopamine and M2 muscarinic receptors (Conklin et al., 1993; Liu et al., 1995). Other studies
with different receptors verified that the C terminus of Gα is involved in direction of receptor
coupling selectivity, which is determined by the C terminus amino acid composition (Conklin et
al., 1996; Kostenis et al., 1997a; Kostenis et al., 1997b). The C terminal amino acids of Giα
important for receptor coupling are -4 cysteine, -3 glycine and -1 phenylalanine, while the C
terminal amino acids of Gqα involved in receptor coupling selectivity are -5 glutamate and -3
asparagine (“-“ represents amino acid position counting from the C terminus) (Wess, 1998).
Although the C terminus of Gα is important for receptor coupling, in some cases it is not
sufficient when present in the context of an inappropriate Gα (Ma et al., 2000; Slessareva and
Graber, 2000). However, reconstitution studies by Natochin et al. indicate that five C- terminal
amino acids of transducin are sufficient for rhodopsin coupling (Natochin et al., 2000b). These
differences support the idea that molecular mechanisms of G protein-receptor coupling
selectivity vary among receptors.
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The N terminus of Gα has also been shown in a variety of experiments to be a
determinant of G protein-receptor coupling selectivity. Early studies indicated that Gα N
terminal regions interact with rhodopsin (Hamm et al., 1988), mastoporan (a wasp venom
mimicking the active receptor state) (Higashijima and Ross, 1991) and α2 adrenergic receptors
(Taylor et al., 1994). Bae et al. demonstrated that the replacement of amino acids 1-210 of Gi1α
with the corresponding amino acids of Gtα impaired, but did not prevent, 5-HT1B receptor
coupling (Bae et al., 1997). Hepler et al showed that cysteines at positions 9 and 10 of Gqα are
important but not critical for receptor coupling (Hepler et al., 1996). Kostenis et al. demonstrated
the importance of the N terminus of Gqα in constraining receptor coupling selectivity. They
showed that deletion of six N- terminal amino acids of Gqα, which are unique for the Gq family,
led to promiscuous coupling so that several Gi/o and Gs coupled receptors gained the ability to
productively couple with this Gqα mutant (Kostenis et al., 1997c). The N terminal αN helix of
Gi2 has been shown to be important for PAR1 thrombin receptor coupling and transferring the
signal between receptor and G protein (Swift et al., 2000).
Other domains important for receptor coupling include the α2 helix-α2/β4 loop domain
(Lee et al., 1995), the α3/β5 loop (Grishina and Berlot, 2000), 20 amino acids in the α helical
domain (Krieger-Brauer et al., 1999) and the αN/β1 loop (Blahos et al., 2001). The α4 helixα4/β6 loop region of Gi1α, which is a known effector interaction domain, has been shown to be
absolutely essential for 5-HT1B serotonergic receptor coupling (Bae et al., 1997). Recently it has
been demonstrated that two amino acids (Gln304 and Glu308) within the α4 helix mediate 5HT1B receptor coupling (Bae et al., 1999). The work of Natochin et al. supports the role of α4/β6
loop as a receptor interacting domain and indicates that Arg310 and Asp311 are involved in the
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interaction with transducin (Natochin et al., 1999). Recent evidence supports the role of α4/β6
loop in receptor coupling (Mody et al., 2000). Data from the Graber laboratory demonstrate that
multiple regions on G protein α subunits including C terminus, α4 helix-α4/β6 loop region and
N terminal part are involved in functional coupling with Gi/o-coupled receptors. It has been
demonstrated that four distinct Gi-coupled receptors (5-HT1A and 5-HT1B serotonergic, A1
adenosine and M2 muscarinic receptors) use slightly different domains on Gi1α for functional
interactions (Ma et al., 2000). Figure B shows the spacefilling model of Gi1αβ1γ2 heterotrimer.
The regions important for receptor coupling are exposed, located on the common Gα surface and
thus are available for receptor interaction.
Taken together, these reports indicate that multiple and different regions on G protein
heterotrimer are intimately involved in selective receptor coupling.
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Thr321
Gln304
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α4 helix-α
α4/β
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γ

α3 helix-α
α3/β
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FIGURE B. Spacefilling representation of the Gα
αi1β
β1γγ2 heterotrimer. This model was
generated from the crystal structure of Gαi1β1γ2 (Wall et al., 1995)( PDB ID is 1GP2) and
colored using RasMol. The α subunit is shown in blue, β in green and γ in yellow. The C and N
termini of Gαi1 are shown in light blue and orange, respectively. The regions that are important
for receptor coupling are described in the text (Section 5).

24

6. SUMMARY AND GOALS
The molecular mechanisms of G protein-receptor coupling are not very clear at present.
The major goal of this project was to understand how the selectivity of G protein-receptor
coupling is achieved at the level of the G protein-receptor interface. The specific aims of this
project were to determine how the selectivity of Gq-M1 muscarinic receptor coupling and Gi1M2 muscarinic receptor coupling is achieved, to assess the generality of molecular mechanisms
underlying G protein-receptor coupling selectivity and to understand how the selectivity of G
protein-receptor coupling is regulated by agonist. Fulfillment of these goals will help us to gain
more understanding of how GPCRs function, and may be helpful for the development of drugs
that act at the G protein-receptor interface.
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CHAPTER II. MATERIALS AND METHODS
1. Materials. [3H]-Oxotremorine-M Acetate ([3H]-OXO-M) (85.8 Ci/mmol), [3H]-NMethyl Scopolamine (70 Ci/mmol) and [35S]-GTPγS (1250 Ci/mmol) were from New England
Nuclear Life Science Products, Inc. (Boston, MA). Atropine Sulfate and Oxotremorine-M
(OXO-M) were from Sigma-Aldrich Corporation (St. Louis, MO). Molecular biology enzymes
were from New England Biolabs (Beverly, MA). Wild type baculovirus DNA and lipofectin
were from Invitrogen (Carlsbad, CA). Anti-Gαi1/2 C- terminal antibodies were from
Calbiochem-Novabiochem Corporation (San Diego, CA). Anti-Gαi1 internal antibodies and
anti-Gαq/11 C- terminal antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Pertussis Toxin was from Calbiochem-Novabiochem Corporation (San Diego, CA). The
ProtoBlot Western Blot reagents were from Promega (Madison, WI). The BCA Protein Assay
reagents were from Pierce (Rockford, IL). All other chemicals were from Sigma-Aldrich
Corporation (St. Louis, MO) or Calbiochem-Novabiochem Corporation (San Diego, CA).
2. Sf9 cell culture. Recombinant receptors and G proteins were produced in Spodoptera
frugiperda (Sf9) insect cells using the baculovirus expression system (Richardson, 1995;
Summers and Smith, 1987). Sf9 cells were grown in suspension in the complete insect cell
FMNH media (Grace’s insect cell culture media (Gibco BRL, Rockville, MD) + 0.35 g/L
NaHCO3, 3.33 g/L lactalbumin, 3.33 g/L TC-yeastolate) supplemented with 10% fetal bovine
serum, at 27°C with constant stirring at 50-60 rpm in the incubator with a gas mixture of 50%
O2/50% air. Cells were seeded at a density 1.25x106 cell/ml and were subcultured every third
day. Only cells with at least 95% viability were used.
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3. Preparation of Sf9 cell membranes containing recombinant receptors. To produce
Sf9 cell membranes containing recombinant receptors Sf9 insect cells were infected at a density
of 3.0 x 106 c/ml with a recombinant baculovirus expressing receptors of interest at a 2-fold
multiplicity of infection. M1 and M2 muscarinic receptor baculoviruses were the kind gift of Dr.
Elliot Ross (University of Texas Southwestern Medical Center, Dallas, Texas). Cells were
harvested 48-60 hrs postinfection depending on cell density and viability. Cells were harvested at
4°C by centrifugation at 170xg (IEC Centrifuge) for 7.5 minutes. Then cells were washed three
times in ice-cold IPBS (7.3 mM NaH2PO4, 60 mM KCI, 47 mM NaCl, 2.0 mM CaCl2, pH 6.2),
resuspended in SGHB1 buffer (10 mM Tris/HCl, 25 mM NaCl, 10 mM MgCl2, 1 mM EGTA,
pH 8.0) with protease inhibitors (2 mg/ml aprotinin, 20 mg/ml benzamidine, 2 mg/ml leupeptin,
2 mg/ml pepstatin and 0.1 mM PMSF) at 0.25 - 0.5 g/ml and snap-frozen in liquid nitrogen. To
prepare membranes cell pellets were thawed in 15x their wet weight of ice-cold SGHB1 buffer
with protein inhibitors and burst by nitrogen cavitation (600 psi, 20 minutes). Cavitated cells
were centrifuged at 4°C for 10 minutes at 500xg to remove the unbroken nuclei and cell debris.
The supernatant from the low speed spin was centrifuged at 4°C for 30 min at 28,000xg. The
supernatant was discarded and the pellets were resuspended in 35 ml of HE buffer (5 mM Hepes,
1 mM EDTA, pH 7.5) with protein inhibitors at concentrations indicated above for each pellet.
The membranes were then washed twice, resuspended in the HE buffer at 1-3 mg protein/ml,
snap frozen in liquid nitrogen and stored at -70°C.
4. Urea stripping of Sf9 membranes expressing M1 muscarinic receptors. Sf9 cell
membranes expressing M1 receptors require treatment with 6 M urea in order to couple with
recombinant Gq. The successful use of this method has been reported before (Hartman and
Northup, 1996; Hellmich et al., 1997; Lindorfer et al., 1998). However the role of urea in this
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process is not clear. One of the possible mechanisms of urea action is inactivation of endogenous
G proteins which interfere with receptor coupling. Another possible mechanism is inactivation of
other membrane proteins which regulate G protein-receptor coupling. For urea stripping,
membranes were thawed, resuspended at about 0.15 µg/µl in binding buffer (50 mM Tris/HCl,
pH 7.5, 5 mM MgCl2, 0.5 mM EDTA) with 120 µM OXO-M and 6 µM GTPγS and incubated
for 30 min at 25°C. Then membranes were centrifuged at 288,000xg for 30 min at 4°C, pellets
were resuspended at approximately 0.6 µg/µl in stripping buffer (HE + 6M Urea, added fresh)
and extracted on ice for 30 minutes. The extract was centrifuged at 142,000xg for 30 min and
4°C and pellets were washed once in HE buffer. Membranes were resuspended in HE buffer at
concentration of about 2 µg/µl and snap frozen in liquid nitrogen. Table I shows the examples of
M1 receptor preparations. After urea treatment about 60% of protein was lost and receptor
number increased. Urea stripping significantly reduced agonist binding by control membranes
(Figure 1). In many cases agonist binding by control membranes was not significantly different
from non-specific binding. Urea treatment significantly improved M1-Gq reconstitution and was
used routinely for the production of M1 receptors. Importantly, the EC50 for Gq interaction with
M1 receptor was 66±23.5 nM (see Results Part I), which is comparable with EC50 of Gi1-M2
interactions (47±4.3 nM) and experimentally useful.
5. Urea stripping of Sf9 membranes expressing M2 muscarinic receptors. Urea
stripping is not required for M2 receptor coupling and it was not used routinely. After urea
stripping about 34% of membrane protein was lost and receptor number did not increase (25.1
pmol/mg before urea treatment and 25.7 pmol/mg after urea treatment for one preparation). The
KD for antagonist NMS also did not significantly change after urea stripping (0.78 nM before and
0.56 nM after). The basal binding to control membranes after urea treatment decreased to the
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level of nonspecific binding resulting in the bigger affinity shift (described in section 12). Figure
3 shows the effect of urea treatment on agonist OXO-M binding to Sf9 cell membranes
expressing M2 muscarinic receptors. Interestingly, our results demonstrate that urea stripping
markedly changes the EC50 of M2-Gi1 interactions making it harder to saturate the receptor
(Figure 3). The EC50 for interaction between Gi1 and unstripped M2 receptor is 47±4.3 nM
(n=8), while EC50 for the urea stripped M2 receptor is 412±5.5 nM (n=2).
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Prep
Number

Before Urea Stripping

After Urea Stripping

BMAX

KD

BMAX

KD

% Protein
Lost

JS-86

5.8 pmol/mg

0.1 nM

7.8 pmol/mg

0.15 nM

63 %

JS-100

5.3 pmol/mg

0.1 nM

6.1 pmol/mg

0.15 nM

69 %

JS-118

5.3 pmol/mg

0.1 nM

6.4 pmol/mg

0.12 nM

65 %

JS-184

N/D

N/D

6.3 pmol/mg

0.17 nM

60 %

JS-229

N/A

N/A

16.4 pmol/mg

0.2 nM

N/A

JS-298

10.9 pmol/mg

0.2 nM

18 pmol/mg

0.3 nM

59 %

JS-336

10.1 pmol/mg

0.2 nM

23 pmol/mg

0.35 nM

66 %

TABLE I. Urea stripping of M1 Muscarinic Receptors. Sf9 cell membranes expressing M1
muscarinic receptors (before urea stripping) were treated with 6M Urea as described in section 4
(Urea stripping of Sf9 membranes expressing M1 muscarinic receptors) and characterized (after
urea stripping). Receptor number (BMAX) and antagonist affinity (KD) were determined as
described in section 10 (Receptor number) using radiolabeled antagonist [3H]-NMS. Protein
concentration was determined using BCA protein assay with BSA as a standard. N/A – data not
available because receptor preparation and urea striping were done in one step. N/D – not done.
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[3H]-OXO-M Bound (fmol/mg)

M1 receptors
175
150

unstripped
stripped

125
100
75
50
25
0

control

Gq

FIGURE 1. Effect of urea stripping on agonist binding to M1 receptors. Agonist binding to
the Sf9 cell membranes expressing M1 muscarinic receptors (JS-86 before stripping and JS-100
after stripping in Table I) was measured in the presence of 5 nM [3H]-OXO-M. 0.18 pmol of
unstripped receptor (expression level 5.8 pmol/mg) and 0.07 pmol of stripped receptor
(expression level 6.1 pmol/mg) in the final volume of 150 µl was used. Data are mean±SEM
from 3-4 experiments where Gq was present in 150 molar excess over receptors. Agonist binding
to control membranes after urea stripping was significantly (p<0.01, t test) lower than agonist
binding to unstripped membranes.
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[3H]-OXO-M Bound (fmol/mg)

M2 receptors
4000

unstripped
stripped

3000
2000
1000
0

control

Gi1

FIGURE 2. Effect of urea stripping on agonist binding to M2 receptors. Agonist binding to
the Sf9 cell membranes expressing M2 muscarinic receptors was measured in the presence of 4.3
nM [3H]-OXO-M. 0.27 pmol of unstripped receptor (expression level 25.1 pmol/mg) and 0.25
pmol of stripped receptor (expression level 25.7 pmol/mg) in the final volume of 150 µl was
used. Gi1 is present in 70 fold molar excess over receptors. Agonist binding to stripped
membranes was significantly (p<0.001, t test) lower than agonist binding to unstripped
membranes. Data are mean±SD from one experiment performed in triplicates.
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FIGURE 3. Effect of urea stripping on M2-Gi1 reconstitution. Membranes expressing M2
receptors were reconstituted with increasing amounts of Gi1 heterotrimers and high affinity
agonist binding was determined as described in section 11 (Gα saturation experiments). EC50 for
M2-Gi1 interactions was determined from the data fit to a single-site interaction model between
receptor and G protein. Data points represent the mean±SD of triplicate determinations from a
representative experiment. The concentrations of [3H]-OXO-M were 4.5-6 nM in all
experiments. A. Unstripped M2 receptors. Apparent affinity between unstripped M2 receptor
and Gi1 is 47.0±4.3 nM (mean±SEM, n=8). The final concentration of unstripped receptor in
representative experiment shown here was 0.82 nM in a final volume of 150 µl. The highest
concentration of G proteins represents a 407 fold molar excess over unstripped receptors. B.
Stripped M2 receptors. Apparent affinity between stripped M2 receptor and Gi1 is 412±5 nM
(mean±SEM, n=2). The final concentration of stripped receptor was 2 nM in a final volume of
150 µl. The highest concentration of G proteins represents a 390 fold molar excess over stripped
receptors.
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6. Expression and purification of G protein α and βγ subunits. G protein Gi1α and
Gβ1γ2 subunits were expressed in Sf9 insect cells and purified using a Waters advanced
purification system as described before (Graber et al., 1992a; Graber et al., 1992b). The major
difference in Gi1α purification from Gq purification described below is that Gi1α was purified
from the supernatant obtained after the first high-speed centrifugation and Gq was purified as a
detergent extracted Gqαβ1γ2HIS heterotrimer.
To produce Gq, Sf9 cells were infected with Gqα, Gβ1 and Gγ2HIS baculoviruses at a
multiplicity of infection 1:1:1, as described by Kozasa and Gilman (Kozasa and Gilman, 1995).
Cells were harvested about 72 hrs postinfection using the same procedure as described for
receptor harvest except 10 µM GDP was added to the final resuspension buffer. To prepare Gq,
cell pellets were thawed in 15x their wet weight of ice-cold homogenization buffer (50 mM
Tris/HCl, pH 8.0, 10 µM GDP, 2 mg/ml aprotinin, 20 mg/ml benzamidine, 2 mg/ml leupeptin, 2
mg/ml pepstatin and 0.1 mM PMSF), burst by nitrogen cavitation (600 psi, 20 minutes) and
centrifuged at 100,000xg for 60 min and 4°C. The pellets were extracted for 1 hr in extract buffer
(50 mM Tris/HCl, pH 8.0, 10 µM GDP, 2 mg/ml aprotinin, 20 mg/ml benzamidine, 2 mg/ml
leupeptin, 2 mg/ml pepstatin, 0.1 mM PMSF, 5mM BME, 1% CHAPS) and centrifuged at
100,000xg for 45 min and 4°C. Gq was purified from the detergent extract using a Waters
Advanced Purification System with all steps done at 4°C. Purification traces are shown in
Figure 4. The supernatant was filtered and loaded onto a 30 ml AP-2 DEAE anion exchange
column. DEAE buffers contained 50 mM Tris, pH 8.0, 0.7% CHAPS, 5 mM BME and 10 µM
GDP. Proteins were eluted with 4 column volumes of a linear gradient from 0-400 mM NaCl
(Figure 4A). Fractions containing G proteins (as indicated by anti Gqα immunoblotting in pilot
experiments, fractions 2-17 in Figure 4A) were pooled and mixed with 2 ml of Ni-NTA
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Superflow resin (4 ml of 50% slurry). The resin was incubated for at least 1hr and loaded into a
15 ml column. The resin was washed with buffer A (20 mM Hepes, pH 8.0, 5 mM Imidazole, 1
mM MgCl2, 100 mM NaCl, 5mM BME, 10 µM GDP, 0.7% CHAPS), then buffer B (the same as
buffer A but with 300 mM NaCl), then buffer A. Each step continued until the baseline was flat
for at least 10 ml. Bound proteins were eluted with buffer C (20 mM Hepes, pH 8.0, 150 mM
Imidazole, 1mM MgCl2, 25 mM NaCl, 5 mM BME, 0.7 % CHAPS) (Figure 4B). Eluate was
diluted 3 times with Q buffer A (20 mM Hepes, pH 8.0, 2 mM MgCl2, 1mM DTT, 0.7%
CHAPS) and loaded onto a 8 ml AP-1 QHR15 anion exchange column. Fractions were eluted
with 4 volumes of linear NaCl gradient from 0-400 nM. Free β1γ2HIS subunits were eluted at 100125 mM NaCl and Gαqβ1γ2HIS heterotrimers were eluted at 200-220 mM NaCl (Figure 4C).
Fractions were concentrated using Amicon-30 concentrators, snap-frozen in liquid nitrogen and
stored at -70°C. Fractions were resolved by SDS-PAGE and immunobloted using anti-αq and
anti-β1 antibodies. Protein concentration was determined using the BCA method with BSA as a
standard. Both Gqαβ1γ2HIS heterotrimers and β1γ2HIS subunits were used in the reconstitution
studies. Figure 5 shows Coomassie Blue stained Gqαβ1γ2HIS heterotrimers (lane 9) and β1γ2HIS
subunits (lane 8) resolved on a 12% SDS-polyacrylamide gel. Gqα was purified from Gq
heterotrimers by elution from Ni-NTA Superflow resin with 10 mN NaF/50 µM AlCl3 (20 mM
Hepes, pH 8.0, 10 mM MgCl2, 100 mM NaCl, 5 mM BME, 0.7 % CHAPS, 10 µM GDP, 10 mM
NaF/50 mM AlCl3) at room temperature. In addition, before 10 mN NaF/50 µM AlCl3 elution
Ni-NTA resin was washed with 10 µM GTPγS to elute endogenous Gα proteins. Ni-NTA eluate
was diluted 3 times with Q buffer A (20 mM Hepes, pH 8.0, 2 mM MgCl2, 1mM DTT, 0.7%
CHAPS) and loaded onto a 8 ml AP-1 QHR15 anion exchange column. Fractions were eluted
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with 4 volumes of linear NaCl gradient from 0-400 nM. Gqα subunits were eluted at 80-100 mM
NaCl. Coomassie Blue stained Gqα is shown in Results section Part I Figure 1C.
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FIGURE 4. Gqαβ
αβ1γ2HIS column purification traces. Gqαβ1γ2HIS and Gβ1γ2HIS were purified as
described in Section 6. A. DEAE AP-2 column (30 ml), B. Ni-NTA column (2 ml), C. QHR15
AP-1 column (8 ml).
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FIGURE 5. Gqαβ
αβ1γ2HIS purification. Protein samples (10 µg for lanes 1-7) from different
stages of Gq purification were separated on 12% SDS-polyacrylamide gel and visualized with
Coomassie Blue stain. Lane 1 – homogenate, lane 2 – supernatant from the first 100,000xg
centrifugation, lane 3 – pellet from the first 100,000xg centrifugation in 1% CHAPS, lane 4 –
pellet from the second 100,000xg centrifugation, lane 5 – supernatant from the second 100,000xg
centrifugation (1% CHAPS extract), lane 6 – DEAE column pool, lane 7 – Ni-NTA column pool,
lane 8 – QHR15 column β1γ2HIS (5 µg), lane 9 – QHR15 column Gqαβ1γ2HIS (10 µg).
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The chimeric Gtα/Gi1α and C terminal Gi1α/Gqα subunits were constructed, expressed
in E.coli and purified in the laboratory of Dr. Heidi Hamm at Northwestern University (currently
at Vanderbilt University Medical Center, Nashville, TN) (Bae et al., 1997; Bae et al., 1999;
Skiba et al., 1996). To construct Gtα/Gi1α and Gi1α/Gqα chimeric genes, E.coli expression
vectors pHis6Gi1α, pHis6Gtα or pHis6Gqα (contain Gi1α, Gtα or Gqα cDNA respectively,
preceded by a nucleotide sequence encoding a hexahistidine tag under the control of a T7
promoter) were used. Chimeric genes were constructed by insertion of unique restriction enzyme
sites into Gi1α or Gtα cDNA using PCR amplification with corresponding oligonucleotide
primers followed by replacement of Gi1α cDNA fragments with corresponding Gtα cDNA or
Gqα cDNA fragments or vice versa. Insertion of new restriction sites has not changed protein
sequences. The hexahistidine tag was used to facilitate purification. Chimeric α subunits were
expressed in E.coli BL21(DE) cells and purified from cell lysates by sequential chromatography
on Ni-NTA resin (His-bond, Novagen) followed by AP-1 QHR15 anion exchange column
(Waters Chromatography). Protein purity was verified by SDS-PAGE and protein concentrations
were determined using the Coomassie Blue method. All the chimeras were active as indicated by
AlF4--dependent conformational change of α subunits in a Fluorescence Assay and GTPγS
binding (Bae et al., 1997; Bae et al., 1999; Skiba et al., 1996).
The Gqi5C recombinant baculovirus was constructed using a plasmid kindly provided by
Dr. Bruce Conklin (Gladstone Institute of Cardiovascular Disease, University of California, San
Francisco). Gqi5C (~1kb) was cut out of pcDNA1 vector using Bam HI and Nsi I and subcloned
into Bam HI/Pst I sites of pVL1393 baculovirus transfer vector (~9.6 kb). This was possible
because Nsi I and Pst I have compatible cohesive ends. After ligation Bam HI site was preserved
and Pst I site was converted to Bgl II site (unique in pVL1393). The pVL1393qi5C construct was
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verified by sequencing. The Gqi5C construct could be cut out of pVL1393 using Bam HI and
Bgl II. However because Gqi5C has an internal Bgl II site, pVL1393qi5C (~10.6 kb) digestion
with Bam HI and Bgl II resulted in production of 3 fragments (~9.6 kb, 834 kb and 258 kb) as
shown in Figure 6A. For production of recombinant virus by homologous recombination
pVL1393Gqi5C was co-transfected with Bac-N-BlueTM DNA (Invitrogen) into Sf9 insect cells.
Recombinant qi5C baculovirus was plaque purified and analyzed by PCR to verify the presence
of insert and to confirm the isolation of pure recombinant plaque. PCR of qi5C viral DNA is
shown in Figure 6B. As expected, PCR of both pVL1393qi5C (used as a positive control) and
qi5C viral DNA resulted in the ~1378 bp product. Restriction of the PCR products from both
pVL1393qi5C and qi5C viral DNA with Bam HI, Bgl II and Afl II (unique to qi5C) resulted in
the production of the same size fragments, further confirming the production of qi5C baculovirus
(Figure 6B). Gqi5 was expressed together with β1γ2HIS in SF9 cell membranes and purified by
the same protocol as Gq. The construction and expression of the q6N and q6N35C chimeric Gα
subunits is described in the Chapter III Part I.
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FIGURE 6. Gqi5C construct visualized on 1% TAE agarose gel stained with ethidium
bromide. A. pVL1393qi5C. Lane 1 – 1kb ladder, lane 2 – uncut pVL1393qi5C, lane 3 –
pVL1393qi5C cut with Bam HI and Bgl II, lane 3 – 100 bp ladder. B. PCR analysis of
recombinant qi5C baculovirus. 0.5 µl from PCR reactions of pVL1393qi5C (lanes 2-5) or qi5C
baculoviral DNA (lanes 8-10 and 12) were loaded on the gel. PVLF and PVLR primers
(Invitrogen) were used. Lane 1 – 1kb ladder, lane 2 - uncut pVL1393qi5C, lane 3 pVL1393qi5C cut with Bam HI, lane 4 - pVL1393qi5C cut with Bgl II, lane 5 - pVL1393qi5C
cut with Afl II, lanes 6, 7 – empty, lane 8 – qi5C baculovirus, lane 9 - qi5C baculovirus cut with
Bam HI, lane 10 - qi5C baculovirus cut with Bgl II, lane 11 – empty, lane 12 - qi5C baculovirus
cut with Afl II, lane 13 – 100 bp ladder.
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7. Fluorescence assay. To measure the folded state of chimeric Gα and to test the ability
of Gα to undergo conformational change indicative of activity, intrinsic fluorescence was
measured with a QM-2000-4 spectrofluorimeter (PTI fluorescence system hardware and Felix
software) at room temperature in a buffer containing 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2
mM MgCl2 and 1µM GDP. The AlF4--dependent conformational changes of activated Gα
subunits were monitored by intrinsic tryptophan fluorescence changes with excitation at 280 nm
and emission at 340 nm. The relative increase in fluorescence of 400 nM Gα subunits was
determined from absorbance readings before and after addition of 10 mM NaF and 20 µM AlCl3
in a total volume of 100 µl. The increase in fluorescence was calculated as ∆F% = (F - Fo)/Fo x
100%. Gi1α contains tryptophans at the positions W131, W211, W258; Gtα at the positions
W127, W207; Gqα at the positions W136, W216, W263. The relative change in intrinsic
fluorescence for individual Gα subunits is consistent with the literature (Skiba et al., 1996) and
as follows: Gi1 48.3±3.2 (n=11), q6N 45±12.2 (n=8), q35C 56.7±5.2 (n=3), q6N35C 54.5±15.6
(n=4), qi5C 47.7±8.4 (n=3), Gq 50±22.9 (n=4). Figure 7 shows an example of the fluorescence
spectra of Gi1α.
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AlF4-

FIGURE 7. Intrinsic tryptophan fluorescence of Gi1α
α. The relative increase in fluorescence
of 400 nM Gi1α was measured before and after the addition of 10 mM NaF and 20 µM AlCl3 in
a total volume of 100 µl. Excitation wavelength was 288 nm, emission wavelength was 341 nm.
Fo = 711.6 counts/sec, F = 913 counts/sec, ∆F% = 28%.
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8. Reconstitution of receptors with G proteins. Frozen membranes were thawed, pelleted
in a refrigerated microcentrifuge at 12,000 rpm for 10 minutes and resuspended at 5-10 mg/ml in
the reconstitution buffer (5 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 500
nM GDP, 0.08% CHAPS). To produce G protein heterotrimers α and βγ subunits were mixed at
the ratio 1 α to 1.3 βγ and diluted in the reconstitution buffer in order to keep reconstitution
volume the same for each sample. G protein heterotrimers were added to the membranes at the
60–200 fold molar excess over the recombinant receptors as indicated by saturation experiments.
The mixture was incubated at 25°C for 20 minutes and held on ice until the start of the binding
assay.
9. Radioligand binding assay. Just prior to the start of the binding assay the reconstitution
mixture was diluted 10-12 fold with binding assay buffer appropriate to the receptor of interest
such that the desired amount of membranes (5-25 µg/assay tube) were contained in 10-50 µl.
Binding buffer was 50 mM Tris, 5 mM MgCl2, 0.5 mM EDTA, pH 7.5. Agonist binding was
determined in the presence of the 5 nM [3H]-OXO-M. Antagonist binding was determined in the
presence of [3H]-NMS. Non-specific binding was determined by addition of 1000-fold excess of
unlabeled ligand atropine sulfate. Incubations were for times sufficient to achieve equilibrium in a
temperature controlled shaker (1 hr) and were terminated by filtration over Whatman GF/C filters
using a Brandel Cell Harvester. The filters were rinsed thrice with 4 ml ice cold 50 mM Tris-Cl,
5 mM MgCl2, 0.5 mM EDTA, 0.01% NaAzide, pH 7.5 at 4 °C, placed in 4.5 ml CytoScint (ICN
Pharmaceuticals, Costa Mesa, CA) and counted to constant error in a scintillation counter.
10. Receptor number. Muscarinic receptor number was determined in the presence of
antagonist [3H]-NMS at concentrations 0.02-8 nM of free [3H]-NMS in a total volume of 500 µl.
Because antagonists do not distinguish between high and low receptor affinity states,
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reconstitution of receptors with G proteins was not required to determine receptor number.
Receptor number (BMAX) and antagonist affinity constant (KD) were derived from the data fit to
the one-site interaction model between receptor and ligand as shown in Figure 8.
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FIGURE 8. Antagonist saturation binding isotherm for M1 and M2 muscarinic receptors.
Data points represent the mean±SD of triplicate determinations from a representative experiment.
Data fit to a single-site interaction model between receptor and ligand. Receptor number and KD
for [3H]-NMS were determined from nonlinear regression analysis. A. M1 receptors. M1
receptor number was determined in the presence of [3H]-NMS at concentrations 0.02-7.3 nM of
free [3H]-NMS in a total volume 500 µl. 11.3 µg of membrane protein/tube was used. B. M2
receptors. M2 receptor number was determined in the presence of [3H]-NMS at concentrations
0.02-7.8 nM of free [3H]-NMS in a total volume 500 µl. 11 µg of membrane protein/tube was
used.
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11. Gα saturation binding experiments. To determine the concentration of Gα needed to
saturate the affinity shift, increasing amounts of G protein heterotrimers were added to the
receptors in the reconstitution and the agonist binding was detected in the binding assay.
Typically, 7 different G protein concentrations in triplicates in the range 10-500 nM were used.
EC50 were generated from nonlinear regression analysis from the data fit to a one site interaction
model between receptor and G protein. An example of Gα saturation binding experiment is
shown in Figure 3.
12. Affinity shift activity assay. M1 and M2 muscarinic receptors exhibit two affinity
states for the agonist Oxotremorine-M with the majority of receptors in the low affinity state. For
affinity shift assay the Sf9 cell membranes expressing individual receptors were reconstituted
with saturating amounts of G protein heterotrimers (60-200 fold molar excess over receptors) as
determined by Gα saturation binding experiments to achieve the maximal specific binding during
the binding assays. For reconstitution of high affinity agonist binding, a single concentration (~5
nM) of [3H]-OXO-M near the high affinity KD of the receptor was used in a final volume of 150
µl. Addition of complete heterotrimers (Gq for M1 receptors and Gi1 for M2 receptors) converted
the low affinity agonist state to the high affinity state, while the addition of 50 µM GTPγS
(functional analog of GTP) disrupted G protein-receptor coupling as shown in Figure 9, which is
in agreement with the ternary complex model. In order to compare the functional interactions of
different G proteins with receptors we express the data as affinity shift activity. We define affinity
shift as the fold-enhancement above buffer controls of high affinity agonist binding in membranes
expressing recombinant receptors reconstituted with G protein heterotrimers. Therefore subunits
that can't stabilize the high affinity state of receptors for agonist (as well as buffer control) will
have an affinity shift activity of 1 and the active subunits will have an affinity shift activity
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significantly greater then 1. The affinity shift activity depends on the variety of factors including
the magnitude of the affinity shift, the actual concentration of agonist used in the assay, the
number of expressed receptors coupled with endogenous G proteins and the number of expressed
receptors coupled by the addition of exogenous G proteins.
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FIGURE 9. Affinity shift activities of M1 and M2 muscarinic receptors. Affinity shift
activity represents the –fold enhancement above buffer controls of high affinity [3H]-OXO-M
binding in membranes expressing M1 (A) or M2 (B) muscarinic receptors reconstituted with G
protein heterotrimers containing the indicated Gα subunit. The concentrations of [3H]-OXO-M
were 4.5-6 nM in all experiments. 50 µM GTPγS was used to disrupt the formation of the ternary
complex. Assay volume was 150 µl. A. M1 receptors. Data represent the mean±SEM from 2-3
experiments performed in triplicates. Gi1±GTPγS was done once (in triplicates). B. M2
receptors. Data represent the mean±SEM from 2-16 experiments performed in triplicates.
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13. Agonist competition binding experiments. Competition binding experiments with a
single concentration of radiolabeled antagonist and the increasing concentrations of non-labeled
agonist were performed to determine the extent of receptor coupling with individual G proteins
and to find the KD for the high and low affinity states for agonist. Receptors were reconstituted
with G proteins at saturating concentrations. Binding assay was performed in the presence of the
agonist OXO-M as a competitor. The 22 different concentrations (in duplicates) of OXO-M were
equally spaced on the log scale in the concentration range 10-12-3X10-2 M. Data were analyzed
by nonlinear regression. Data reported are the result of the best fit (one-site vs. two-sites
inhibition fit) as determined by the F test. The Cheng-Prusoff correction (Ki=IC50/1+[ligand]/KD)
was used to calculate KD values. Figure 10 shows the results of competition binding experiments
for M1 receptor control membranes and M1 receptors reconstituted with Gq, and M2 receptors
control membranes and M2 receptors reconstituted with Gi1. Agonist competition experiments
with control membranes were best fit to a one-site interaction model (low affinity sites), while
agonist competition experiments with membranes reconstituted with G proteins were best fit to a
two-site interaction model (high and low affinity sites). Table II shows the coupling parameters
derived from the agonist competition experiments of M1 and M2 Muscarinic receptors
reconstituted with different G proteins described in the latter Chapter III.
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FIGURE 10. Agonist competition binding against a fixed concentration of radiolabeled
antagonist for M1 (A) and M2 (B) muscarinic receptors. [3H]-NMS binding to control
membranes (no exogenous G proteins) or to membranes reconstituted with 200 fold excess of G
proteins over receptors was measured in a final volume of 500 µl. Concentrations of [3H]-NMS
(around 0.8 nM for M1 receptor and 2 nM for M2 receptor) were 4 times the KD of [3H]-NMS for
a particular receptor preparation. Increasing concentrations of OXO-M (in duplicates) in the
range 10-12-3x10-12 M were used. Data were analyzed by nonlinear regression and an F-test was
used to compare one-site vs. two-site fits. The Cheng-Prusoff correction was used to calculate
KD values. Agonist competition experiments with control membranes were best fit to a one-site
interaction model, while agonist competition experiments with membranes reconstituted with G
proteins were best fit to a two-site interaction model. Data points shown here are the results of
representative experiments. A. M1 receptors. The KD values in control membranes were
19.1±2.7 µM (n=2) which was not different from the low affinity KD obtained from the 2-site fits
with membranes reconstituted with Gq. Gq coupled 18±2.3% (n=2) of M1 receptors with high
affinity KD of 14.1±12.3 nM (n=2) and the low affinity KD of 14.3±2.9 µM (n=2). B. M2
receptors. The KD values in control membranes were 8.6±2.2 µM (n=2) which was not different
from the low affinity KD obtained from the 2-site fits with membranes reconstituted with Gi1.
Gi1 coupled 38.5±5.6% (n=3) of M2 receptors with high affinity KD of 2.6±2.2 nM (n=3) and
the low affinity KD of 3.3±0.9 µM (n=2).
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TABLE II. Coupling parameters of M1 and M2 Muscarinic Receptors with Gα
α Subunits

Gα
Gi1

M1 Receptors

M2 Receptors

% R High

KD High

KD Low

12.9±3.9 % (2)

8.9±8.9 nM (2)

6±2.1 µM (2)

*

% R High

KD High

KD Low

38.5±5.6 % (3)

2.6±2.2 nM (3)

3.3±0.9 µM (3)

*

38.3±4.5 % (2)

1.4±0.5 nM (2)

2.3±0.1 µM (2)

*

q6N

26.6±1.2 % (2)

30.2±11.3 nM (2)

4.3±0.9 µM (2)

q6N35C

24±6.3 % (3)

6.5±6.2 nM (3)

2.6±1.7 µM (3)

27.3±6.8 (5)

240 ±128 nM (5)

10.1±3.1 µM (5)

Gq

18±2.3 % (2)

14.1±12.3 nM (2)

14.3±2.9 µM (2)

7.4±0.2 % (2)

0.04±0.01 nM (2)

9.6±1.9 µM (2)

Control





19.1±2.7 µM (2)





8.6±2.2 µM (2)

Data derived from the competition binding experiments between a single concentration of radiolabeled antagonist [3H]-Scopolamine
methyl chloride and increasing concentrations of non-labeled agonist Oxotremorine M. Receptors were reconstituted with saturating
amounts of G proteins as indicated by Gα Saturation experiments. Agonist concentrations (22 data points in duplicates) were equally
spaced on the log scale in the range of 10-12-3X10-2 M. Data were analyzed by nonlinear regression and an F test was used to compare
one-site vs. two site fits. The Cheng-Prusoff correction was used to calculate KD values. Agonist competition experiments with
control membranes (no exogenous G proteins) were best fit to a one-site interaction model. The low affinity KD obtained from the 2site fits with the reconstituted membranes did not differ significantly from the KD values in control membranes (Tukey’s Multiple
Comparison Test) with the exception of Gi1, q6N q6N35C and with M1 membranes (*- p<0.05). Data shown are the mean ± SEM
from 2-5 independent experiments.
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14. Receptor stimulated [35S]-GTPγS binding assay. A GTPγS binding assay was used to
analyze receptor-catalyzed GDP/GTP exchange on G protein α subunits. Typically 1.3 pmol of
receptors was reconstituted with 80 pmol of G protein heterotrimers (1.3 fold excess of αover
βγ) for 15 min at 30°C in reconstitution buffer (25 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM
MgCl2, 1 mM EDTA, 200 nM GDP, 0.08% CHAPS). After reconstitution the mixture was
diluted 10 fold with GTPγS Binding buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 25 mM MgCl2,
1 mM DTT, 0.1 mg/ml BSA). Reactions were initiated by the addition of 25 µl of membrane
mixture to 25 µl of GTPγS with or without agonist. Final assay conditions were 50 nM Gα, 0.8
nM receptor, 2 µM GDP, 100 nM GTPγS as a mixture of 1nM [35S]-GTPγS

(~125,000

cpm/well) and cold GTPγS, with or without agonist in a final volume of 50 µl. In experiments
with single agonist concentration 2 µM Oxotremorine-M was used. Use of MultiScreen 96 well
plates (Millipore) allowed collection of samples at 30 second intervals for 4-6 minutes for M2
receptors or 3 minute intervals for 18 minutes for M1 receptors. Filters were rinsed three times
with 100 µl of ice-cold wash buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 25 mM MgCl2)
Radioactivity retained on the filters was counted to constant error in a liquid scintillation counter.
Greater than 1500 cpm were observed at the shortest time points and ligand depletion was less
than 15% at the longest time-points. Data were analyzed by linear regression and agonist driven
GTPγS binding was reported as the ratio of the slopes in the presence and absence of agonist
provided the slopes were significantly different (p < 0.05).

If the slopes did not differ

significantly a value of 1.0 was used for the slope ratio. GTPγS binding in the absence of agonist
represented as moles of GTPγS per mole of receptor.
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15. ADP-Ribosylation of Gα by pertussis toxin. Pertussis Toxin (1.1 µg/µl) was
activated by the addition of an equal volume of activation buffer (5 mM Hepes, pH 7.5, 100 mM
NaCl, 5 mM MgCl2, 1 mM EDTA, 0.08% CHAPS, 40 mM DTT, 2µM GDP) and incubation for
40 min at 32°C. G protein heterotrimers (3 µg α plus 3.6 µg βγ) were ribosylated for 1 hr at 32°C
in a total volume of 20 µl containing 10 µl of activated PTX and 400 µM NAD+. Ribosylation
reactions were reconstituted with membranes under the same conditions described above. At the
end of incubation the mixture was diluted 9 fold with binding assay buffer and used in the
affinity shift assay.
16. Analysis of the data. The data were analyzed using GraphPad Prism software
package (GraphPad Software, San Diego, CA). Data were represented as the mean±SEM from
multiple experiments unless indicated otherwise. One-way ANOVA was used to analyze the
differences in activity between G proteins. Curve fitting was done using nonlinear regression
analysis.
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Abbreviations and Textual Footnotes— 1The abbreviations used are: PLCβ, phospholipase
Cβ; PTX, pertussis toxin; GTPγS, guanosine 5'-3-O-(thio)triphosphate; CHAPS, 3-[(3cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; OXO-M, oxotremorine-M; NMS,
N-methyl scopolamine.
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ABSTRACT
The molecular basis of selectivity of M1 and M2 muscarinic receptor coupling to heterotrimeric
G proteins has been studied using receptors expressed in Sf9 cell membranes and reconstituted
with purified chimeric Gα subunits containing different regions of Gi1α and Gqα. The abilities
of G protein heterotrimers containing chimeric α subunits to stabilize the high affinity state of
the receptors for agonist and to undergo receptor stimulated guanine nucleotide exchange was
compared with G protein heterotrimers containing either native Gi1α or Gqα. The data confirm
the importance of the proper context of the C- terminus of Gα by demonstrating that the Cterminus of Gi1α, when placed in the context of Gqα, prevents coupling to muscarinic M1
receptors, while the C- terminus of Gqα, when placed in the context of Gi1α, prevents coupling
to muscarinic M2 receptors. However, C- terminal amino acids of Gqα placed in the context of
Gi1α were not sufficient to allow M1 receptor coupling nor were C-terminal amino acids of
Gi1α placed in the context of Gqα sufficient for M2 receptor coupling. The unique six amino
acid N- terminal extension of Gqα when added to the N- terminus of Gi1α neither prevented M2
receptor coupling nor permitted M1 receptor coupling. A Gi1α based chimera containing both
N- and C- terminal regions of Gqα gained the ability to productively couple M1 receptors
suggesting that the proper context of both N- and C- termini is required for muscarinic receptor
coupling.
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INTRODUCTION
Heptahelical receptors transfer a variety of extracellular signals to intracellular effectors
by coupling to heterotrimeric guanine nucleotide-binding proteins (G proteins) (Gilman, 1987).
The mechanisms responsible for selectivity in G protein mediated signaling pathways remain
poorly understood (Wess, 1998). Direct contacts with receptors have been demonstrated for both
α and βγ subunits (Phillips and Cerione, 1992; Heithier et al., 1992; Conklin and Bourne, 1993;
Kisselev et al., 1994; Taylor et al., 1996; Azpiazu et al., 1999; Ernst et al., 2000). Although
recent evidence suggests both β and γ interact selectively with receptors (Kisselev et al., 1995;
Yasuda et al., 1996; Richardson and Robishaw, 1999; Hou et al., 2000), the α subunits appear to
play a more prominent role in establishing the selectivity of G protein-receptor coupling. Using
different receptor systems and various methodologies the C- terminus and α5 helix (Hamm et
al., 1988; Conklin et al., 1993; Gilchrist et al., 1998; Natochin et al., 2000), N- terminus and αN
helix (Kostenis et al., 1997a; Swift et al., 2000), α4 helix and α4/β6 loop (Bae et al., 1997), α2
helix and α2/β4 loop (Lee et al., 1995) and α3/β5 loop (Grishina and Berlot, 2000) domains of
Gα subunits have been shown to be involved in receptor coupling.
Muscarinic receptors are typical Class I heptahelical receptors. When expressed in Sf9
cells they demonstrate structural integrity and display the expected ligand binding properties
(Dong et al., 1995; Weill et al., 1997). The family of human muscarinic receptors includes five
molecularly distinct members. M1, M3, and M5 are Gq/11 coupled receptors that stimulate
phospholipid breakdown through activation of phospholipase Cβ (PLCβ)1, while M2 and M4 are
Gi/o coupled receptors that mediate the inhibition of adenylyl cyclase and activation of K+
channels (Wess, 1996; Hosey et al., 1999). Muscarinic receptors also regulate additional
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signaling processes, including stimulation of MAP kinase pathways and regulation of other ion
channels (Gutkind, 1998; Hosey et al., 1999).
The C- terminus of Gα subunits is the most studied determinant of receptor coupling
selectivity to date. Numerous studies including transfection experiments (Conklin et al., 1993),
synthetic peptide competition experiments (Hamm et al., 1988), ADP-ribosylation of Gα by
Pertussis toxin (PTX) (West, Jr. et al., 1985) and direct reconstitution studies (Natochin et al.,
2000) indicate that the extreme C- terminus of Gα interacts with receptors. With respect to
selectivity, Conklin, Bourne and Wess demonstrated that substitution of the last 3-5 C- terminal
residues of Gqα with the corresponding sequences of Giα, Goα or Gzα allowed PLCβ
stimulation by A1 adenosine, D2 dopamine, α2 adrenergic and M2 muscarinic receptors, which
are normally coupled to Gi/o family members (Conklin et al., 1993; Liu et al., 1995).
Furthermore, site-directed mutagenesis revealed receptor contact sites for the C- terminus of Giα
and Gqα on M2 and M3 muscarinic receptors respectively (Liu et al., 1995; Kostenis et al.,
1997b; Kostenis et al., 1997c). The N- terminus of Gα has also been shown to be a determinant
of G protein-receptor coupling selectivity (Hepler et al., 1996; Kostenis et al., 1997a; Swift et
al., 2000). Importantly, Kostenis et al. suggested a role for the unique N- terminal extension of
Gqα in constraining receptor coupling selectivity by showing that deletion of the six N- terminal
amino acids of Gqα (MTLESI) led to promiscuous coupling of this Gq mutant with several Gi/o
and Gs coupled receptors (Kostenis et al., 1997a).
Our study directly examines the interactions of M1 and M2 Muscarinic receptors with Gq
and Gi1 proteins in an Sf9 cell membrane based reconstitution system in which the coupling
behavior of receptors of interest can be studied by reconstitution with exogenously supplied,
purified G protein subunits (Clawges et al., 1997). This system allows the analysis of both the
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ability of G proteins to stabilize the high affinity state of receptor for agonist and the ability of
the receptors to catalyze guanine nucleotide exchange on Gα. Our results show that the Cterminus of Gα although critical, is not sufficient for M1 or M2 receptor coupling. Furthermore,
the six amino acid N- terminal extension of Gqα neither allow M1 receptor coupling nor
constrain M2 receptor coupling. In summary, the data suggest that the appropriate context of
both N- and C- termini is required for selective receptor coupling.
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MATERIALS AND METHODS
Materials. [3H]-Oxotremorine-M (85.8 Ci/mmol) and [35S]-GTPγS (1250 Ci/mmol) were
from New England Nuclear Life Science Products, Inc. (Boston, MA). Molecular biology
enzymes were from New England Biolabs (Beverly, MA). Wild type baculovirus DNA and
lipofectin were from Invitrogen (Carlsbad, CA). Anti-Gαi1/2 C- terminal antibodies were from
Calbiochem-Novabiochem Corporation (San Diego, CA). Anti-Gαi1 internal antibodies and
anti-Gαq/11 C- terminal antibodies were from Santa Cruz Biotechnology. Pertussis Toxin was
from Calbiochem-Novabiochem Corporation (San Diego, CA). The ProtoBlot Western Blot
reagents were from Promega (Madison, WI). The BCA Protein Assay reagents were from Pierce
(Rockford, IL). All other chemicals were from Sigma-Aldrich Corporation (St. Louis, MO) or
Calbiochem-Novabiochem Corporation (San Diego, CA).
Construction of Gα chimeric Genes. H6pQE-60-Gi1Q3C and H6pQE-60-Gi1Q35C
plasmids were the kind gift of Dr. Heidi Hamm (Vanderbilt University, Nashville, TN) and are
based on H6pQE-60-Gi1 originally described by Lee et al (Lee et al., 1994). The pcDNA1Gqi5C plasmid was the kind gift of Dr. Bruce Conklin (Gladstone Institute of Cardiovascular
Disease, University of California, San Francisco). To construct pVLSG-Gi1Q6N the nucleotides
coding for the six N- terminal amino acids of mouse Gαq (MTLESI) were inserted into the
BamH1/Nco1 sites of pVLSG-Gi1 (Graber et al., 1992) using synthetic oligonucleotides to
create a duplex linker. H6pQE-60-Gi1Q3C was used to construct both Gi1Q6N3C and
Gi1Q6N35C. H6pQE-60-Gi1Q3C was digested with EcoR1 and Nco1 and recircularized using
synthetic oligonucleotides to create a duplex linker encoding the six N- terminal amino acids of
mouse Gαq (MTLESI) resulting in the removal of the His6-tag and creation of the intermediate
pQE-60-Gi1Q6N3C. A duplex linker was used to subclone the NcoI/HindIII fragment of pQE77

60-Gi1Q6N3C into NcoI/EcoRI sites of pVLKD. The pVLKD vector was constructed from the
commercially available baculovirus expression vector pVL1393 by removing the BamH1 site
and adding an Nco1 site with a duplex linker between the BamH1 and XbaI sites of the pVL1393
poly-linker. The BamH1/HindIII fragment of H6pQE-60-Gi1Q35C was subcloned into the
BamH1/EcoRI sites of pVLKD-Gi1Q6N3C using a duplex linker. This resulted in the
replacement of the BamH1/HindIII fragment of pVLKD-Gi1Q6N3C with the corresponding
fragment from H6pQE-60-Gi1Q35C creating pVLKD-Gi1Q6N35C. To create pVL1393-Gqi5C,
the BamHI/NsiI fragment coding for Gqi5C was cut from pcDNA1 and subcloned into the
BamHI/PstI sites of pVL1393. All constructs were verified by sequencing and restriction
analysis. PVLSG-Gi1Q6N, pVLKD-Gi1Q6N35C and pVL1393-Gqi5C transfer vectors were
used to create recombinant baculoviruses as described (Graber et al., 1994).
Expression and purification of G protein α and βγ subunits. The chimeric Gi1Q35C α
subunit was constructed, purified after expression in E.coli, and kindly provided by Dr. Heidi
Hamm of Vanderbilt University. While bacterially expressed subunits lack the N- terminal
acylation of native and baculovirus expressed subunits, and contain a HIS6 tag at the extreme Nterminus, their EC50 values for receptor interactions are indistinguishable from those of native or
baculovirus expressed subunits (Bae et al., 1997). Gq was purified as detergent extracted
Gαqβ1γ2HIS heterotrimer from Sf9 cells infected with Gqα, β1 and γ2HIS baculoviruses as
described by Kozasa and Gilman (Kozasa and Gilman, 1995) using sequential chromatography
on DEAE anion exchange, Ni-NTA Superflow resin and QHR15 anion exchange columns. Free
β1γ2HIS subunits were eluted at 100-125 mM NaCl and Gαqβ1γ2HIS heterotrimers were eluted at
200-220 mM NaCl from the QHR15 column. Gqi5 was purified in the same manner as Gq. The
HA-epitope tag present between residues 125 and 130 of Gαqi5C has been shown not to affect
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functionality (Conklin et al., 1993). Gαq and Gαqi5C were purified from heterotrimers by
elution from Ni-NTA Superflow resin with 10 mM NaF/50 µM AlCl3 and final purification on a
QHR15 column. Gi1α was expressed in Sf9 insect cells and purified as described (Bae et al.,
1999). Gi1Q6N and Gi1Q6N35C were expressed and purified from Sf9 cells using identical
procedures as for Gi1α. All G protein α subunits except Gi1Q35C and Gqi5 contained only
native protein sequences.
Intrinsic tryptophan fluorescence assay. An assay was performed to verify that Gα
subunits could bind GDP and adopt the active conformation in the presence of AlF-4 (Skiba et al.,
1996). Intrinsic fluorescence was measured with a QM-2000-4 spectrofluorimeter (PTI
fluorescence system hardware and Felix software) at room temperature in a buffer containing 50
mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM MgCl2 and 1µM GDP. The AlF4--dependent
conformational changes of activated Gα subunits were monitored by intrinsic tryptophan
fluorescence changes with excitation at 280 nm and emission at 340 nm. The relative increase in
fluorescence of 400 nM Gα subunits was determined from absorbance readings before and after
addition of 10 mM NaF and 20 µM AlCl3 in a total volume of 100 µl. The increase in
fluorescence was calculated as ∆F% = (F - Fo)/Fo x 100%. The relative change in intrinsic
fluorescence for individual Gα subunits was consistent with the literature (Skiba et al., 1996)
and as follows: Gi1 48.3±3.2 (n=11), q6N 45±12.2 (n=8), q35C 56.7±5.2 (n=3), q6N35C
54.5±15.6 (n=4), qi5C 47.7±8.4 (n=3), Gq 50±22.9 (n=4). Protein concentrations were
determined using the BCA protein assay with BSA as a standard.
Preparation of Sf9 cell membranes containing recombinant receptors. Baculoviruses
expressing M1 and M2 muscarinic receptors were the kind gift of Dr. Elliott Ross (University of
Texas Southwestern Medical Center, Dallas, Texas). Sf9 cell membranes containing recombinant
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muscarinic receptors were produced as described (Bae et al., 1999). Briefly, Sf9 cells were
infected at a density of 3.0 x 106 cells/ml with a recombinant baculovirus expressing M1 or M2
muscarinic receptors at a 2 fold multiplicity of infection. Infected cells were harvested 60-72 hrs
post-infection for M1 receptors and 48-56 hrs post-infection for M2 receptors. To prepare
membranes, cell pellets were thawed in 15x their wet weight of ice-cold SGHB1 buffer (10 mM
Tris/HCl, 25 mM NaCl, 10 mM MgCl2, 1 mM EGTA, pH 8.0) with protease inhibitors (2 mg/ml
aprotinin, 20 mg/ml benzamidine, 2 mg/ml leupeptin, 2 mg/ml pepstatin and 0.1 mM PMSF) and
burst by nitrogen cavitation (20 minutes at 600 PSI). Cavitated cells were centrifuged at 4°C for
10 minutes at 500xg. The supernatant was centrifuged at 4°C for 30 min at 28,000xg. The pellets
were resuspended in 35 ml of HE buffer (5 mM Hepes, 1 mM EDTA, pH 7.5) with protease
inhibitors. The membranes were washed twice, resuspended in HE buffer at 1-3 mg protein/ml,
snap frozen in liquid nitrogen and stored at -70°C. M1 receptor coupling required removal of
endogenous proteins with 6M Urea essentially as described by Northup (Hartman and Northup,
1996). For urea stripping, membranes were thawed, resuspended at about 0.15 mg/ml in binding
buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 0.5 mM EDTA) with 120 µM Oxotremorine-M
and 6 µM GTPγS, and incubated for 30 min at 25°C. Following centrifugation at 288,000xg for
30 min at 4°C, pellets were resuspended at approximately 0.6 mg/ml in stripping buffer (HE+6M
Urea) and extracted on ice for 30 minutes. The urea extract was centrifuged at 142,000xg for 30
min at 4°C and pellets were washed twice in HE buffer. Urea stripped membranes were
resuspended in HE buffer at a concentration of about 2 mg/ml and snap frozen in liquid nitrogen.
Receptor number in membrane preparations was determined using the muscarinic receptor
antagonist [3H]-N-methyl Scopolamine (NMS) at concentrations from 0.03-8 nM of free [3H]-
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NMS under the same conditions as used in the affinity shift assay (see below). Membrane
protein concentrations were determined using the BCA protein assay with BSA as a standard.
Reconstitution of receptors with exogenous G proteins. Frozen membranes were
thawed, pelleted in a refrigerated microcentrifuge at 10,000xg for 10 minutes and resuspended at
5-10 mg/ml in the reconstitution buffer (25 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1
mM EDTA, 500 nM GDP, 0.08% CHAPS). G protein α and βγ subunits were mixed at a ratio of
1:1.3 and diluted in reconstitution buffer to keep the reconstitution volume the same for each
sample. Typically, 0.8 pmol of receptor was reconstituted with 80 pmol of G protein
heterotrimers (based on Gα). The mixture was incubated at 25°C for 20 minutes and held on ice
briefly until the start of the binding assay.
Affinity Shift Assay. Just prior to the binding assay the reconstitution mixture was diluted
10-12 fold with binding buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 0.5 mM EDTA).
Agonist binding was determined in the presence of 5 nM [3H]-Oxotremorine-M. Non-specific
binding was determined in the presence of 10 µM atropine sulfate. Binding to equilibrium was
for 1 hour at 25°C in a temperature controlled shaker and was terminated by filtration over
Whatman GF/C filters using a Brandel Cell Harvester. The filters were rinsed three times with 4
ml of ice cold wash buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 0.5 mM EDTA, 0.01%
NaAzide), placed in 4.5 ml CytoScint (ICN Pharmaceuticals, Costa Mesa, CA) and counted to
constant error in a scintillation counter. The final concentrations of receptors and G protein
heterotrimers in the binding assay were 1.5-1.7 nM and 150-500 nM respectively, in a final
volume of 150 µl. Specific binding in the absence of exogenous G-proteins averaged 50 DPM
for M1 receptors and 326 DPM for M2 receptors. Because muscarinic receptors exhibit ratios as
high as 30,000-fold for the high and low affinity states for agonists such as oxotremorine M
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(Oxo-M) and acetylcholine (Berrie et al., 1984; Florio and Sternweis, 1989) specific binding for
M1 receptors reconstituted with Gq averaged 1614 DPM while that for M2 receptors
reconstituted with Gi1 averaged 7682 DPM. The actual concentrations of agonist varied slightly
among experiments which resulted in different magnitudes of absolute binding. In order to
compare the results among experiments it was necessary to express the data as affinity shift
activities. Affinity shift is defined as the fold-enhancement above buffer controls of high affinity
agonist binding in membranes expressing recombinant receptors reconstituted with G protein
heterotrimers. Subunits that can't stabilize the high affinity state of receptors for agonist (as well
as buffer controls) have affinity shift activities of 1, while active subunits have affinity shift
activities significantly greater then 1. Control experiments determined the concentrations of G
proteins required to saturate the affinity shift activities of all receptor G-protein combinations
used in this study.
Gα saturation binding experiments. To determine the concentration of Gα needed to
saturate the affinity shift, increasing amounts of G protein heterotrimers were added to the
receptors in the reconstitution and agonist binding was detected in the binding assay as described
above. Typically, 7 different G protein concentrations in triplicates in the range 10-500 nM were
used. EC50 values were generated from nonlinear regression analysis of data fit to a one-site
interaction model between receptor and G protein.
ADP-Ribosylation of Gα by Pertussis Toxin. Pertussis Toxin (1.1 µg/µl) was activated
by the addition of an equal volume of activation buffer (5 mM Hepes, pH 7.5, 100 mM NaCl, 5
mM MgCl2, 1 mM EDTA, 0.08% CHAPS, 40 mM DTT, 2µM GDP) and incubation for 40 min
at 32°C. G protein heterotrimers (3 µg α plus 3.6 µg βγ) were ribosylated for 1 hr at 32°C in a
total volume of 20 µl containing 10 µl of activated PTX and 400 µM NAD+. Ribosylation
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reactions were reconstituted with membranes under the same conditions described above. At the
end of the reconstitution incubation the mixture was diluted 9 fold with binding assay buffer and
used in the affinity shift assay.
Muscarinic receptor-stimulated [35S]-GTPγS Binding Assay. A GTPγS binding assay
was used to analyze receptor-catalyzed GDP/GTP exchange on G protein α subunits. Typically
1.3 pmol of receptors was reconstituted with 80 pmol of G protein heterotrimers (1.3 fold excess
of α over βγ) for 15 min at 30°C in reconstitution buffer (25 mM Hepes, pH 7.5, 100 mM NaCl,
5 mM MgCl2, 1 mM EDTA, 40 µM GDP, 0.08% CHAPS). After reconstitution the mixture was
diluted 10 fold with GTPγS Binding buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 25 mM MgCl2,
1 mM DTT, 0.1 mg/ml BSA). Reactions were initiated by the addition of 25 µl of membrane
mixture to 25 µl of GTPγS with or without Oxotremorine-M. Final assay conditions were 50 nM
Gα, 0.8 nM receptor, 2 µM GDP, 100 nM GTPγS as a mixture of 1nM [35S]-GTPγS (~125,000
cpm/well) and cold GTPγS, with or without 2µM Oxotremorine-M in a final volume of 50 µl.
Use of MultiScreen 96 well plates (Millipore) allowed collection of samples at 30 second
intervals for 4-6 minutes for M2 receptors or 3 minute intervals for 18 minutes for M1 receptors.
Filters were rinsed three times with 100 µl of ice-cold wash buffer (50 mM Tris-HCl, pH 8.0,
100 mM NaCl, 25 mM MgCl2). Radioactivity retained on the filters was counted to constant
error in a liquid scintillation counter. Greater than 1500 cpm were observed at the shortest time
points and ligand depletion was less than 15% at the longest time-points. Data were analyzed by
linear regression, and agonist driven GTPγS binding was reported as the ratio of the slopes in the
presence and absence of agonist provided the slopes were significantly different (p<0.05). If the
slopes did not differ significantly a value of 1.0 was used for the slope ratio. GTPγS binding in
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the absence of agonist (moles of GTPγS per mole of receptor) are reported in the legend to
Figure 5.
Analysis of the data. Data analysis was done using the GraphPad Prism software package
(GraphPad Software, San Diego, CA). For affinity shift assays, triplicate determinations were
used within each experiment and experiments were repeated 2-5 times as indicated. Rates of
GTPγS binding were determined from linear regression of eight individual determinations at 30
second or 3 minute intervals within each experiment and experiments were repeated 3-5 times as
indicated.

Data represent the mean ± SEM from multiple experiments unless otherwise

indicated.
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RESULTS AND DISCUSSION
Molecular mechanisms of selectivity in G protein-receptor coupling are still not
completely understood (Wess, 1998). Intact organisms employ various mechanisms including
regulation of receptor and G protein expression levels, compartmentalization of signaling
complexes, and the activity of accessory proteins, to regulate the selectivity of signaling along G
protein mediated pathways. However, at the level of the G protein-receptor interface, the primary
recognition is governed by the amino acid sequences of both G protein and receptor. G protein α
subunits are considered the major determinant of coupling selectivity and several domains of Gα
have been shown to be important for receptor coupling. In this study we investigated the roles of
the N- and C- termini of Gqα and Gi1α in directing the selectivity of M1 and M2 muscarinic
receptor coupling in a reconstituted system. To do so we tested a series of chimeric Gα subunits
composed from different portions of Gqα and Gi1α for their ability to stabilize the high affinity
agonist binding state of receptors and for their ability to undergo agonist stimulated guanine
nucleotide exchange.
Figure 1A shows the secondary structure of the chimeric Gα subunits used in this study.
The q6N chimera has been constructed by addition of the unique six amino acid N-terminal
extension of Gqα (MTLESI) to the N- terminus of Gi1α. Q35C has been constructed by the
replacement of thirty-five C-terminal amino acids of Gi1α with the corresponding amino acids of
Gqα. There are fourteen amino acids that are different between Gi1α and Gqα in this region.
Q6N35C has been constructed by addition of the six N- terminal amino acids of Gqα (MTLESI)
to the q35C construct. The qi5C chimera (Conklin et al., 1993) has five C-terminal amino acids
of Gqα (EYNLV) replaced with the corresponding amino acids of Gi1α (DCGLF). All
constructs used for protein expression were verified by DNA sequencing. All proteins except
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q35C were purified after expression in Sf9 cells. Q35C was purified after expression in bacteria
and is the only Gα subunit in this study with a HIS6 tag at the extreme N-terminus. Previous
work, with bacterially expressed subunits containing a HIS6 tag at the extreme N- terminus,
demonstrated that their EC50 values for receptor interactions are indistinguishable from those of
native or baculovirus expressed subunits (Bae et al., 1997). Furthermore, all of the α subunits
used in this study bound GDP and adopted the active conformation in the presence of AlF-4 as
shown by an enhancement of intrinsic tryptophan fluorescence (see Materials and Methods)
comparable to that reported for other G protein preparations (Skiba et al., 1996). In order to
verify that the purified proteins had the expected domain switching between Gα subunits,
chimeric proteins were separated on 12% SDS-polyacrylamide gel and immunoblotted with
antibodies selective for unique sequences within the Gα subunits. Immunoblots of purified
chimeric Gα subunits are shown in Figure 1B. As expected, Gi1, q6N, q6N35C and q35C, but
not qi5C or Gq, were recognized by an antibody against internal Gαi1 sequence. Although the
antibody directed against Gαi1/2 C- terminal sequence recognized Gi1 and q6N, it did not
recognize q6N35C and q35C verifying that the C- terminal domains of q6N35C and q35C are
different from the C- terminal domain of Gi1. In addition, the antibody directed against Gαi1/2
C- terminal sequence recognized the qi5C chimera demonstrating that C- terminal amino acids of
Gi1α are present in qi5C. Q6N35C and q35C were also recognized by the antibody against
Gαq/11 C-terminal sequences, as was Gqα, further supporting the domain switching. The
antibody against Gqα internal sequence recognized Gq only. This antibody did not recognize
qi5C because an internal HA tag in the qi5C construct (amino acid positions 125-130) disrupts
the recognition epitope of the antibody against Gqα internal sequence (amino acids 115-133).
The presence of the qi5C chimera was proven by immunoblotting with anti-HA tag antibodies
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(Fig.1B). Therefore, immunoblotting with different antibodies verified the domain switching
between wild type α subunits in the α subunit chimeras used in this study. Figure 1C shows
Coomassie Blue stained Gα subunits resolved on a 12% SDS-polyacrylamide gel. All of the α
subunits used in this study were estimated to be at least 80% pure. The presence of doublets and
triplets on the gel is likely to be due to the presence of α subunits in different states of lipid
modification or guanine nucleotide binding. This interpretation is supported by the fact that these
bands are recognized by the antibodies specific to the protein of interest (Figure 1B).
In order to study the role of N- and C- termini of Gqα and Gi1α in M1 and M2
muscarinic receptor coupling, G protein heterotrimers containing chimeric α subunits were
reconstituted with Sf9 cell membranes containing expressed M1 or M2 muscarinic receptors and
their ability to form a high affinity ternary complex with the expressed receptors was determined
by affinity shift assay. Figure 2 shows the affinity shift activities of wild type and chimeric α
subunits with M1 and M2 muscarinic receptors which were determined with saturating
concentrations of G proteins. The affinity shift assay has been completely described for several
receptors expressed in Sf9 cells (Figler et al., 1996; Clawges et al., 1997) and is based on earlier
work with native receptors (Asano et al., 1985; Pobiner et al., 1991). Briefly, the affinity shift
assay detects the formation of the high affinity state of the receptor as an enhanced level of
agonist binding upon ternary complex formation. Control experiments, shown in Figure 3, in
which G proteins were titrated at fixed agonist concentration (5 nM [3H]-OXO-M), were used to
determine the concentration of G protein required to saturate affinity shift activity. The EC50
values for reconstitution of high affinity agonist binding for individual Gα subunits shown in the
inset tables of Figure 3 are not significantly different, which is in agreement with earlier work
suggesting that differences in G protein-receptor coupling manifest themselves as differences in
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agonist affinities rather than differences in EC50 values (Bae et al., 1997). The Gα subunits for
which inset data are lacking displayed either weak saturable activity (as shown in experiments
where doubling G protein concentrations did not increase affinity shift activity) or no activity
even at high concentrations (300-500 nM) of G proteins (data not shown). By saturating affinity
shift activities we eliminated the possibility that the differences in the affinity shifts shown in
Figure 2 were caused by differences in specific activities of the Gα subunit preparations.
As expected, in the affinity shift assay M1 receptors coupled with Gq and M2 receptors
coupled with Gi1 (Figure 2). We used both loss of function and gain of function approaches to
investigate the role of the C- terminus of Gqα in M1 muscarinic receptor coupling. As shown in
Figure 2, the qi5C chimera has very little ability to couple M1 receptors compared with native
Gqα, verifying the important role of the Gqα C- terminus. Because Conklin, Bourne and Wess
have demonstrated in transfection studies that the five C- terminal amino acids of Gi1α, when
placed in the Gqα context, were sufficient to couple M2 muscarinic receptors (Conklin et al.,
1993; Liu et al., 1995), we used a gain of function approach as a criteria to test if the C- terminus
of Gqα placed in the Gi1α context was sufficient to couple M1 muscarinic receptors.
Interestingly, even thirty-five C-terminal amino acids of Gqα in the Gi1α context were not
sufficient to couple M1 receptors (Figure 2). We have also tested chimeras with three, five and
eleven C- terminal amino acids of Gqα in place of those from Gi1α and found they were not
sufficient for M1 receptor coupling (data not shown). We conclude, therefore, that the Cterminus of Gqα, although required, is not sufficient for proper Gq-M1 receptor coupling and
that other domains of Gqα must be present. Intriguingly, Natochin et al. reported that eleven Cterminal residues of Gtα in the Gsα context were sufficient for rhodopsin coupling in a
reconstituted system (Natochin et al., 2000). Such differences seem to indicate that molecular
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determinants of G protein-receptor coupling selectivity differ among individual receptors and
their cognate G proteins.
In order to investigate the role of the unique six amino acid N- terminal extension of Gqα
(MTLESI) in M1 receptor coupling, we added these amino acids of Gqα to the N- terminus of
Gi1α. However, this chimera (q6N), also did not gain the ability to couple M1 receptors (Figure
2, compared with Gi1 and Gq). To investigate the possibility that both N- and C- termini of Gqα
are required for proper M1 receptor coupling, we created the double chimera, q6N35C, which
has the six N- terminal amino acids and thirty-five C- terminal amino acids of Gqα in the Gi1α
context. Interestingly, q6N35C had a significantly enhanced ability (p<0.01-0.001, Tukey’s
Multiple Comparison Test) to shift the agonist affinity of M1 muscarinic receptors, indicating
that the appropriate context of N- and C- termini is required for proper receptor coupling (Figure
2). However, the activity of q6N35C chimera in the affinity shift assay was significantly lower
(p<0.05, Tukey's Multiple Comparison Test) than the activity of Gq (Figure 2). At least two
explanations can be suggested for this difference in activity. First, other domains of Gqα or,
possibly, a longer N- terminal portion of Gqα, are needed for full M1 receptor coupling. Second,
since Cys9 and Cys10 of Gqα have been shown to be important but not critical for receptor
coupling (Hepler et al., 1996), the lack of Cys10 in the q6N35C chimera may explain the lower
activity. Kostenis and others have suggested that the unique six amino acid N- terminal extension
of Gqα prevents Gi/o-coupled receptors (including M2 muscarinic) and Gs-coupled receptors
from coupling to Gq (Kostenis et al., 1997a). We tested if these six N- terminal amino acids of
Gqα could restrict M2 receptor coupling in the affinity shift assay. As shown in Figure 2, the six
N- terminal amino acids of Gqα added to the N- terminus of Gi1α did not prevent M2 receptor
coupling in a reconstitution system.
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The important role of the C- terminus of Gi1α in receptor coupling was verified by the
loss of function of the q35C chimera in the affinity shift assay with M2 receptors (Figure 2). In
similar experiments, q5C and q11C chimeras also failed to couple with M2 receptors (data not
shown). The q6N35C chimera also had no coupling activity with the M2 receptor (Figure 2).
As discussed below, the low level affinity shift activity of both Gq and qi5C in coupling the M2
receptor is due to a small amount of contaminating Sf9 cell Gi/o-like protein in these
preparations (see Figure 4). Therefore, the data indicate that the M2 receptor has an absolute
requirement for the proper context of the C-terminus of the coupling G protein. Interestingly,
gain of function experiments indicated that the five C- terminal amino acids of Gi1α placed in
the context of Gqα were not sufficient for optimal M2 receptor coupling as measured by the
affinity shift assay (qi5C chimera, Figure 2). Because qi5C only minimally couples M2
receptors, it is tempting to speculate that cooperation between appropriate N- and C- termini are
also critical for full Gi1-M2 muscarinic receptor coupling.

Previous reconstitution studies

demonstrated a role for a poorly defined region within the first 210 amino acids of Gi1α that is
important for 5-HT1B receptor coupling (Bae et al., 1997). However, since only the six amino
acid N-terminal extension that is unique to Gqα subunits was tested in this study such
speculation may be premature and the structural determinants of coupling may differ
significantly between M1 and M2 receptors. The failure of qi5C to couple appreciably in our
reconstitution assays is in contrast with the results of Liu, Conklin and others, who demonstrated
in transfection assays that the qi5C construct conferred coupling to several Gi/o coupled
receptors, including the M2 receptor (Liu et al., 1995). While the precise reasons for such
different observations in transfection versus reconstitution assays are unknown, several factors
are likely to contribute. In transfection assays proteins of interest are overexpressed in a limited
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percentage of cells and coupling is inferred from effector activities which are substantially
amplified at several points in the signal transduction cascade. On the other hand, all cellular
components are present and the integration and assembly of membrane structures occurs in a
cellular context. Reconstitution experiments directly examine the G protein-receptor interface
and allow controlled stoichiometries of components, however they require the G protein to
associate with the receptor after the receptor has been integrated into cellular membranes and
may not allow the participation of all components responsible for receptor-G protein coupling.
Thus, reconstitution experiments are likely to more precisely identify the G protein domains
directly involved in the receptor-G protein interface, while transfection experiments are likely to
identify the domains that permit coupling in a cellular context without revealing the precise
mechanism or required stoichiometries. Ultimately both contribute to our understanding of
coupling although neither may completely reflect the actual situation in living tissues.
In addition to the expected Gq-M1 and Gi1-M2 receptor coupling, we observed a low
level of Gi1-M1 and Gq-M2 receptor coupling in the affinity shift assay (Figure 2). The basis for
this coupling was explored with the use of pertussis toxin (PTX). PTX is known to uncouple
Gi/o proteins from their cognate receptors by ADP-ribosylating a C- terminal cysteine in Gi/oα
subunits (West, Jr. et al., 1985). We ADP-ribosylated G protein heterotrimers using PTX and
reconstituted them with M1 or M2 muscarinic receptors. The results shown in Figure 4 indicate
that PTX treatment completely uncoupled Gi1 from M2 receptors as expected. Surprisingly, PTX
treatment also completely uncoupled Gq from M2 receptors, but not Gq from M1 receptors. As
Gqα is not a substrate for ADP-ribosylation by PTX we attribute the Gq-M2 receptor coupling to
the presence of small amounts of endogenous Sf9 Gi/o family proteins in our Gq preparation
which was undetectable by immunoblotting (Figure 1A). A similar contamination of Gq purified
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after expression in Sf9 cells by endogenous Gi/o proteins was reported by Kozasa (Kozasa and
Gilman, 1995). This contaminating activity is not present in the q35C and q6N35C preparations
(see Figure 2) as they are purified from the soluble fraction of expressing cells which contains
few, if any, endogenous G proteins, while Gq and qi5C are purified from a detergent extract of
the particulate fraction from expressing cells which would be expected to contain endogenous G
proteins (see Materials and Methods). In addition, PTX treatment prevented Gi1-M1 receptor
coupling (Figure 4). Therefore, our data indicate that M1 muscarinic receptors weakly couple
with Gi1, while M2 muscarinic receptors probably don’t couple with Gq. Our data agree well
with the data of Burford et al. who demonstrated that M1 receptors, especially when expressed at
high levels, can couple to both pertussis toxin sensitive and insensitive G proteins, while M2
receptors couple only with pertussis toxin sensitive G proteins (Burford et al., 1995). DeLapp et
al. also demonstrated that M1 receptors were able to couple to inhibitory G proteins while M2
receptors coupled to Gq/11 only weakly (DeLapp et al., 1999).
In order to compare the ability of Gα subunits to be activated by receptors, muscarinic
receptor-catalyzed GDP/GTP exchange was measured as agonist-stimulated GTPγS binding.
Figure 5 shows the fold differences in slopes between agonist-driven and basal nucleotide
exchange on various Gα subunits. The inset graph shows moles of GTPγS bound in membranes
expressing M2 muscarinic receptors with or without reconstitution with Gi1 in the presence or
absence of agonist. All chimeras were analyzed in the same fashion and the rates of GTPγS
binding were determined from the slopes of the lines. Data for M2 receptor-catalyzed GTPγS
binding demonstrated that q6N exchanged guanine nucleotides at a rate comparable to Gi1, while
the rest of the Gα subunits were inactive (Figure 5). With the M1 receptor, both Gq and q6N35C
exchanged guanine nucleotides upon agonist stimulation, while the rest of the Gα subunits were
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inactive (Figure 5). These data agree well with the affinity shift data (Figure 2) and support our
main conclusion that both the N- and C- termini of Gqα are required for effective M1 receptor
coupling.
Although the affinity shift data indicate that the M1 receptor couples weakly with Gi1
(Figure 2), and that this coupling is abolished by PTX treatment (Figure 4), we did not see
agonist stimulated M1 receptor mediated exchange on Gi1. Thus while the high affinity agonist
binding state of G protein coupled receptors is thought to be a ternary complex containing
nucleotide free G protein, and GDP release is accepted as the rate-limiting step in nucleotide
exchange (Gilman, 1987), our data indicate that it is possible to stabilize the high affinity state of
the receptor without stimulating guanine nucleotide exchange. Such discrepancies have been
noted in a previous study (Bae et al., 1999) and are likely to be related to the fact that the affinity
shift assay measures an equilibrium condition among agonist, receptor and G protein in the
absence of guanine nucleotides after an hour or more of incubation, while the agonist driven
GTPγS binding assay measures the kinetics of GTPγS binding in the first few minutes after
mixing these components.
The N- terminus of Gα subunits, together with amino acids from switch I and switch II
are binding sites for Gβγ subunits in the G protein heterotrimer (Wall et al., 1995). Mutations at
the N- terminus of Gα may affect its interactions with βγ, which acts as a guanine nucleotide
dissociation inhibitor for Gα. Kostenis et al. have suggested that the six N- terminal amino acids
of Gqα (MTLESI) form a tightly folded protein subdomain that prevents Gi/o- and Gs-coupled
receptors from accessing Gqα, thereby regulating coupling selectivity (Kostenis et al., 1998).
Our results demonstrate that the addition of the six N- terminal amino acids of Gqα to the Nterminus of Gi1α does not restrict M2 receptor coupling. Therefore we can say that the q6N
93

chimera interacted with βγ properly. Our data suggest that N- and C- termini of Gqα cooperate to
couple M1 receptors. While the crystal structure of Gq is not available, and the crystal structure
of the Gi1 heterotrimer (with GDP bound) lacks four amino acids from the N- terminus and six
amino acids are from the C- terminus (Wall et al., 1995), it appears that the Gα C- terminus in
the heterotrimer is accessible and not buried within a compact microdomain. The N-terminus and
αN helix are turned away from the body of Gα to interact with βγ. The structure of the Gi1
heterotrimer indicates that Val34 and Arg32 are the N- terminal amino acids of Gi1α that come
close to Leu348, the most C- terminal Gα residue in the structure. However, because the
structural orientation of the extreme N- and C- termini in Gq is not known, and also because the
crystal structure of a nucleotide-free G protein heterotrimer is not available, the structural basis
for cooperativity between the extreme N- and C- termini of Gqα is not yet understood. One
possibility is that the N- and C- termini of Gα might interact to form a single receptor binding
site. Alternatively, there might be two separate sites on the receptor for the N- and C- termini
which have to be recognized for the receptor to activate G proteins. Muradov and Artemyev
suggested that coupling between N- and C- terminal domains of Gtα is responsible for low basal
GDP/GTP exchange in Gtα (Muradov and Artemyev, 2000). Since Gqα is also known to have
low basal GDP/GTP exchange this concept may in principal apply to Gqα.
Taken together, our data indicate that the context of the C- terminus of Gα, although
critical, is not sufficient for M1 or M2 muscarinic receptor coupling. In addition, the unique six
amino acid N- terminal extension of Gqα is neither sufficient to allow M1 muscarinic receptor
coupling, nor sufficient to prevent M2 muscarinic receptor coupling. Rather, the appropriate
context of both N- and C- termini of Gα is required for functional coupling to M1, and possibly,
M2, muscarinic receptors. Q6N35C represents an easily purified, relatively stable, and soluble
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Gα subunit with the ability to functionally couple with M1 muscarinic receptors. As a reagent it
therefore offers significant advantages to native Gqα, which is difficult to purify, requires
detergents for solubility and is easily inactivated by denaturation.
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FIGURE 1. A. Secondary structure of chimeric Gα
α subunits. Numbers on the right of the
wild type forms of Gαi1 and Gαq indicate their total amino acid residues. Numbers within the
designations for the chimeras indicate the number of amino acids switched between Gαi1 and
Gαq. The diagram on the bottom depicts the secondary structural domains common to Gα
subunits. B. Immunoblot analysis of purified chimeric α subunits. Proteins were purified as
described in Methods, electrophoresed on SDS-polyacrylamide gels and immunoblotted with
antibodies indicated at the right of each panel. Each lane contained 75 ng of the indicated
purified α subunit. C. Coomassie stain of purified Gα
α subunits. 500 ng of purified alpha
subunits were resolved on a 12% SDS-polyacrylamide gel and visualized with coomassie blue
stain. The order of proteins on coomassie gel is the same as indicated above the immunoblot.
Lane 1 is Gi1, lane 2 is q6N, lane 3 is q35C, lane 4 is q6N35C, lane 5 is qi5C, lane 6 is Gq.
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FIGURE 2. Affinity shift activity of Gα
α subunits with M1 and M2 muscarinic receptors.
Affinity shift activities represent the fold enhancement above buffer controls of high affinity
[3H]-Oxo-M binding in membranes expressing the indicated muscarinic receptor (1-2 nM)
reconstituted with a saturating excess (100-200 nM) of G protein heterotrimers containing the
indicated Gα subunits. Data are the mean ± SEM from 3-5 experiments where the concentration
of Oxo-M was ~5 nM. The dotted line represents an affinity shift activity of 1, the level of
activity observed in the absence of exogenous G proteins or in the presence of inactive G protein
heterotrimers.
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FIGURE 3. Concentration dependence of Gα subunits in agonist binding to M1 and M2
muscarinic receptors. Sf9 cell membranes expressing either M1 (left panel) or M2 (right panel)
muscarinic receptors were reconstituted with increasing concentrations of G protein
heterotrimers containing the indicated Gα subunit. Receptor concentrations were 0.95 nM for
M1 and 0.82 nM for M2. High affinity agonist binding was determined in the presence of 5 nM
[3H]-OXO-M. Data were fit to a single-site interaction between receptor and G protein and are
the mean ± SD of triplicate determinations from a representative experiment. The inset tables
show the EC50 values (mean ± SEM) from the indicated number of experiments for individual
Gα subunits. For each receptor, the individual EC50 values did not differ significantly from one
another (One-way ANOVA or t-test).
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FIGURE 4. Affinity shift activity of Gα subunits following ADP-ribosylation by Pertussis
Toxin. Affinity shift activities represent the fold enhancement above buffer controls of high
affinity [3H]-Oxo-M binding in membranes expressing the indicated muscarinic receptor (1-2
nM) reconstituted with a saturating excess (100-200 nM) of G protein heterotrimers containing
the indicated Gα subunits with or without ADP-ribosylation by Pertussis Toxin. Data are the
mean ± SD of triplicate determinations from a representative experiment repeated twice with
similar results. Gα subunits without pertussis toxin treatment contained all of the reagents
(except Pertussis Toxin) and underwent the same treatment as those treated with toxin. The
dotted line represents an affinity shift activity of 1, the level of activity observed in the absence
of exogenous G proteins or in the presence of inactive G protein heterotrimers.
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FIGURE 5. Muscarinic receptor-catalyzed GDP/GTP exchange on Gα
α subunits. GDP/GTP
exchange was measured as GTPγS binding in membranes expressing the indicated muscarinic
receptor reconstituted with G protein heterotrimers containing the indicated Gα subunits. Bars
represent the fold-enhancement by agonist above basal nucleotide exchange in the absence of
agonist on Gα subunits and are the mean ± SEM from 3-8 experiments. Final conditions in the
binding assay were 50 nM Gα, 0.8 nM receptor, 2 µM GDP, 100 nM GTPγS (~125,000
cpm/well), with or without 2 µM Oxotremorine-M in a final volume of 50 µl. The asterisks
above the bars indicate values significantly different than 1.0 (p < 0.05, one-sample t-test) and
the absence of error bars indicates that there was no significant difference between basal and
agonist driven rates in any experiment. The inset graph depicts moles of GTPγS bound per mole
of receptor in membranes expressing M2 muscarinic receptors with or without reconstitution
with Gi1 in the presence and absence of 2 µM Oxo-M as indicated. The lines are least squares
regression lines and the slopes represent the rate of GTPγS binding. Rates of GTPγS binding to
all Gα subunits were determined as shown in the inset graph and the mean basal rates of GTPγS
binding (mol GTPγS/mol receptor/min) were as follows- Gi1, 0.23; Q6N, 0.25; Q35C, 0.10;
Q6N35C, 0.12; Gqi5C, 0.04; Gq, 0.08. The basal rate for Gi1 was significantly greater than all
other subunits except Q6N (p < 0.05, Tukey’s Multiple Comparison Test).
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Abbreviations and Textual Footnotes— 1The abbreviations used are: GPCRs, G protein
coupled receptors; GTPγS, guanosine 5'-3-O-(thio)triphosphate; OXO-M, Oxotremorine-M; 5HT, Hydroxytryptamine; CCPA, chloro-N6-cyclopentyladenosine, R-PIA, R-phenylisopropyl
adenosine.
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ABSTRACT
The molecular basis of selectivity in receptor-G protein coupling has been explored by
comparing the abilities of G protein heterotrimers containing chimeric Gα subunits, comprised
of various regions of Gi1α, Gtα and Gqα, to stabilize the high affinity state of serotonin,
adenosine and muscarinic acetylcholine receptors. The data indicate that multiple and distinct
determinants of selectivity exist for individual receptors. While the A1 adenosine receptor does
not distinguish between Gi1α and Gtα sequences, the 5-HT1A and 5-HT1B serotonin and M2
muscarinic receptors can couple with Gi1 but not Gt. It is possible to distinguish domains that
eliminate coupling and hence are defined as “critical”, from those that impair coupling and hence
are defined as “important”. Domains within the N terminus, α4 helix, and α4 helix-α4/β6 loop of
Gi1α are involved in 5-HT and M2 receptor interactions. Chimeric Gi1α/Gqα subunits verify the
critical role of the C terminus in receptor coupling, however, the individual receptors differ in the
Gα amino acids that are required for coupling. Furthermore, the EC50 for interactions with Gi1
differ among the individual receptors. These results suggest that coupling selectivity ultimately
involves subtle and cooperative interactions among various domains on both the G protein and
the associated receptor as well as the G protein concentration.

109

INTRODUCTION
A large number of diverse seven transmembrane spanning cell surface receptors mediate
signaling to a variety of intracellular effectors by coupling to the heterotrimeric guanine
nucleotide-binding regulatory proteins (G proteins) (Pierce et al., 2002). The mechanisms
responsible for selectivity in G protein mediated signaling pathways are not fully understood
(Wess, 1998; Albert and Robillard, 2002). Although it is known that at the molecular level the
selectivity in G protein-receptor coupling is determined by amino acid sequences of both
receptor and G protein, the individual amino acids involved in this selective recognition have
not been completely identified. Different receptor systems and different methodologies indicate
that the in the Gα subunit C terminus and α5 helix (Hamm et al., 1988; Conklin et al., 1993;
Gilchrist et al., 1998; Natochin et al., 2000), N terminus and αN helix (Hamm et al., 1988;
Hepler et al., 1996; Kostenis et al., 1997; Swift et al., 2000), α4 helix and α4/β6 loop (Bae et
al., 1997; Natochin et al., 1999; Blahos et al., 2001), α2 helix and α2/β4 loop (Lee et al., 1995),
α3/β5 loop (Grishina and Berlot, 2000), αN/β1 loop (Blahos et al., 2001) and amino acids 110119 from the α helical domain (Krieger-Brauer et al., 1999) are involved in receptor coupling
selectivity. Some of these domains contact the receptor directly, while others regulate receptor
coupling selectivity indirectly by playing a role in nucleotide exchange. Despite the fact that
many of the receptor interacting domains have been identified, the relationship between receptor
subtypes and Gα domains involved in receptor coupling has not been clearly established. Thus,
it is difficult to predict which Gα domains will be utilized by a specific receptor. Here we
propose that individual receptors recognize specific patterns formed by amino acids of Gα thus
making G protein interface look different for different receptors. The C terminus of Gα is a well
accepted receptor recognition domain, which contacts receptors directly (Conklin and Bourne,
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1993). Although individual C terminal amino acids important for receptor coupling have been
identified in several Gα subunits, the specific Gα amino acids participating in receptor
recognition may differ among receptors. The α4 helix-α4/β6 loop domain, first described as an
effector domain, has been shown to be important for 5-HT1B receptor coupling to Gi1 (Bae et
al., 1997). Later it was demonstrated that Gln304 and Glu308 in the α4 helix of Gi1α are
important for 5-HT1B receptor coupling (Bae et al., 1999). However the generality of the role
for the α4 helix-α4/β6 loop domain in receptor coupling selectivity has not been determined.
Gi1α and Gtα are closely related Gα subunits, which belong to the Gi/o class of G
protein α subunits, share 68% homology, and have nearly identical overall structures. Although
the 5-HT1B receptor discriminates between Gi1 and Gt (Skiba et al., 1996; Bae et al., 1997) the
fact that their C termini are identical render Gi1α/Gtα chimeras useless for exploring the role of
this domain in receptor coupling. However, the extreme C terminus of Gqα differs from that of
Gi1α by four amino acids, while their α5-helixes differ by additional nine amino acids. Thus
Gi1α/Gqα chimeras are ideal for studying the role of this domain in coupling. Since several
different GPCRs1 can couple to the same G protein, we wanted to test the hypothesis that
individual receptors utilize slightly different domains on Gα subunits to achieve coupling. G
protein-receptor coupling selectivity may also be regulated at the level of G protein
concentration. In fact, Clawges et al. demonstrated that 5-HT1A and 5-HT1B receptors
distinguish themselves by the affinity with which they interact with G proteins (Clawges et al.,
1997). Therefore we also wanted to test the generality of this mechanism with different
receptors. Here we compare the coupling behavior of four Gi/o-coupled receptors (5-HT1A and
5-HT1B serotonin, A1 adenosine and M2 muscarinic) by reconstituting them with G protein
heterotrimers containing native or chimeric Gα’s composed of Gαi1, Gαt and Gαq. Our data
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demonstrate that selective coupling between Gi1 and the members of Gi/o-coupled receptor
family is directed by multiple and distinct Gα domains and is regulated at the level of G protein
concentration.
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EXPERIMENTAL PROCEDURES
Materials. [3H]-Oxotremorine-M Acetate ([3H]-OXO-M) (85.8 Ci/mmol), [3H]Hydroxytryptamine

Binoxalate

([3H]-5-HT)

(25.5

Ci/mmol)

and

[3H]-Chloro-N6-

cyclopentyladenosine ([3H]-CCPA) (30 Ci/mmol) were from New England Nuclear Life
Science Products, Inc. (Boston, MA). Atropine Sulfate, 5-Hydroxytryptamine (5-HT) and Rphenylisopropyl adenosine (R-PIA) were from Sigma-Aldrich Corporation (St. Louis, MO).
Adenosine deaminase was from Roche Molecular Biochemicals (Indianapolis, IN). The BCA
Protein Assay reagents were from Pierce (Rockford, IL). All other chemicals were from SigmaAldrich Corporation (St. Louis, MO) or EMD Biosciences (formerly Calbiochem-Novabiochem
Corporation; San Diego, CA).
Expression and purification of proteins. The expression and purification of the Gαi1 and
Gβγ subunits was as previously described (Graber et al., 1992a; Graber et al., 1992b). The
chimeric Gαi1/Gαt subunits were constructed, expressed in E. coli and purified as described
(Skiba et al., 1996). The Gi1/Q3C, Gi1/Q5C and Gi1/Q11C chimeras were made from pHis6Gαi1
using the silent BamHI site introduced at amino acid position 212 (Skiba et al., 1996). The
pHis6Gαi1 cDNA was amplified by PCR reaction with primer oligonucleotides containing the
desired mutations. The PCR products were digested with BamHI and HindIII, and the BamHIHindIII fragment was used to replace the coresponding fragment from pHis6Gαi1. To construct
Gi1/Q35C, the C-terminal portion of a Gqα cDNA was amplified by PCR reaction, followed by
digestion with BglII and HindIII. The digested PCR fragment was inserted into the BglII and
HindIII sites of the Chi13 plasmid (Bae et al., 1997). Functional characterization of all bacterial
subunits included GTPγS binding, AlF4--dependent conformational change (measured as an
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increase in intrinsic tryptophan fluorescence) or binding to the cGMP phosphodiesterase γ
subunit (Skiba et al., 1996; Bae et al., 1997; Bae et al., 1999).
Preparation of Sf9 membranes containing expressed receptors. Sf9 cells were infected
with a recombinant baculovirus expressing the desired receptor, cultured and harvested as
previously described (Graber et al., 1992b). To prepare membranes, harvested cells were thawed
in 15x their wet weight of ice cold homogenization buffer (10 mM Tris-Cl, pH 8.0 at 4 °C, 25
mM NaCl, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF, 20 µg/ml of benzamidine
and 2 µg/ml of each of aprotinin, leupeptin and pepstatin A) and burst by nitrogen cavitation (600
psi, 20 minutes). Cavitated cells were centrifuged at 4 °C for 10 minutes at 500 x g to remove the
unbroken nuclei and cell debris. The supernatant from the low speed spin was centrifuged at 4 °C
for 30 min at 28,000 x g. The supernatant was discarded and the pellets were resuspended and
pooled in 35 ml of HE buffer (5 mM NaHEPES, l mM EDTA, pH 7.5) containing the same
protease inhibitors as used in the homogenization buffer. Adenosine receptor HE buffer included
100 mM NaCl in addition to the above components. The membranes were washed twice in HE,
resuspended in the same buffer at a concentration of 1-3 mg protein/ml, aliquoted, snap frozen in
liquid nitrogen, and stored at -70 °C.
Reconstitution of receptors with exogenous G-proteins. Frozen membranes were thawed,
pelleted in a refrigerated microcentrifuge (10 min, 12,000 rpm) and resuspended at about 10
mg/ml in a reconstitution buffer consisting of 5 mM NaHEPES, 100 mM NaCl, 5 mM MgCl2, 1
mM EDTA, 500 nM GDP, 0.04% CHAPS (0.08% CHAPS for M2 receptor), pH 7.5. G protein
subunits were diluted in the same buffer such that the desired amount of subunit was contained in
1-5 µl. Typically, 1-2 µl of G protein subunits were added to 40 µl of membrane suspension, the
mixture was incubated at 25 °C for 15 minutes and held on ice until the start of the binding assay.
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Radioligand binding. Just prior to the start of the binding assay the reconstitution mixture
was diluted 10-12 fold with binding assay buffer appropriate to the receptor of interest such that
the desired amount of membranes (5-25 µg/assay tube) were contained in 10-50 µl. Binding
buffer for 5-HT and M2 receptors was 50 mM Tris, 5 mM MgCl2, 0.5 mM EDTA, pH 7.5.
Binding buffer for A1 adenosine receptor was 10 mM HEPES, 5 mM MgCl2, 1 mM EDTA, pH
7.4. Radioligand binding in the affinity shift assay was determined in the presence of the [3H]OXO-M for M2 muscarinic receptor, [3H]-5-HT for 5-HT serotonin receptors and [3H]-CCPA for
A1 adenosine receptor. Adenosine deaminase was added to the [3H]-CCPA solution at 12 µg/ml
in binding buffer. Non-specific binding was determined by addition of 1000-fold excess of
unlabeled ligand– 5-HT for 5-HT receptors, atropine sulfate for M2 receptor and R-PIA for A1
receptor. Incubations were for times sufficient to achieve equilibrium in a temperature controlled
shaker (1 hr for M2 receptor, 1.5 hrs for 5-HT receptors, 2 hrs for A1 receptor) and were
terminated by filtration over Whatman GF/C filters using a Brandel Cell Harvester. The filters
were rinsed thrice with 4 ml ice cold 50 mM Tris-Cl, 5 mM MgCl2, 0.5 mM EDTA, 0.01%
NaAzide, pH 7.5 at 4 °C, placed in 4.5 ml CytoScint (ICN Pharmaceuticals, Costa Mesa, CA) and
counted to constant error in a scintillation counter. For reconstitution of high affinity agonist
binding in affinity shift assays, a single concentration of radioligand near the high affinity KD of
the receptor of interest was used in a final volume of 150 µl. [3H]-5-HT radioligand purity was
monitored by HPLC or TLC using an appropriate mobile phase. Radioligands were repurified or
replaced when the radiochemical purity fell below 85%.
Affinity shift activity assay. The Sf9 cell membranes expressing individual receptors were
reconstituted with saturating amounts of native or chimeric Gi1 protein heterotrimers (≥25 nM or
40-400 fold molar excess over receptors) to achieve the maximal specific binding during the
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binding assays. Because the magnitude of the affinity shifts observed with native Gi1 protein
heterotrimers varied significantly among the individual receptors affinity shift activity was
normalized to Gi1 activity and expressed as % affinity shift activity, which is (Chimera
Reconstituted Binding - Control Binding/Gil Reconstituted Binding - Control Binding) x100.
Analysis of the data. Data analysis was done using the GraphPad Prism software package
(GraphPad Software, San Diego, CA). For affinity shift assays, triplicate determinations were
used within each experiment and experiments were repeated 3 or more times. Data represent the
mean ± SEM from multiple experiments. One-way ANOVA with Tukey’s multiple comparison
post test was used to compare the activities of chimeras.
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RESULTS
Previously we have shown that amino acids 299-318 and 1-219 of Gi1α are molecular
determinants of 5-HT1B receptor coupling (Bae et al., 1997) and that two amino acids in the α4
helix of Gi1α (Gln304 and Glu308) are especially important for 5-HT1B receptor coupling (Bae
et al., 1999). The goal of the present study was to examine the generality of the these findings
among closely related members of the Gi/o-coupled receptor family. Our general strategy
involves reconstitution of purified G proteins containing chimeric α subunits with receptors
expressed in Sf9 insect cell membranes and comparison of the abilities of these chimeric G
proteins to stabilize the high affinity agonist binding state of the receptors in an affinity shift
activity assay. In the present study we compared the coupling behavior of four different Gi/ocoupled receptors: 5-HT1A and 5-HT1B serotonin receptors, M2 muscarinic receptors and A1
adenosine receptors.
Affinities of individual receptors for G proteins- First we determined the concentration
of G proteins in the binding assay that produced the maximum affinity shift for each receptor.
Increasing amounts of G protein heterotrimers were reconstituted with individual receptors and
EC50 values for reconstitution of high affinity agonist binding were determined. The data
indicate that A1, 5-HT1A, 5-HT1B and M2 receptors have different EC50 values for Gi1 (Figure
1). A1 receptors have the highest apparent affinity (0.4 nM) and M2 receptors have the lowest
apparent affinity (47 nM) for the Gi1 heterotrimer. 5-HT receptors have intermediate EC50
values of 3.7 nM and 16.2 nM for the 5-HT1A and 5-HT1B receptors respectively. Titration
experiments similar to those shown in Figure 1 were used to determine the concentration of
chimeric G proteins needed to saturate affinity shift activities with individual receptors. For
individual receptors, the EC50 values of the active chimeras were not significantly different and
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even high concentrations (>600 nM) of inactive chimeras did not have affinity shift activity
(data not shown). All affinity shift activities were determined with saturating concentrations of
G proteins.
Affinity shift activity of chimeric Gα subunits- Figure 2 depicts the secondary
structures of the Gi1α/Gtα chimeras used in this study. All of these chimeras have been
previously described and were used to study Gi1α domains involved in 5-HT1B receptor
coupling (Skiba et al., 1996; Bae et al., 1997; Bae et al., 1999). Figure 3, in which 100%
activity corresponds to the affinity shift activity of Gi1, shows the per cent affinity shift activity
of Chi2, Chi3, Chi6, Chi13 and Chi21. Chi6 was constructed as a soluble analog of Gtα and has
the same functional properties as Gtα (Skiba et al., 1996). Chi6 is primarily Gtα in character as
it includes N- terminal amino acids 1-215 and C- terminal amino acids 295-350 of Gtα with the
amino acids corresponding to 216-294 from Gi1α to maintain solubility. In this region there are
just 26 amino acids that differ between Chi6 and Gtα. As shown in Figure 3, Chi6 was inactive
with 5-HT1A, 5-HT1B and M2 muscarinic receptors. Earlier experiments with native transducin
demonstrated it also failed to couple with the 5-HT receptors (Clawges et al., 1997). In contrast,
the data in Figure 3 demonstrate Chi6 was 74% active with the A1 adenosine receptor,
indicating that A1 adenosine receptor doesn't discriminate well between Gt and Gi1 sequences.
Although the activity of Chi6 with the A1 adenosine receptor was significantly lower (p<0.001)
than the activity of Gi1, the magnitude of the difference was too small to be of use in identifying
the precise domains responsible for the reduced activity. However, the inability of the 5-HT1A,
5-HT1B and M2 muscarinic receptors to couple with Chi6 allowed us to use additional chimeras
containing less Gtα sequence to more precisely identify the domains required for coupling.
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We first examined whether the N- terminal or C- terminal portion of Gi1α was critical
for receptor coupling. Chi21 has N- terminal amino acids 1-215 of Gtα with the rest of the
molecule Gi1α sequence (Figure 2). Chi21 was fully active with the A1 adenosine receptor,
indicating that the A1 receptor does not distinguish between N- terminal amino acid sequences
of Gi1α and Gtα (Figure 3). The activity of Chi21 with 5-HT1A, 5-HT1B and M2 receptors was
significantly (p<0.001) reduced (44%, 57% and 42% respectively, Figure 3) demonstrating that
amino acids 1-219 of Gi1α contain an important determinant of Gi coupling with these
receptors. Chi2 has the C- terminal amino acids 295-350 of Gtα with the rest of the chimera
Gi1α sequence (Figure 2). Figure 3 demonstrates that amino acids 299-354 of Gi1α contain
residues critical for 5-HT1A, 5-HT1B and M2 receptor coupling because the affinity shift activity
of Chi2 with these receptors (2%, 9% and 23% respectively) was not significantly different
from Chi6 activity. In contrast, Chi2 was fully active with A1 adenosine receptors supporting
our conclusion that A1 adenosine receptor does not distinguish well between Gi1α and Gtα
sequences. To further evaluate the role of amino acids 299-354 of Gi1α in 5-HT and M2
receptor coupling we tested two additional chimeras, Chi3 and Chi13 (Figure 2). Chi3 has
amino acids 299-319 of Gi1α replaced with the corresponding amino acids of Gtα (amino acids
295-315) while Chi13 has the 35 C-terminal amino acids of Gi1α replaced with the
corresponding amino acids of Gtα. As shown in Figure 3, the affinity shift activities of Chi3
show that amino acids 299-319 of Gi1α (α4-helix and α4/β6-loop) are critical for 5-HT1A, 5HT1B and M2 receptor coupling, but not for A1 adenosine receptor coupling. In contrast, Chi13,
with six amino acids variant from Gi1α, was active with all four receptors indicating that the 35
C-terminal amino acids of Gi1α and Gtα are functionally interchangeable in coupling these
receptors. Nevertheless, the significantly (p<0.01) reduced activity of Chi13 (85.9%) with the
119

M2 receptor and the significantly (p<0.01) increased activity with both 5-HT1A (128%) and 5HT1B (124.5%) receptors suggest subtle differences in the coupling mechanism of these
receptors. The role of the extreme C-terminus of Gi1α cannot be evaluated with these chimeras
because the eight C-terminal amino acids of Gi1α and Gtα are identical.
Role of the α4-helix and α4/β6-loop of Gi1α in receptor coupling- In order to
investigate α4-α4/β6 region of Gi1α in more detail we used several additional chimeras to
subdivide this region (Figure 4). Chi22 has the α4 helix of Gi1α replaced with that from Gtα
while Chi25 has the α4/β6 loop of Gi1α replaced with that from Gtα. Chi23 has the α4/β6 loop
of Gi1α replaced with that from Gtα and also switches the Glu in Gi1α at the end of the α4 helix
for the Leu found in Gtα. Chi24 has the central part of the α4/β6 loop with two variant amino
acids switched between Gi1α and Gtα. These chimeras were fully active with the A1 adenosine
receptor (data not shown), supporting our conclusion that the A1 receptor does not use the α4α4/β6 region to distinguish between Gt and Gi1 (see Figure 3). Figure 5 shows the affinity shift
activity of these chimeras with 5-HT1A, 5-HT1B and M2 receptors. Chi22 had low affinity shift
activity with all three receptors indicating that a critical determinant of coupling selectivity for
these receptors is located in the α4 helix of Gi1α (Figure 5). For the 5-HT1B receptor, the
activity of Chi22 was significantly higher than the activity of Chi3 (p<0.01), indicating that the
α4/β6 loop may also play a role in 5-HT1B receptor coupling. This conclusion is supported by
the Chi25 activity with the 5-HT1B receptor (73%), which was significantly (p<0.001) lower
than the activity of Gi1 (100%). However, Chi25 was 91% as active with M2 muscarinic
receptor) which was not significantly different (p>0.05) from Gi1 activity) and was 121% as
active with the 5-HT1A receptor (which was significantly (p<0.001) higher than Gi1). Clearly
the α4/β6 loop is utilized differently by these receptors. Chi24 was fully active with all three
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receptors (Figure 5) which suggests that the reduced activity of Chi25 with the 5-HT1B receptor
is due to the replacement of Asp309 by Glu at the beginning of the α4/β6 loop (Figure 4).
Figure 5 also shows the affinity shift activity of Chi23 was significantly reduced (p<0.001)
compared with the activity of both Gi1 and Chi25 for all three receptors. Chi23 differs from
Chi25 by just one amino acid (replacement of Glu308 from Gi1α for Leu from Gtα) indicating
that Glu308 is important for coupling to 5-HT1A, 5-HT1B and M2 receptors. Taken together, the
data indicate that the α4 helix (Glu308 in particular) is important for all three receptors, and that
the α4/β6 loop (probably Asp309) is also important for 5-HT1B receptors.
Defining individual amino acids in the α4-α4/β6 region of Gi1α− To prove the role of
Glu308 in receptor coupling and also to study the role of other amino acids in the α4-α4/β6
region of Gi1α we used chimeras in which amino acids Ala301, Gln304, Cys305, Glu308,
Lys312 and Thr316 of Gi1α were replaced individually or in combinations with the
corresponding amino acids of Gtα. All of the mutants used here have been previously described
(Bae et al., 1999). First we studied the role of these amino acids with a loss of function assay.
Mutants in which amino acids of Gi1α were replaced individually or in combinations with the
corresponding amino acids of Gtα would be expected to exhibit reduced affinity shift activities
if these amino acids were important for coupling. Replacement of Ala301 with Asn did not
reduce activity (Gi1A301N, Figure 6) demonstrating that Ala301 is not important for coupling
any of the receptors tested. When Gln304 was changed to Lys (Gi1Q304K, Figure 6) activity
with 5-HT1A and M2 receptors was significantly (p<0.001) reduced, but as reported previously
(Bae et al., 1999), this single amino acid replacement did not significantly reduce affinity shift
activity with 5-HT1B receptors (Figure 6). The activity of Gi1C305V shows that Cys305 is
important for M2 muscarinic receptors (67% activity, p<0.001) but not important for either 5-
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HT receptor (Figure 6). Glu308 is an important amino acid for all three receptors as the
Gi1E308L mutant displays 62%, 73% and 61% of activity with 5-HT1A, 5-HT1B and M2
receptors respectively (p<0.001) (Figure 6). Lys312 and Thr316 are not important for coupling
these receptors and the increased activity of Gi1K312M and Gi1T316V with the 5-HT1A
receptor (p<0.001) is consistent with the increased activity of Chi25 with this receptor.
Data obtained with three double mutants (Gi1Q304K/C305V, Gi1Q304K/E308L,
Gi1C305V/E308L) and a triple mutant (Gi1Q304K/C305V/E308V) support the conclusions
drawn from the point mutants (Figure 6). The activity of the Gi1Q304K/E308L mutant was
lower than the activity of either Gi1Q304K or Gi1E308L for all receptors supporting the
importance of both Gln304 and Glu308 in receptor coupling. The role of Cys305 in M2 receptor
coupling is supported by the observation that the activity of Gi1Q304K/C305V mutant was
significantly lower than the activity of the Gi1Q304K mutant (p<0.05). Furthermore, the
activity of the triple mutant (Gi1Q304K/C305V/E308V) was the lowest of all with the M2
receptor, supporting the idea that Gln304, Cys305 and Glu308 are all important for M2 receptor
coupling. On the other hand, the conclusion that Cys305 is not important for coupling the 5HT1A and 5-HT1B receptors is supported by the observations that the 304/305 and 305/308
double mutants have similar activities with these receptors as the Q304K and E308L single
mutants and the 304/305/308 triple mutant is similar in activity to the 304/308 double mutant
with these receptors.
Gain of function assays, in which amino acids from Gi1α replaced those from Gtα in
Chi22 were used to confirm the role of the amino acids identified in the loss of function assay.
The data in Figure 7 demonstrate that substituting back Ala301 does not lead to gain of function
with any of the receptors tested, supporting the conclusion that Ala301 of Gi1α is not important
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for receptor coupling. Substituting back Gln304 (Chi22K300Q) resulted in significant (p<0.001)
gain of activity with 5-HT1B receptors which is in contrast to the absence of a loss of activity
with 5-HT1B receptors when Gln304 was mutated to Lys in Gi1α. Similarly, substituting back
Cys305 in the Chi22V301C mutant also resulted in significant (p<0.05) gain of activity with 5HT1B receptors. The precise reasons for these anomalies are unknown but may be related to the
actual role of these amino acids in the context of their neighbors. Substituting back Glu308
alone (Chi22L304E) resulted in a gain of affinity shift activity of 48% with 5-HT1A receptors
(p<0.001), 38% with 5-HT1B receptor (p<0.001) but only 17% (p>0.05) with M2 receptors.
However, when both Gln304 and Glu308 were substituted back into Chi22 sequence
(Chi22K300Q/L304E), a full gain of activity was observed with 5-HT1A and 5-HT1B receptors,
as Chi22K300Q/L304E activity was not significantly different from activity of Gi1 (100%). The
gain of function with M2 receptors was significant (45% gain of activity, p<0.001), though still
less than the activity of Gi1. Taken together, the data indicate that Gln304 and Glu308 of
Gi1α are important for 5-HT1A, 5-HT1B and M2 receptor coupling, and that Cys305 of Gi1α is
important for M2 receptor coupling in addition to Gln304 and Glu308.
Role of C terminus of Gi1α in receptor coupling- Alignment of the C-terminal
sequences of Gi1α and Gtα indicates that their extreme eight C-terminal amino acids are
identical (Figure 8). Because numerous studies have indicated the C terminus of Gα plays a
significant role in receptor coupling, we decided to investigate the role of C terminus of Gi1α in
5-HT1A, 5-HT1B, A1 and M2 receptor coupling using Gi1α/Gqα C-terminal chimeras. As shown
in the sequence alignments in Figure 8, the extreme C-terminus of Gqα differs from that of
Gi1α in just four amino acids. Loss of function experiments may demonstrate partial or
complete loss of activity. As shown in Figure 9, replacement of just two of these amino acids
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with those from Gqα in the Q3C mutant significantly lowers the affinity shift activity with all
four receptors. The nearly complete loss of affinity shift activity (0.3% and 11.2%, respectively)
with 5-HT1B serotonin and A1 adenosine receptors suggests that these amino acids are critical
for coupling, while the more modest decrease in activity (65% and 68% activity, respectively)
with the 5-HT1A and M2 receptors suggest these amino acids are important, but not critical, for
coupling. Substitution of the five C-terminal amino acids of Gi1α with those from Gqα
eliminates coupling with the A1 adenosine receptor while substitution of 11 C-terminal amino
acids are required for complete loss of 5-HT1A receptor coupling (Figure 9). These data indicate
that the 5-HT1A, 5-HT1B, A1 adenosine and M2 muscarinic receptors differ in their utilization of
the C-terminal amino acids of Gi1α for coupling.
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DISCUSSION
G protein-receptor coupling can be regulated by a variety of mechanisms (Wess, 1998;
Albert and Robillard, 2002). At the G protein-receptor interface, the selectivity of coupling is
regulated by the amino acid sequences of both receptor and G protein. By comparing the
coupling mechanism of four closely related receptors to the same G proteins, we found that
receptors use multiple domains on Gα to achieve selective coupling. Coupling selectivity is also
regulated by the G protein concentration as demonstrated by the significant differences among
the EC50 values for Gi1-receptor interactions. This suggests that in living cells the expression
levels of specific G protein subunits may regulate receptor coupling preferences.
At the level of Gα domains, the major difference we found is that the A1 adenosine
receptor does not discriminate well between Gi1α and Gtα sequences. In contrast, the 5-HT and
M2 receptors couple with Gi1 but fail to couple with Gt. This selectivity allowed us to use
Gi1α/Gtα chimeras to define domains on Gi1α important for coupling with these receptors. Our
findings indicate that amino acids especially important for receptor coupling are located in the
α4 helix. In addition, the 5-HT1B receptor may require Asp309 at the beginning of α4/β6 loop
for optimal coupling. The corresponding amino acid in Gtα is Glu305, and while both are
negatively charged, glutamate is one -CH2 group bigger than aspartate. Thus replacement of
aspartate with glutamate may decrease 5-HT1B receptor coupling because of the change in the
size of the receptor interacting surface on Gα. In addition, we demonstrated that within the α4
helix–α4/β6 loop region of Gi1α the amino acids that are involved in receptor coupling differ
slightly among the receptors. While all three receptors utilize Gln304 and Glu308, the M2
receptor also uses Cys305 and the 5-HT1B receptor may use Asp309. Interestingly, interaction of
the 5-HT1A receptor with the K312M mutant actually leads to an increased affinity shift. This
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increase in affinity shift activity may represent tighter coupling of the receptor with the chimera.
Other investigators have also demonstrated the importance of this region of Gα in receptor
coupling. Natochin et al. demonstrated the role of Arg310 and Asp311 in interaction of Gtα
with rhodopsin (Natochin et al., 1999). Blahos et al. demonstrated that α4-α4/β6-β6-α5 region
of Gα16 is important but not critical for interaction with metabotropic glutamate receptor 8
(Blahos et al., 2001). In contrast, the work of Grishina and Berlot shows that α4/β6 loop of Gαs
is not important for interactions with β2 adrenergic receptor (Grishina and Berlot, 2000). Using
gain of function experiments, Ho and Wong demonstrated that incorporation of α4/β6 loop of
Gαz into a Gαt backbone was not sufficient for δ-opioid receptor coupling (Ho and Wong,
2000). Taken together, these results support the idea that even if different receptors recognize
the same general domain on Gα subunits, the specific amino acids involved in receptor
interactions may be different.
Another region of Gi1α important for 5-HT and M2 receptor coupling is the N terminus,
as affinity shift activity with Chi21 was lower than with Gi1 for these receptors. According to
the literature, the amino acids that bind to the receptor map to approximately positions 1-30 of
the α subunits (Hamm et al., 1988). This region, which includes the N terminus and the αN
helix, contains the most differences between Gi1α and Gtα with 15 variant amino acids
compared with just 9 variants from amino acids 31 to 219. Another significant difference
between Gi1α and Gtα is that the αN helix of Gtα is 4 amino acids shorter than the αN helix of
Gi1α. Thus it is possible that amino acids 1-30 are important but not critical for 5-HT and M2
receptor coupling.
Although the C terminus of Gα subunits is postulated to directly contact the receptor and
mediate receptor coupling selectivity, our data show that the specific amino acids involved in
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this recognition differ among the receptors studied. Cys351 (position −4), Gly352 (position −3)
and Phe354 (position −1) in Gi family members have been shown to be important for mediating
selectivity of receptor coupling (reviewed in) (Wess, 1998). Gain of function studies with Gq/i
chimeras (Conklin et al., 1993; Conklin et al., 1996) indicate that five C terminal amino acids of
Gi are sufficient for coupling to A1 and M2 receptors while three C terminal amino acids of Gi
are not enough for A1 receptor coupling (Conklin et al., 1993). Although so far it has not been
possible to successfully solve the structure of the Gα C terminus in the context of the whole
molecule (the C terminus is disordered in the crystal), the structure of the C- terminal
undecapeptide of Gtα bound to activated rhodopsin has been resolved by NMR spectroscopy
(Koenig et al., 2002). In this C- terminal decapeptide, the first eight residues form an α helix
which is terminated by an αL type C-cap (Aurora et al., 1994) with C terminal glycine (Gly348
in Gtα, Gly352 in Gi1α) in the center of the reverse turn (Kisselev et al., 1998). Thus the
observation that in case of A1 receptor three C terminal amino acids of Gi1α are critical in the
loss of function experiments but five C terminal amino acids are required to gain coupling may
be explained by the fact that this αL C-cap, which is disrupted in Gi1/Q3C chimera, is required
for A1 receptor coupling. This is probably also true for the 5-HT1B receptor. Our M2 receptor
data indicate that although this αL C-cap structure is important, it is not critical for receptor
coupling. For the 5-HT1A receptor three C terminal amino acids of Gi1α are important while
amino acids at the positions −4 and −5 (Asp350 and Cys351) are not important (activities of
Gi1/Q3C and Gi1/Q5C are the same). Gi/Q5C and Gi/Q11C are different in three amino acids,
which are probably involved in 5-HT1A receptor coupling. Some additional amino acids
involved in 5-HT1A receptor coupling are located in the α5 helix (see Figure 8) as evident from
the activity of Gi1/Q35C chimera. Taken together, our results support the idea that different
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receptors may recognize a specific pattern of amino acids which form receptor recognition
surfaces.
Figure 10 depicts the structure of the Gαi1β1γ2 G protein heterotrimer. Six amino acids
from the C terminus and four amino acids from the N terminus are missing in this structure (Wall
et al., 1995). The domains of Gi1α discussed herein are surface exposed and located on the G
protein surface that is presumed to face the receptor. They are therefore available for receptor
coupling. However, while some amino acids may be involved in coupling by making direct
contact with receptors, others may be involved indirectly by playing a role in guanine nucleotide
exchange. Amino acids Glu304, Glu308 and Asp309 are surface exposed and so are also
available for receptor coupling. Molecular modeling indicates that Gi1Q304K, Gi1E308L and
Gi1304/308 mutations alter the surface potential (Bae et al., 1999), while Gi1D309E mutation
alters steric interactions because Glu is one CH2 group larger then Asp (water-accessible
surfaces of native Gi1 and Gi1D309E were constructed and superimposed in Insight II; not
shown). Therefore, structural considerations are consistent with our conclusions. In summary,
here we demonstrated that four closely related Gi/o coupled receptors distinguish themselves by
the affinity with which they interact with Gi1 and by their use of multiple domains of Gi1α for
selective coupling.
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FIGURE 1. Concentration dependence of Gi1 in affinity shift assays for individual Gi1coupled receptors. Sf9 cell membranes expressing the indicated Gi1-coupled receptors were
reconstituted with increasing concentrations of Gi1 heterotrimer. The affinity shift activities,
percent of Gi1 for each receptor were fit to a single-site interaction between receptor and G
protein. Saturation was achieved for each receptor, however for visual purposes the curves have
been extended to a common endpoint. Shown are the data from representative experiments.
EC50 data are the mean ± SEM from 3 or more independent experiments.
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FIGURE 2. Secondary structure of Gα
α subunits. Numbers above the chimeric structures
indicate the junction points of Gαt and Gαi1 sequences and refer to the amino acid positions in
Gtα. Numbers for the wild type forms of Gtα and Gi1α represent their total amino acid
residues.

The bottom diagram depicts the secondary structural domains common to Gα

subunits.
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FIGURE 3. Functional coupling of receptors to the indicated Gi1/Gt chimeras. Sf9 cell
membranes expressing individual receptors were reconstituted with the indicated chimeric Gα
and βγ subunits. Data represent the affinity shift activities, percent of Gi1 as mean ± SEM from
3 or more independent experiments for each receptor. Exogenous G proteins were present in 40200 fold molar excess over receptors during reconstitution to achieve the maximal specific
binding during the binding assays.
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FIGURE 4. Primary sequence alignment of the α4-α
α4/β
β6 loop region of Gi1α
α and Gtα
α. The
boxes indicate the regions of Gi1α that were substituted with the corresponding sequences from
Gαt to generate the indicated Gi1α/Gtα chimeras.
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FIGURE 5. Functional coupling of receptors to the indicated Gi1/Gt chimeras. Sf9 cell
membranes expressing individual receptors were reconstituted with the indicated chimeric Gα
and βγ subunits. Data represent the affinity shift activities, percent of Gi1 as mean ± SEM from 3
or more independent experiments for each receptor. Exogenous G proteins were present in 40200 fold molar excess over receptors during reconstitution to achieve the maximal specific
binding during the binding assays.
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FIGURE 6. Functional coupling of receptors to the indicated Gi1α
α point mutants. Sf9 cell
membranes expressing individual receptors were reconstituted with the indicated chimeric Gα
and βγ subunits. Data represent the affinity shift activities, percent of Gi1 as mean ± SEM from
3 or more independent experiments for each receptor. Exogenous G proteins were present in 40200 fold molar excess over receptors during reconstitution to achieve the maximal specific
binding during the binding assays.
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FIGURE 7. Functional coupling of receptors to the indicated Chi22 point mutants. Sf9 cell
membranes expressing individual receptors were reconstituted with the indicated chimeric Gα
and βγ subunits. Data represent the affinity shift activities, percent of Gi1 as mean ± SEM from
3 or more independent experiments for each receptor. Exogenous G proteins were present in 40200 fold molar excess over receptors during reconstitution to achieve the maximal specific
binding during the binding assays.
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FIGURE 8. Sequence alignment of 35 C terminal amino acids of Gtα
α, Gi1α
α and Gqα
α. The
sequences of Gtα and Gqα are compared to Gi1α sequence. Depicted in bold are amino acids of
Gtα and Gqα that are different from corresponding amino acids of Gi1α.
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FIGURE 9. Functional coupling of receptors to the indicated Gi1/Gq chimeras. Sf9 cell
membranes expressing individual receptors were reconstituted with the indicated chimeric Gα
and βγ subunits. Data represent the affinity shift activities, percent of Gi1 as mean ± SEM from
3 or more independent experiments for each receptor. Exogenous G proteins were present in 40400 fold molar excess over receptors during reconstitution to achieve the maximal specific
binding during the binding assays.
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FIGURE 10. Spacefilling representation of the Giαβ
αβ1γ
αβ γ2 heterotrimer. The image was
generated using GRASP (developed by A. Nicholls and B. Honig, Columbia University) with
coordinates from Wall et al. (Wall et al., 1995). The α subunit is shown in metallic blue and the
βγ dimmer is in yellow. The regions involved in receptor coupling as discussed herein are the
α4-helix and α4/β6-loop in pink, Gln304 in red, Glu308 in green, Asp309 in blue, the Cterminus in cyan, and the N-terminus and αN-helix in gray.
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ABSTRACT
Molecular mechanisms of G protein coupling to M2 muscarinic and A1 adenosine receptors
were investigated in a Sf9 cell membrane reconstitution system. Functional G protein-receptor
interactions were assessed with affinity shift, agonist competition and agonist-driven nucleotide
exchange assays. Chi3, a chimeric Gα with the α4-α4/β6 domain of Gtα in a Gi1α context,
required significantly higher concentrations of agonist for functional interactions with both
receptors.

Intriguingly, at high concentrations of agonist, Chi3 had a greater nucleotide

exchange rate than Gi1 with both receptors, indicating that the α4 helix-α4/β6 loop domain may
play a fundamental role in nucleotide exchange. A second chimera, Q6N35C, which contains the
α4-α4/β6 domain of Gi1α, also required significantly higher concentrations of agonist for
functional interactions with M2 muscarinic receptors. However, nucleotide exchange rates on
Q6N35C were significantly lower than on Gi1 at all concentrations of agonist. Our results
suggest that agonist and G protein may stabilize multiple and distinct active conformations of
receptors.
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INTRODUCTION
G protein coupled receptors (GPCRs) can be activated by a variety of extracellular
signals which they transduce through heterotrimeric G proteins to different intracellular effectors
(Pierce et al., 2002). The molecular mechanisms of GPCR action are not completely understood.
The two-state modified ternary complex model is currently the most widely accepted receptor
model (Samama et al., 1993). According to this model, GPCRs exist in equilibrium between
inactive R and active R* conformations. The R* conformation is stabilized by guanine
nucleotide free G proteins and binds agonist with higher affinity than the R conformation.
Accumulating data suggest that multiple R* conformations of the same receptor subtype for
different agonists may exist (Perez et al., 1996; Krumins and Barber, 1997; Watson et al., 2000;
Waelbroeck, 2001; Ghanouni et al., 2001; Kenakin, 2001). Also it has been demonstrated that G
protein type can have an effect on agonist efficacy (Yang and Lanier, 1999). Presumably, ligandspecific R* states have different affinities for different G proteins resulting in different response
(Cordeaux et al., 2001). In addition to the ligand-specific receptor states the existence of
receptor-specific G protein conformations has also been suggested (Wenzel-Seifert and Seifert,
2000). This may indicate that G proteins play an active role in receptor coupling by either
stabilizing or inducing a specific R* conformation already produced by agonist. This hypothesis
is partially supported by the suggestion of Seifert et al. that receptor state that promotes GDP
release and the state that stabilizes the ternary complex can be different (Seifert et al., 2001).
Here we used a Sf9 cell membrane reconstitution system to investigate how G protein
type and agonist concentration can regulate G protein-receptor coupling. In this study we used
two Gi-coupled receptors - A1 adenosine and M2 muscarinic receptors. Using chimeric
Gi1α/Gtα and Gi1α/Gqα subunits we demonstrated previously that the C terminus of Gi1α is

144

critical for M2 muscarinic and A1 adenosine receptor coupling and that the α4-α4/β6 region of
Gα is critical for M2 muscarinic receptor coupling but is not important for A1 adenosine
receptor coupling (Ma et al., 2000). Here we used two chimeric Gα subunits. Chi3 is a Gi1α
based chimera in which the α4-α4/β6 region of Gi1α has been replaced with the corresponding
region of Gtα (Bae et al., 1997). Q6N35C is also a Gi1α based chimera which has 35 C-terminal
amino acids of Gi1α replaced with the corresponding amino acids from Gqα and 6 N-terminal
amino acids of Gqα added to the N terminus of Gi1α (Slessareva JE, 2001). Using affinity shift,
agonist competition and agonist-stimulated GDP/GTP exchange assays we demonstrate that the
agonist affinity of the R* conformation depends on the identity of the coupling G protein. Our
results indicate that there may be multiple active receptor conformations depending on both the
nature of G protein with which receptor interacts and the agonist concentration. The two-state
model does not adequately explain the existence of multiple activated states of receptors and
therefore our results are relevant with respect to receptor theory.
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MATERIALS AND METHODS
Materials. [3H]-Oxotremorine-M Acetate ([3H]-OXO-M) (85.8 Ci/mmol), [3H]-NMethyl Scopolamine (70 Ci/mmol), [3H]-Cyclopentyl-1,3-dipropylxanthine ([3H]-DCPX) and
[35S]-GTPγS (1250 Ci/mmol) were from New England Nuclear Life Science Products, Inc.
(Boston, MA). [125I]-Aminobenzyladenosine ([125I]-ABA) was a kind gift of Joel Linden
(University of Virginia). Oxotremorine-M, Atropine Sulfate, Chloro-N6-cyclopentyladenosine
(CCPA) and R-phenylisopropyl adenosine (R-PIA) were from Sigma-Aldrich Corporation (St.
Louis, MO). Adenosine deaminase was from Roche Molecular Biochemicals (Indianapolis, IN).
The BCA Protein Assay reagents were from Pierce (Rockford, IL). All other chemicals were
from Sigma-Aldrich Corporation (St. Louis, MO) or Calbiochem-Novabiochem Corporation
(San Diego, CA).
Preparation of Sf9 cell membranes containing recombinant receptors. To produce Sf9
cell membranes containing recombinant receptors Sf9 insect cells were infected at a density of
3.0 x 106 cells/ml with recombinant baculoviruses expressing receptors of interest at a 2-fold
multiplicity of infection. Cells were harvested by centrifugation (170xg for 7.5 minutes at 4°C)
48-60 hrs postinfection depending on cell density and viability. Cell pellets were washed three
times in ice-cold IPBS (7.3 mM NaH2PO4, 60 mM KCI, 47 mM NaCl, 2.0 mM CaCl2, pH 6.2),
resuspended in SGHB1 buffer (10 mM Tris/HCl, 25 mM NaCl, 10 mM MgCl2, 1 mM EGTA,
pH 8.0) with protease inhibitors (2 mg/ml aprotinin, 20 mg/ml benzamidine, 2 mg/ml leupeptin,
2 mg/ml pepstatin and 0.1 mM PMSF) at 0.25 - 0.5 g/ml and snap-frozen in liquid nitrogen. To
prepare membranes cell pellets were thawed in 15x their wet weight of ice-cold SGHB1 buffer
with protease inhibitors and burst by nitrogen cavitation (600 psi, 20 minutes). Cavitated cells
were centrifuged at 4°C for 10 minutes at 500xg to remove nuclei and cell debris. The
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supernatant from the low speed spin was centrifuged at 4°C for 30 min at 28,000xg. The
supernatant was discarded and the pellets were resuspended in 35 ml of HE buffer (5 mM Hepes,
1 mM EDTA, pH 7.5) with protease inhibitors at the concentrations indicated above. For the
adenosine receptor HE buffer was supplemented with 100 mM NaCl. Membranes were washed
twice, resuspended in the HE buffer at 1-3 mg protein/ml, snap frozen in liquid nitrogen and
stored at -70°C.
Reconstitution of receptors with G proteins. Frozen membranes were thawed, pelleted in
a refrigerated microcentrifuge at 12,000 rpm for 10 minutes and resuspended at 5-10 mg/ml in
reconstitution buffer (5 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 500 nM
GDP, 0.08% CHAPS for muscarinic receptors and 0.04% CHAPS for adenosine receptors). G
protein subunits were purified as previously described (Bae et al., 1997). To produce G protein
heterotrimers α and βγ subunits were mixed at the ratio of 1:1.3 and diluted in reconstitution
buffer to keep the reconstitution volume the same for each sample. G protein heterotrimers were
added to the membranes at the 60–150 fold molar excess over the recombinant receptors which
was sufficient to saturate the affinity shift activity as shown in Figure 1. The mixture was
incubated at 25°C for 20 minutes and hold on ice until the start of the binding assay.
Radioligand binding assays. Just prior to the start of the binding assay the reconstitution
mixture was diluted 10-12 fold with binding assay buffer appropriate to the receptor of interest
such that the desired amount of membranes (5-25 µg/assay tube) were contained in 10-50 µl.
Binding buffer for M2 receptors was 50 mM Tris, 5 mM MgCl2, 0.5 mM EDTA, pH 7.5.
Binding buffer for A1 adenosine receptor was 10 mM HEPES, 5 mM MgCl2, 1 mM EDTA, pH
7.4. Radioligand binding in the affinity shift assay was determined in the presence of 5 nM [3H]Oxotremorine M for M2 muscarinic receptor and 0.75 nM [3H]-Cyclopentyl-1,3-
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dipropylxanthine for A1 adenosine receptor in a final volume of 150 µl. Adenosine deaminase
was added to the [3H]-CCPA solution at 12 µg/ml in binding buffer. Non-specific binding was
determined by addition of 1000-fold excess of unlabeled ligand – atropine sulfate for M2
receptor and R-phenylisopropyl adenosine for A1 receptor. Incubations were for times sufficient
to achieve equilibrium in a temperature controlled shaker (1 hr for M2 receptor and 2 hrs for A1
receptor) and were terminated by filtration over Whatman GF/C filters using a Brandel Cell
Harvester. The filters were rinsed thrice with 4 ml ice cold 50 mM Tris-Cl, 5 mM MgCl2, 0.5
mM EDTA, 0.01% NaAzide, pH 7.5 at 4 °C, placed in 4.5 ml CytoScint (ICN Pharmaceuticals,
Costa Mesa, CA) and counted to constant error in a scintillation counter. M2 receptor number
was determined in the presence of [3H]-Scopolamine methyl chloride at concentrations 0.0317.41 nM of free [3H]-NMS. A1 receptor number was determined in the presence of saturating
amounts of Gi1 and [3H]-CCPA at concentrations 0.2–40 nM.
Competition binding experiments. The extent of receptor coupling with individual G
proteins and the KD for the high and low agonist affinity states were determined in competition
binding experiments between a single concentration of radiolabeled antagonist and increasing
concentrations of non-labeled agonist. [3H]-Scopolamine methyl chloride was used for M2
receptors and [3H]-Cyclopentyl-1,3-dipropylxanthine for A1 receptors. The agonists used were
Oxotremorine M for M2 receptors and Chloro-N6-cyclopentyl adenosine for A1 receptors.
Receptors were reconstituted with saturating amounts of G proteins as described above. Agonist
concentrations were equally spaced on the log scale in the range of 10-12-3X10-2 M for M2
receptors and 10-14-3X10-5 M for A1 receptors. Data were analyzed by nonlinear regression and
the F test was used to compare one-site vs two site fits. The Cheng-Prusoff correction was used
to calculate KD values.
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Receptor stimulated [35S]-GTPγS binding assay. A GTPγS binding assay was used to
analyze receptor-catalyzed GDP/GTP exchange on G protein α subunits. Typically 1.3 pmol of
receptors were reconstituted with 80 pmol of G protein heterotrimers (1.3 fold excess of α over
βγ) for 15 min at 30°C in reconstitution buffer (25 mM Hepes, pH 7.5, 100 mM NaCl, 5 mM
MgCl2, 1 mM EDTA, 200 nM GDP, 0.08% CHAPS for M2 receptor and 0.04% CHAPS for A1
receptor). After reconstitution the mixture was diluted 10 fold with GTPγS Binding buffer (50
mM Tris, pH 8.0, 100 mM NaCl, 25 mM MgCl2, 1 mM DTT, 0.1 mg/ml BSA). Reactions were
initiated by the addition of 25 µl of membrane mixture to 25 µl of GTPγS with or without
agonist. Final assay conditions were 50 nM Gα, 0.8 nM receptor, 10 nM GDP, 10 nM GTPγS as
a mixture of 1nM [35S]-GTPγ and cold GTPγS, with or without agonist in a final volume of 50
µl. Use of MultiScreen 96 well plates (Millipore) allowed collection of samples at 30 second
intervals for 4-6 minutes. Filters were rinsed three times with 100 µl of ice-cold wash buffer (50
mM Tris-HCl, pH 8.0, 100 mM NaCl, 25 mM MgCl2) Radioactivity retained on the filters was
counted to constant error in a liquid scintillation counter. Greater than 1500 cpm were observed
at the shortest time points and ligand depletion was less than 15% at the longest time-points. The
rate of GTPγS binding for each Gα at each agonist concentration was taken as the slope
determined by linear regression. If the slope was significantly different from basal (zero agonist),
the fold-enhancement over basal GTPγS binding was calculated as the ratio of the slopes. If the
slopes were not significantly different the ratio was assigned a value of 1. The ratios were plotted
against log agonist concentration and the data fit to a sigmoidal dose-response relationship.
Analysis of the data. The data were analyzed using GraphPad Prism software package
(GraphPad Software, San Diego, CA).
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RESULTS AND DISCUSSION
The goal of this paper was to understand how the G protein-receptor coupling is regulated
by agonist concentration and also to investigate how identity of Gα can regulate the affinity of
agonist for receptor. A1 adenosine receptors and M2 muscarinic receptors are both capable to
couple to Gi1. The important difference between these receptors however is that A1 receptors
can couple Gt but M2 receptors can not (Ma et al., 2000). As reported previously, the α4-α4/β6
region of Gi1α is critical for M2 receptor coupling and the C terminus of Gi1α is critical for both
A1 and M2 receptor coupling (Ma et al., 2000). Figure 1 shows Gα proteins used in this study.
Chi3, which has the α4-α4/β6 region of Gi1α replaced with the corresponding region from Gtα,
can couple A1 adenosine receptors but can not couple M2 muscarinic receptors very well, while
Q6N35C was inactive with both receptors as shown in the insets in Figure 2. To ensure that all
experiments were done at saturating G protein concentration, Gα saturation experiments were
performed as shown in Figure 2. Our results demonstrate that the increase in high affinity agonist
binding following reconstitution with exogenous G proteins is a saturable phenomenon. Chi3
enhances agonist binding with adenosine receptors almost as well as Gi1 but has very little
activity with muscarinic receptors while q6N35C is unable to couple either receptor. The ability
of individual G proteins to enhance high affinity agonist binding to different extents suggests that
the actual agonist affinity of a receptor depends on the identity of the coupling G protein.
To investigate how the G protein-receptor coupling is regulated by agonist concentration,
agonist competition experiments against a fixed concentration of radiolabeled antagonist and
increasing concentrations of agonist were performed. These experiments can detect the formation
of the ternary complex of agonist, receptor and nucleotide-free G protein and determine the
actual affinity of the high affinity state of the receptor. Figure 3 shows the agonist competition
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experiments with A1 and M2 receptors reconstituted with Gi1, Chi3 and q6N35C. Insets in
Figure 3 show the percentages of receptors coupled with G proteins and the KD for the high
affinity state of receptors. The percentages of the coupled receptors were not significantly
different between different G proteins, indicating that the differences between G proteins
manifest themselves as the differences in the KD for the formation of the high affinity state of the
receptor. Gi1, used as a positive control, had highest affinity for high affinity receptor state with
both A1 adenosine and M2 muscarinic receptors (0.01 nM and 2.6 nM respectively). With A1
adenosine receptor Chi3 had the same activity as Gi1 and the KD for the formation of high
affinity state was not much different for Gi1 and Chi3 (Figure 3A). Q6N35C was inactive in
affinity shift assay with A1 receptors but could form the ternary complex as indicated by the
agonist competition assay (Figure 3A). However as seen in inset in Figure 3, KD for the
formation of the high affinity state was 155 times higher for q6N35C than for Gi1 (1.71 nM vs.
0.011 nM). With M2 muscarinic receptor, Chi3 was only weakly active and q6N35C was
completely inactive in the affinity shift assay (Figure 2B). In the agonist competition assay
(Figure 3B) Chi3 formed the ternary complex with high affinity KD of 26.9 nM, which is 10
times higher than Gi1. Q6N35C, which was completely inactive in the affinity shift assay with
M2 muscarinic receptor, formed the ternary complex with the high affinity KD of 239.8 nM (92
times higher than Gi1) (Figure 3B). Data in Figure 3 demonstrate that G proteins unable to
couple receptors in the affinity shift assay gained the ability to couple the receptors at higher
agonist concentration. Our results indicate that the actual affinity of the high-affinity agonist
binding state of a receptor depends on the identity of the coupling G protein and may vary over
several orders of magnitude. This suggests that there are multiple active receptor conformations
and that agonist and G protein may differentially stabilize such states.
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Agonist competition experiments look at the G protein binding to the receptor as
indicated by the formation of the high affinity receptor state. However they don’t provide
information about G protein activation step. To investigate if G protein binding at higher agonist
concentration seen in agonist competition assay leads to G protein activation we performed
agonist dose-response of GDP/GTP exchange assay. Figure 4 shows the agonist concentration
dependence of GDP/GTP exchange on Gi1, Chi3 and q6N35C for A1 adenosine (Figure 4A) and
M2 muscarinic (Figure 4B) receptors. As seen in inset table in Figure 4, the functional coupling
of individual G proteins to receptors at significantly different concentrations of agonist is also
seen in GDP/GTP exchange assays. With the exception of q6N35C and the A1 adenosine
receptor, there is a strong correlation between the high affinity agonist KD (Figure 3) and the
agonist EC50 values for GDP/GTP exchange (Figure 4) which supports the conclusion that there
are multiple active receptor states that are differentially stabilized by agonist and G proteins. The
inability of the A1 adenosine receptor to catalyze GTPγS binding to q6N35C at any
concentration of agonist is not understood. However the fact that q6N35C can bind to A1
adenosine receptors but can not be activated supports the idea of multiple active receptor
conformations. Intriguingly, with both receptors, at high concentrations of agonist Chi3 has a
significantly greater nucleotide exchange rate than Gi1. Transducin is known to have very low
basal GTP binding and to undergo the greatest receptor stimulation of GTP binding when
coupled to rhodopsin (Fawzi and Northup, 1990) suggesting that the α4-α4/β6 domain (which is
from transducin in Chi3) may play a fundamental role in nucleotide exchange. Figure 5 shows
different views of Gi1αβ1γ2 heterotrimer in order to illustrate the location of α4-α4/β6 domain
relative to the guanine nucleotide binding site. The α4-α4/β6 domain is not a part of the guanine
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nucleotide binding site (Sprang, 1997). However it can play a role by affecting conformation of
the regions directly involved in guanine nucleotide exchange.
GPCRs are proteins in nature, so they can exist in multiple conformations. However not
all conformations have a physiological role. The idea that different agonists stabilize different
active receptor conformations has been actively discussed and experimentally tested (Tucek,
1997; Kenakin, 1997; Kenakin, 2001). The important characteristic of receptor active states is
their ability to interact with G proteins or other membrane proteins and initiate a response.
Supposedly different active receptor conformations expose different sequences in intracellular
loops which may account for the ability of one receptor subtype to couple to several G proteins.
Thus the nature of agonist dictates which active receptor conformation will prevail and signal
through a certain pathway. However in this scheme G proteins play rather a passive role. Earlier
work of Clawges et al. demonstrated that different Gα subunits (Goα, Gi1α, Gi2α, Gi3α)
enhanced the high affinity [3H]-HT binding to 5-HT receptors to different extent, suggesting that
actual affinity of high affinity state can be different depending on the nature of G protein
(Clawges et al., 1997). Yang and Lanier demonstrated that G protein type have an effect on
agonist efficacy by showing that the expression of Goα1 together with α2 adrenergic receptor
increased the relative efficacy of clonidine but Gi1α did not, without changing the ability of
clonidine to interact with and stabilize the receptor (Yang and Lanier, 1999). Cordeaux at al.
showed that D2 Dopamine receptors have higher affinity for Go than Gi2 and that this preference
depends on agonist used, indicating that different active receptor conformations have different
abilities to couple with G proteins (Cordeaux et al., 2001). Using fusion protein approach
Wenzel-Seifert and Seifert demonstrated that β2 adrenergic receptor couples better with Gs than
Gi and Gq, and is able to discriminate between different members of Gi and Gq families, as
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judged by the ternary complex formation (Wenzel-Seifert and Seifert, 2000). Using full and
partial agonists they also demonstrated that G protein type have an effect on pharmacological
properties of the receptor. Here we used one agonist for each receptor and different G proteins to
investigate how G proteins affect agonist affinity for the receptor in a reconstitution system. We
demonstrated that the G proteins unable to couple to receptors in the affinity shift assay were
able to couple to receptors at higher agonist concentrations. Importantly, the ability of G proteins
to bind to receptor at higher agonist concentrations correlated with G protein activation at higher
agonist concentrations, with the exception of q6N35C and A1 adenosine receptors. Our results
indicate that agonist and G protein may stabilize multiple and different active receptor
conformations. We propose the following mechanism by which G proteins can regulate receptor
coupling. Receptor activation by agonist produces at least one activated R* state capable to
couple with G proteins. G proteins in turn can bind to receptor and change its conformation so
that GDP release could occur and ternary complex with high affinity for agonist could form. If G
protein is unable to change receptor conformation, ternary complex will not form. If the receptor
conformation in the formed ternary complex is not able to activate the G protein, G protein
binding but not activation will be seen, as in case of q6N35C and A1 adenosine receptors. Thus
different G proteins will stabilize different R* conformations. Importantly, the formation of these
different R* is regulated by agonist concentration. The physiological relevance of this however is
not understood.
In summary, we provided new evidence that agonist and G protein may differently
stabilize multiple active receptor conformations and that the existence of these active states is
regulated by agonist concentration. These findings are relevant with respect to receptor theory. In
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addition, we propose that α4-α4/β6 region of Gtα may play a role in guanine nucleotide
exchange by affecting the conformation of the guanine nucleotide binding site.
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FIGURE 1. Secondary structure of chimeric Gα
α subunits. Numbers on the right of the wild
type forms of Gtα, Gi1α and Gqα indicate their total amino acid residues. Numbers within the
designations for the chimeras indicate the number of amino acids switched between wild type
Gα subunits. The diagram on the bottom depicts the secondary structural domains common to
Gα subunits.
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FIGURE 2. Concentration dependence of Gi1 in affinity shift assays for A1 adenosine (A)
and M2 muscarinic (B) receptors. Sf9 cell membranes expressing the indicated Gi-coupled
receptors were reconstituted with increasing concentrations of Gi1 heterotrimer. High affinity
agonist binding was determined in the presence of 0.4 nM [125I]-ABA for A1 adenosine receptors
and 5 nM [3H]-OXO-M for M2 muscarinic receptors. Typically, each reconstitution used 0.8
pmol of M2 receptors and 0.1 pmol of A1 receptors. The highest concentration of G proteins
used is an estimated 380-fold excess over expressed receptors. Data were fit to a single-site
interaction between receptor and G protein and are the mean ± SD of triplicate determinations
from a representative experiment. The inset graphs show normalized affinity shift activities
obtained with saturating concentrations of heterotrimers containing chimeric Gα subunits
expressed as the % of that obtained with a saturating concentration of Gi1. The final
concentrations of receptors and G protein heterotrimers in the binding assay were 1.5 nM and
150 nM for M2 receptors respectively and 0.7 nM and 28 nM for A1 receptors respectively in a
final volume of 150 µl. For each receptor the EC50 values did not differ significantly between
Gi1 and Chi3. No significant affinity shift activity was observed with q6N35C with either
receptor.
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FIGURE 3. Agonist competition binding against a fixed concentration of radiolabeled
antagonist for A1 adenosine (A) and M2 muscarinic (B) receptors. Receptors were
reconstituted with saturating amounts of the indicated G proteins (at least 200-fold excess over
receptors) as shown in Figure 1 and binding was determined in a final volume of 500 µl.
Antagonist binding was determined in the presence of 0.8 nM [3H]-DCPX for A1 adenosine
receptors and 1.5 nM [3H]-NMS for M2 muscarinic receptors and increasing concentrations of
unlabeled agonists as indicated. Data were analyzed by nonlinear regression and an F-test was
used to compare one-site vs two site fits. The Cheng-Prusoff correction was used to calculate KD
values. Agonist competition experiments with control membranes (no exogenous G proteins)
were best fit to a one-site interaction model indicating that the small amount of receptor coupling
with endogenous G proteins does not contribute significantly to the results (data not shown).
The KD values in control membranes were 48.9 nM (n=1) for the A1 adenosine receptor and 8.6
± 2.2 µM (n=2) for the M2 muscarinic receptor. These values did not differ significantly from
the low affinity KD obtained from the 2-site fits with the reconstituted membranes.
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FIGURE 4. Dose-response of receptor-catalyzed GDP/GTP exchange on Gα
α subunits for
A1 adenosine (A) and M2 muscarinic (B) receptors. Receptors were reconstituted with
saturating amounts of the indicated G proteins. The fold-enhancement by agonist in the rate of
GTPγS binding (determined by linear regression) to each Gα subunit at the indicated
concentrations was determined as described in Methods and the data fit to a sigmoidal doseresponse relationship. Final conditions were 50 nM Gα, 0.8 nM receptor, 10 nM GDP, 10 nM
GTPγS (as a mixture of 1nM [35S]-GTPγS and cold GTPγS), with or without agonist in a final
volume of 50 µl. *There was no significant agonist stimulation of GTPγS binding to q6N35C by
the A1 adenosine receptor and the data shown are adequately fit by linear regression with zero
slope.
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FIGURE 5. Structural representation of different views of Gi1αβ
αβ1γ2 heterotrimer. Different
views of Gi1 heterotrimer are shown to illustrate the spatial proximity of the α4 helix and GDP.
Pictures were generated using RASMOL. Coordinates are from Wall et al. Gβ subunit is shown
in redorange and Gγ subunit is shown in bluegreen. The rest of the molecule is Gα subunit. C
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region (amino acids 299-319) is in red. Other guanine nucleotide binding regions are shown in
white as indicated by Sprang (Sprang, 1997).
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CHAPTER IV. DISCUSSION
In recent years much progress has been made in understanding the mechanisms of G
protein-coupled receptor (GPCR) action. However the molecular mechanisms controlling G
protein-receptor coupling are still not completely understood. Based on the human genome
sequence, the total number of human GPCRs is close to 750. This number includes 376 GPCRs
for endogenous ligands (Vassilatis et al., 2003), about 350 olfactory receptors and 30 other
chemosensory receptors (Glusman et al., 2001; Zozulya et al., 2001). These GPCRs presumably
couple with heterotrimeric G proteins composed from α, β and γ subunits. Many different
heterotrimers can be produced from 20 α subunits, 6 β subunits and 12 γ subunits. Therefore,
the question of selectivity in G protein-receptor coupling arises (Gudermann et al., 1996; Wess,
1998). Intact organisms employ various mechanisms to regulate the signal flow through G
protein-mediated pathways, including regulation of G protein and receptor expression levels
(Vassilatis et al., 2003), compartmentalization of signaling complexes, and the activity of
accessory proteins (Neubig, 1994; Gudermann et al., 1996; Wess, 1998; Albert and Robillard,
2002). The major goal of this project was to understand how the selectivity of G proteinreceptor coupling is achieved at the level of the G protein-receptor interface, where the primary
recognition is governed by the amino acid sequences of both G protein and receptor. This
project was specifically aimed at determining the selectivity of G protein-muscarinic receptor
coupling with additional goals to assess the generality of molecular mechanisms underlying G
protein-receptor coupling and to understand how the selectivity of G protein-receptor coupling
is regulated by agonist concentration. Dysfunctions of G proteins and receptors are implicated
in a growing number of diseases (Iiri et al., 1998) and uncovering the molecular mechanisms of
G protein and receptor action will ultimately lead to better disease treatments (Farfel et al.,
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1999; Levine, 1999; Spiegel, 1999). GPCRs are encoded by 1-3 % of the genes in human
genome and are the targets of more than 30% of therapeutically used drugs (Wise et al., 2002).
However only 10% of all GPCRs are used as drug targets at present. Therefore, studying the
mechanisms of G protein-receptor coupling may suggest new approaches in treating disease
states and may help to develop new drugs that act at the G protein-receptor interface.
This study utilized the Sf9 cell membrane-based reconstitution system, which is well
established and described in the literature (Figler et al., 1996; Clawges et al., 1997; Bae et al.,
1997; Bae et al., 1999). Using this system, the coupling behavior of receptors of interest with
exogenously supplied, purified G proteins can be studied. In contrast to cell transfection
experiments, reconstitution experiments directly examine the G protein-receptor interface and
allow controlled stoichiometries of components. Importantly, this system allows the analysis of
both the ability of G proteins to stabilize the high affinity state of receptors for agonist and the
ability of the receptors to catalyze guanine nucleotide exchange on Gα. An important step
toward completion of this project was the establishment of an M1-Gq reconstitution system
which had not been accomplished before. Compared with Gi1, Gq is harder to purify in
significant amounts because Gq is not soluble and needs to be purified as a detergent extract
from Sf9 membranes (Kozasa and Gilman, 1995), while the soluble Gi1 can be purified from
the Sf9 cytosol (Graber et al., 1992). Additionally, in contrast to the M2 reconstitution system,
M1 receptors require treatment with 6 M Urea in order to couple with exogenous G proteins.
The successful use of urea treatment to achieve coupling has been reported before for different
receptors (Hartman and Northup, 1996; Hellmich et al., 1997; Lindorfer et al., 1998). The
mechanism of urea action is not clear. For Gi-coupled receptors Lim and Neubig demonstrated
that membrane extraction with urea uncouples receptors from endogenous G proteins by
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inactivating them (Lim and Neubig, 2001). However, endogenous Sf9 G proteins alone can not
account for the inability of M1 receptors to couple to exogenous Gq without urea treatment
because, as revealed by the careful examination, only a small per cent (~0.3 %) of receptors is
precoupled to endogenous G proteins. Possibly, in addition to endogenous G proteins urea also
removes some structural constraints which interfere with receptor coupling. Since the urea
treatment was not required to establish M2-Gi1 reconstitution, inactivation of endogenous G
proteins is not the only mechanism of urea action.
As discussed in Chapter III Part I, in addition to the expected Gq-M1 and Gi1-M2
receptor coupling, we also saw a low level of Gi1-M1 and Gq-M2 receptor coupling in the
affinity shift assay (Figure 2, page 98). The basis for this coupling was explored with the use of
pertussis toxin (Figure 4, page 100). Pertussis toxin is known to uncouple Gi/o proteins from
their cognate receptors by ADP-ribosylating a C- terminal cysteine in Gi/oα subunits (West, Jr.
et al., 1985). My data demonstrated that M1 receptors have limited ability to couple to Gi1,
while M2 receptors can not couple to Gq. The low level of M2-Gq coupling seen in Figure 2
(page 98) was attributed to the contamination of the Gq preparations with low levels of
endogenous Gi. A similar contamination of Gq purified after expression in Sf9 cells by
endogenous Gi/o proteins was reported by Kozasa (Kozasa and Gilman, 1995). The fact that
endogenous Gi in the Gq preparations could not be detected by immunoblotting suggested that
contamination levels were low. Contamination with endogenous Gi was only present in Gq and
Gqi5C preparations, which were purified as detergent extracts from membranes as opposed to
the Gi1 and other chimeras, which was purified as soluble protein from the cytosol. At present
not much is known about Sf9 endogenous Gi. Fall armyworm Spodoptera frugiperda and
tobacco hornworm Manducta secta belong to the order Obtectomera. A sequence of the Go
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protein from the Manducta secta has been published (Horgan et al., 1995) and contains the C
terminal cysteine which is required for the PTX ribosylation. The Sf9 endogenous Gi is a
substrate for the PTX ribosylation, as demonstrated in the Chapter III Part I. Based on the
closeness of the species, we may speculate that the Sf9 endogenous Gi may have similar amino
acid composition. As an interesting sideline observation, my data suggest that endogenous Gi
from Sf9 cell membranes has different properties than recombinant Gi1. Data in Chapter II
Table II (page 67) show that the high affinity state of M2 receptor stabilized by endogenous G1,
which is present as contamination in the Gq preparation, has higher affinity for agonist (0.04
nM) than does the high affinity state stabilized by recombinant Gi1 (2.6 nM). The value for the
high affinity state stabilized by recombinant Gi1 for Oxotremorine is in good agreement with
the data of Sharif et al. for the high affinity state of a mixture of M1-M4 muscarinic receptors
from animal tissues for Oxotremorine (2.5 nM) (Sharif et al., 1995). Furthermore, Dong et al.
indicate that affinities of muscarinic receptor subtypes for Oxotremorine are not significantly
different from each other (Dong et al., 1995).
Data presented in Chapter III Part I deal with the molecular mechanisms of M1 and M2
muscarinic receptor coupling with Gq and Gi1 proteins. As described in the Introduction,
different Gα domains have been shown to be important for receptor coupling. However, Chapter
III Part I focuses on the role of the N- and C- termini of Gqα and Gi1α in muscarinic receptor
coupling. The C terminus of Gα has been shown to interact with receptors using different
experimental approaches including transfection experiments (Conklin et al., 1993), synthetic
peptide competition experiments (Hamm et al., 1988), ADP-ribosylation of Gα by pertussis
toxin (West, Jr. et al., 1985) and direct reconstitution studies (Natochin et al., 2000). The C
terminus of Gα is critical for coupling to many receptors. However, as we show in Chapter III
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Part I, the C terminus although critical (in the loss of function experiments), is not sufficient (in
the gain of function experiments) for muscarinic receptor coupling (Figure 2, page 98). Conklin
et al. have demonstrated in the cell transfection experiments that substitution of the last five C
terminal residues of Gqα with corresponding sequences of Giα, Goα or Gzα allowed PLCβ
stimulation by receptors normally coupled to Gi/o such as A1 adenosine and D2 dopamine
receptors (Conklin et al., 1993). The same was demonstrated later for M2 muscarinic receptor
(Liu et al., 1995). My data, that the C terminus of Gi1α in the Gqα context is not sufficient for
M2 receptor coupling, are in contrast with results of Liu, Conklin and others. While the precise
reasons for such different observations in transfection versus reconstitution assays are unknown,
several factors are likely to contribute. In transfection assays proteins of interest are
overexpressed in a limited percentage of cells and coupling is inferred from effector activities
which are substantially amplified at several points in the signal transduction cascade. On the
other hand, all cellular components are present and the integration and assembly of membrane
structures occurs in a cellular context. Reconstitution experiments directly examine the G
protein-receptor interface and allow controlled stoichiometries of components, however they
require the G protein to associate with the receptor after the receptor has been integrated into
cellular membranes and may not allow the participation of all components responsible for
receptor-G protein coupling. Thus, reconstitution experiments are likely to more precisely
identify the G protein domains directly involved in the receptor - G protein interface, while
transfection experiments are likely to identify the domains that permit coupling in a cellular
context without revealing the precise mechanism or required stoichiometries. Ultimately both
contribute to our understanding of coupling although neither may completely reflect the actual
situation in living tissues. The fact that the C termini of Gqα and Gi1α were not sufficient for
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M1 and M2 receptor coupling indicated that other domains of Gα are required for proper
receptor coupling. However this conclusion is not universal, because as others and we have
demonstrated, molecular determinants of G protein-receptor coupling differ among individual
receptors and their cognate G proteins. For example, Natochin et al. reported that eleven Cterminal residues of Gtα in the Gsα context were sufficient for rhodopsin coupling in a
reconstitution system (Natochin et al., 2000).
The N terminus of Gα has also been shown in variety of experiments to be a determinant
of G protein-receptor coupling selectivity (Hamm et al., 1988; Higashijima and Ross, 1991;
Hepler et al., 1996; Bae et al., 1997; Swift et al., 2000). Kostenis et al. demonstrated the
importance of the N terminus of Gqα in constraining receptor coupling selectivity. They showed
that deletion of six N- terminal amino acids of Gqα, which are unique for Gq family, led to
promiscuous coupling so that several Gi/o and Gs coupled receptors gained the ability to
productively couple with this Gqα mutant (Kostenis et al., 1997). Kostenis et al. have suggested
that the six N- terminal amino acids of Gqα (MTLESI) form a tightly folded protein subdomain
that prevents Gi/o- and Gs-coupled receptors from accessing Gqα, thereby regulating coupling
selectivity (Kostenis et al., 1998). We demonstrated that the addition of the unique six amino
acid N- terminal extension of Gqα to the N- terminus of Gi1α neither permitted M1 receptor
coupling, nor prevented M2 receptor coupling (Figure 2, page 98). Interestingly, a Gi1α based
chimera, q6N35C, containing both N- and C- terminal regions of Gqα, gained the ability to
productively couple M1 receptors. This suggests that the proper context of both N- and Ctermini is required for M1 muscarinic receptor coupling (Figure 2, page 98). Importantly, my
data demonstrated that q6N35C chimera can couple to M1 muscarinic receptors in the affinity
shift assay and be activated in the GDP/GTP exchange assay (Figure 5, page 102). Q6N35C
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represents an easily purified, relatively stable, and soluble Gα subunit with the ability to
functionally couple with M1 muscarinic receptors. As a reagent it therefore offers significant
advantages to native Gqα, which is difficult to purify, requires detergents for solubility and is
easily inactivated by denaturation. Our data suggest that N- and C- termini of Gqα cooperate to
couple M1 receptors. However, because the structural orientation of the extreme N- and Ctermini in Gq is not known, and also because the crystal structure of a nucleotide-free G protein
heterotrimer is not available, the mechanism of cooperativity between the extreme N- and Ctermini of Gqα is not yet understood. It is also tempting to speculate that cooperation between
appropriate N- and C- termini are also critical for Gi1-M2 muscarinic and, possible, other
receptor coupling. Reconstitution studies in Chapter III Part II demonstrated a role for a poorly
defined region within the first 210 amino acids of Gi1α that is important for 5-HT1A and 5-HT1B
serotonergic and M2 muscarinic receptor coupling (Chi21 in Figure 3, page 131). However,
since only the six amino acid N-terminal extension that is unique to Gqα subunits was tested in
this study such speculation may be premature and the structural determinants of coupling may
differ significantly between receptors. In fact, as shown in Figure 3 (page 131) A1 adenosine
receptor is different from the receptors mentioned above is that it does not distinguish between
Gi1α and Gtα sequences.
Chapter III Part II investigates the molecular determinants of Gi1-receptor coupling more
precisely, making the emphasis on the role of the α4 helix-α4/β6 loop of Gi1α in receptor
coupling. The α4 helix-α4/β6 loop region of Gi1α has been shown to be absolutely essential for
5-HT1B serotonergic receptor coupling (Bae et al., 1997). Our results demonstrated that the α4
helix-α4/β6 loop of Gi1α is also critical for M2 receptor coupling (Chi3 in Figure 3, page 131)
and that amino acids Gln304, Cys305 and Glu308 in the α4 helix are especially critical for

172

coupling. The work of Natochin et al. points to the α4/β6 loop as a receptor interacting domain
and indicates that Arg310 and Asp311 are involved in the interaction with transducin (Natochin
et al., 1999). Mody et al. demonstrated that incorporation of α4/β6 and α5 regions of Gzα into
G16α improved recognition of resulting chimera by Gi/o-coupled receptors (Mody et al., 2000).
Our data in Part II demonstrated that α4 helix-α4/β6 loop of Gi1α was also critical for 5-HT1A
receptor coupling (Chi3 in Figure 3, page 131). Interestingly, 5-HT1B receptor in addition to the
amino acids in the α4 helix uses Asp309 at the beginning of the α4/β6 loop. The most intriguing
finding in the Part II is that A1 adenosine receptor does not distinguish between the α4 helixα4/β6 loop region of Gi1α and Gtα (Figure 3, page 131). There are two possible explanations
for this phenomenon. First, A1 adenosine receptor may not use the α4 helix-α4/β6 loop region of
Gi1α for coupling. In this case the coupling properties of A1 adenosine receptor are radically
different from these of 5-HT serotonergic and M2 muscarinic receptors. Second, A1 adenosine
receptor may use the α4 helix-α4/β6 loop region for coupling but does not have preference for
the amino acid sequence of this region. In fact, 9 from 21 amino acid difference in the α4 helixα4/β6 loop region between Gi1α and Gtα is sufficient to eliminate the coupling with 5-TH
serotonergic and M2 muscarinic receptors but not with A1 adenosine receptors. To distinguish
between these possibilities, other chimeric Gα subunits need to be created and tested for the
ability to couple with A1 adenosine receptor. From data in Part I we may conclude that because
M1 muscarinic receptor gained a strong coupling with just the N- and C- termini of Gqα, it is
also not sensitive to the subtype specificity of the α4 helix-α4/β6 loop region. However activity
of q6N35C chimera in affinity shift assay with M1 receptor was lower than activity of Gq,
indicating that other domains of Gqα may be important for M1 receptor coupling. Taken
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together, these data lead to the discussion of the generality of molecular mechanisms underlying
G protein-receptor coupling.
Other domains of Gα, in addition to those discussed above have been shown to be
important for different receptors. Lee et al demonstrated that the α2 helix-α2/β4 loop region in
addition to the C terminus, which was not sufficient by itself, is important for C5a receptor
activation by G16α subunits (Lee et al., 1995). Krirgel-Brauer et al. demonstrated that amino
acids 100-119 in the α helical domain of Gsα are a contact site for β-adrenergic receptor
(Krieger-Brauer et al., 1999). The α3/β5 loop of Gsα has also been shown to interact with β2adrenergic receptors (Grishina and Berlot, 2000). A recent report by Blahos et al. identified the
αN/β1 loop as a novel site on Gα16 which recognize metabotropic glutamate receptor 8 (Blahos
et al., 2001). Taken together, our data and data from other laboratories, indicate that multiple and
distinct determinants of selectivity exist for individual receptor families. In Chapter III Part II we
made an interesting observation regarding the critical role of the C terminus of Gα for receptor
coupling. We demonstrated that different amino acids within the C terminus of Gi1α are critical
for different receptors (Figure 9, page 137). While 3 C terminal amino acids of Gi1α were
important but not critical for 5-HT1A and M2 receptor coupling, they were critical for 5-HT1B and
A1 adenosine receptor coupling. The 5 C terminal amino acids of Gi1α were critical for M2
receptor coupling, while more than 11 C terminal amino acids of Gi1α were critical for the 5HT1A receptor coupling. These differences may relate to the structure of the Gi1α C terminus.
Although so far it has not been possible to successfully solve the structure of the Gα C terminus
in the context of the whole molecule (the C terminus is disordered in the crystal), the structure of
the C- terminal decapeptide of the Gtα bound to rhodopsin has been resolved (Koenig et al.,
2002). In this C- terminal decapeptide, the first eight residues form an α helix which is
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terminated by an αL type C-cap (Aurora et al., 1994) with C terminal glycine (Gly348 in Gtα,
Gly352 in Gi1α) in the center of the reverse turn (Kisselev et al., 1998). This αL C-cap structure
might be critical for A1 adenosine and 5-HT1B serotonin receptor coupling and important but not
critical for M2 muscarinic and 5-HT1A receptor coupling. Taken together, our results support the
idea that different receptors may recognize a specific pattern of amino acids which form receptor
recognition surfaces. Importantly, the domains of Gi1α discussed herein are surface exposed and
located on the G protein surface that is presumed to face the receptor. They are therefore
available for receptor coupling. The spacefilling representation of the Gαi1β1γ2 heterotrimer is
shown in Figure 10 (page 138).
Another important observation that we have made regarding the generality of the
mechanisms of G protein-receptor coupling deals with the apparent affinity of individual
receptors for the same G protein. We showed that individual receptors distinguish themselves by
the EC50 with which they interact with Gi1 (Figure 1, page 129). A1 receptors have the highest
apparent affinity (0.4 nM) and M2 receptors have the lowest apparent affinity (47 nM) for Gi1
heterotrimer. 5-HT receptors have intermediate EC50 values (3.7 nM and 16.2 nM respectively).
These results extend the earlier findings of Clawges et al with 5-HT serotonergic receptors
(Clawges et al., 1997). These data suggest that in living cells the expression levels of specific G
protein subunits may regulate receptor coupling preferences. However we have to consider the
existence of different mechanisms which regulate G protein-receptor coupling in the cell
environment. Thus more studies are needed to test this hypothesis in vivo. Taken together, data
indicate that coupling selectivity ultimately involves subtle and cooperative interactions among
various domains on both the G protein and the associated receptor as well as the G protein
concentration.
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The initiating event in the activation of G protein mediated signaling is agonist binding to
receptor. Therefore we also wanted to investigate how the agonist concentration might regulate
G protein-receptor coupling. In Chapter III Part III we demonstrated that G proteins unable to
couple receptors in the affinity shift assay, which uses a single low concentration of agonist, in
fact formed a ternary complex at higher agonist concentration in competition binding assay
(Figure 3, page 160). The functional coupling of individual G proteins to receptors at
significantly different concentrations of agonist was also seen in GDP/GTP exchange assays
(Figure 4, page 162). Interestingly, the A1 adenosine receptor was not able to catalyze the
nucleotide exchange on the q6N35C chimera at any agonist concentration but was able to form a
high affinity agonist binding state in agonist competition assay, indicating that G protein could
bind to the receptor but could not be activated. In Part I we describe the case where M1
muscarinic receptor can couple Gi1 in the affinity shift assay but can not activate Gi1 the
agonist-stimulated nucleotide exchange assay (see Figure 2, page 98 and Figure 5, page 102).
These results indicate that it is possible to stabilize the high affinity state of receptor without
stimulating guanine nucleotide exchange. Such discrepancies have been noted in a previous
study with the 5-HT1B receptor and a set of chimeric Gα subunits (Bae et al., 1999). Taken
together these results indicate that there may be multiple active receptor conformations
depending on both the nature of G protein with which receptor interacts and the agonist
concentration.
The two-state modified ternary complex model is currently the most widely accepted
receptor model (Samama et al., 1993). According to this model, GPCRs exist in equilibrium
between inactive R and active R* conformations. The R* conformation is stabilized by guanine
nucleotide free G proteins and binds agonist with higher affinity than the R conformation.

176

Rapidly accumulating data suggest that multiple R* conformations of the same receptor subtype
for different agonists may exist (Perez et al., 1996; Krumins and Barber, 1997; Watson et al.,
2000; Waelbroeck, 2001; Ghanouni et al., 2001; Kenakin, 2001; Gazi et al., 2003). The idea that
different agonists stabilize different active receptor conformations has been actively discussed
and experimentally tested (Tucek, 1997; Kenakin, 1997; Kenakin, 2001). However in this
scheme G proteins play rather a passive role. Earlier work of Clawges et al. demonstrated that
different Gα subunits (Goα, Gi1α, Gi2α, Gi3α) enhanced the high affinity [3H]-HT binding to
5-HT receptors to different extent, suggesting that actual affinity of the high affinity state can be
different depending on the nature of the coupling G protein (Clawges et al., 1997). Yang and
Lanier demonstrated that G protein type have an effect on agonist efficacy by showing that the
expression of Goα1 together with α2 adrenergic receptor increased the relative efficacy of
clonidine while Gi1α did not (Yang and Lanier, 1999). Using full and partial agonists WenzelSeifert and Seifert demonstrated that G protein type have an effect on pharmacological properties
of the receptor (Wenzel-Seifert and Seifert, 2000). They showed that efficacies of different β2
adrenergic receptor ligands differ from each other depending on the G protein available for
coupling. Furthermore, they found differences in the pharmacology of β2 adrenergic receptor
between its Gs, Gi and Gq coupled states. We propose the following mechanism by which G
proteins can regulate receptor coupling. Receptor activation by agonist produces at least one
activated R* state capable of coupling with G proteins. G proteins in turn can bind to receptor
and produce an active receptor conformation that leads to GDP release and formation of a
ternary complex with high affinity for agonist. If the G protein is unable to stabilize such a
receptor conformation, the ternary complex will not form. If the receptor conformation in the
ternary complex is not able to promote GTP binding to the G protein, G protein binding but not
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activation will be seen, as in case of q6N35C and A1 adenosine receptors (Figure 3, page 160
and Figure 4, page 162) or in case of Gi1 and M1 muscarinic receptor. Thus different G proteins
will stabilize different R* conformations. Importantly, the formation of these different R* may
be regulated by agonist concentration in addition to the agonist structure. Using transferred
nuclear Overhauser effect NMR spectroscopy, Dratz et al. detected the low-affinity interaction
between inactive rhodopsin and C terminus of Gtα (Dratz et al., 1993), supporting the idea that
G proteins can bind to the receptor in the absence of agonist. Subsequently, agonist activation of
receptor leads to high affinity interactions between G protein and receptor. Although the twostate model of receptor action is very useful as a model, it does not adequately explain the
existence of multiple activated states of receptors. There are debates in the literature regarding
the existence of the multiple R* species (Tucek, 1997; Kenakin, 1997; Strange, 1999; Kenakin,
2001). Our results support the idea of multiple active receptor conformations as opposed to the
one active R* state and suggest that the two state receptor activation model needs to be changed.
In summary, this project presents interesting findings regarding the molecular
mechanisms that regulate G protein-receptor coupling and helps us to understand better how the
GPCRs function. Future studies should be aimed at assessing the generality of these findings
and their applicability to the in vivo situation. Furthermore, studies investigating how the
differences in the G protein-receptor coupling affect downstream signaling may suggest new
ways in which signal transduction along the G protein-mediated pathways could be modulated.
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